

DEPARTMENT OF
MICROBIOLOGY, TUMOR AND CELL BIOLOGY
Karolinska Institutet, Stockholm, Sweden

**NK CELL EDUCATION AND ADHESION
MOLECULES – IMPLICATIONS FOR
IMMUNOTHERAPY**

Arnika Kathleen Wagner



**Karolinska
Institutet**

Stockholm 2016

Cover Illustration by Arnika K. Wagner, 2016

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet. Printed by Universitetservice US-AB

© Arnika K. Wagner, 2016

ISBN 978-91-7676-327-8

NK cell Education and Adhesion Molecules –
Implications for Immunotherapy

THESIS FOR DOCTORAL DEGREE (Ph.D.)

AKADEMISK AVHANDLING

som för avläggande av medicine doktorexamen vid Karolinska Institutet offentligen
försvaras i Föreläsningssalen Hillarp, Retziusväg 8, Karolinska Insitutet, Solna

Fredagen den 10 juni, 2016, kl 9:00

By

Arnika Kathleen Wagner

Principal Supervisor:

Klas Kärre
Karolinska Institutet
Department of Microbiology, Tumor
and Cell Biology

Co-supervisors:

Maria H. Johansson
Karolinska Institutet
Department of Microbiology, Tumor
and Cell Biology

Petter Höglund
Karolinska Institutet
Department of Medicine, Huddinge

Opponent:

Andreas Diefenbach
University of Mainz, Germany
Institute of Molecular Biology

Examination Board:

Robert Harris
Karolinska Institutet
Department of Medicine, Solna

Susanna Cardell
Göteborgs Universitet
Department of Biomedicine

Yenan Bryceson
Karolinska Institutet,
Department of Medicine, Huddinge
Universitet i Bergen, Norge

“No one can do it alone. As you navigate through the rest of your life, be open to collaboration. Other people and other people’s ideas are often better than your own. Find a group of people who challenge and inspire you, spend a lot of time with them, and it will change your life.”

(...)

“... besides, it’s much more fun to fail and succeed with other people.”

Amy Poehler, Harvard Commencement speech 2011

ABSTRACT

NK cells have a key role in immune surveillance. They detect aberrant expression of stress-induced molecules and MHC class I molecules with an array of activating and inhibitory receptors. Inhibitory receptors are not only important during the effector phase to guarantee tolerance towards self cells, but also provide the means to learn what self is, during a process termed NK cell education. This mechanism ensures that only NK cells expressing inhibitory receptors for self MHC-I become functionally responsive to react to down-regulation of MHC-I in otherwise normal cells.

Recent evidence suggests that education is tunable and changes according to the net signaling input an individual NK cell receives. In **paper I**, we studied such retuning effects of NK cell education in different settings relevant to immunotherapy and asked whether they would impair anti-tumor responses. We used two mouse models of clinically relevant approaches to interfere with inhibitory receptor signaling, antibody mediated checkpoint blockade of inhibitory receptors, and allogeneic adoptive transfer. Despite adaptation of NK cell responsiveness resulting in tolerance to healthy MHC-I cells, we could still detect efficient anti-tumor responses.

To date, there is no known marker that distinguishes educated from hypo-responsive NK cells. In **paper II** we investigated the relationship between the adhesion molecule and activating receptor DNAM-1 and the education state of mouse NK cells. DNAM-1 expression appeared early in development prior to inhibitory receptors for MHC-I. We observed in several experimental situations that DNAM-1 levels are higher on NK cells that have Ly49 inhibitory receptors for self MHC-I, and thus are considered to be educated. Furthermore, we found an MHC-I independent, tight correlation between DNAM-1 expression and the inhibitory receptor NKG2A. Based on the data, we propose a model for how DNAM-1 levels may influence NK cell functions in different developmental and functional stages.

While NK cell education ensures strong tolerance to most normal cells, one exception is the interaction with DCs. Cross-talk between NK cells and DCs can lead to functional maturation of both cell types, but may also result in NK cell-mediated killing of the DC under certain conditions. In **paper III**, we analyzed the impact of an inflammatory environment on this interaction. We report that non-inflammatory DCs are relatively resistant to NK cell killing, while under inflammatory conditions, NK cells kill DCs via recognition of CD155 and ICAM-1 by DNAM-1 and LFA-1.

In **paper IV** we explored the possibility of NK cell activation by vaccination with alpha-galactosyl-ceramide (α GalCer) loaded exosomes directed to stimulate iNKT cells. We observed a preferential proliferation of educated NK cells in response to iNKT cell activation, as opposed to published results in virus models where preferential proliferation of uneducated cells is observed. This results in increased missing self killing of normal cells, and increased killing of both MHC-I⁺ and MHC-I⁻ tumor cells. Together, these findings contribute to illustrate the role of NK cells and NK cell education in immune surveillance against cancer cells. The thesis discusses these results in light of NK cells and their application in immunotherapy.

LIST OF SCIENTIFIC PAPERS

- I. **Arnika K. Wagner***, Stina L. Wickström*, Rossana Talerico, Sadia Salam, Tadepally Lakshmikanth, Hanna Brauner, Petter Höglund, Ennio Carbone, Maria H. Johansson*, Klas Kärre*
Retuning of mouse NK cells after interference with MHC class I sensing adjusts self-tolerance but preserves anticancer response
Cancer Immunol Res. 2016 Feb;4(2):113-23.

- II. **Arnika K. Wagner**, Nadir Kadri, Johanna Snäll, Petter Brodin, Gunther Bernhardt, Petter Höglund, Klas Kärre* and Benedict J. Chambers*
Expression of DNAM-1 (CD226) is associated with education status of NK cells
Submitted

- III. Laura E. Smith, Marcin A. Olszewski, Anna-Maria Georgoudaki, **Arnika K. Wagner**, Thomas Hägglöf, Mikael C.I. Karlsson, Margarita Dominguez-Villar, Francisco Garcia-Cozar, Steffan Mueller, Inga Ravens, Günter Bernhardt and Benedict J. Chambers
Sensitivity of dendritic cells to NK-mediated lysis depends on the inflammatory environment and is modulated by CD54/CD226 driven interactions
Journal of Leukocyte Biology, 2016, volume 100

- IV. **Arnika K. Wagner***, Ulf Gehrman*, Stefanie Hiltbrunner, Valentina Carannante, Nadir Kadri, Hanna Brauner, Klas Kärre* and Susanne Gabrielsson*
 α -Galactosyl-Ceramide and exosome-induced iNKT cell activation mediate increased missing self recognition and preferential proliferation of educated NK cells
Manuscript

* denotes equal contribution

PUBLICATIONS NOT INCLUDED IN THIS THESIS

Nadir Kadri, **Arnika K. Wagner**, Sridharan Ganesan, Klas Kärre, Stina L. Wickström, Maria H. Johansson, Petter Höglund
Dynamic Regulation of NK Cell Responsiveness
Curr Top Microbiol Immunol. 2016;395:95-114.

Joanna S. Kritikou, Carin I.M. Dahlberg, Marisa A.P. Baptista, **Arnika K. Wagner**, Pinaki P. Banerjee, Lavesch Amar Gwalani, Cecilia Poli, Sudepta K. Panda, Klas Kärre, Susan M. Kaech, Fredrik Wermeling, John Andersson, Jordan S. Orange, Hanna Brauner, Lisa S. Westerberg
Interleukin-2 is sufficient to restore killing capacity of Wiskott-Aldrich syndrome protein-deficient NK cells in vivo
Under Revision

Thuy Thanh Luu, Sridharan Ganesan, **Arnika Kathleen Wagner**, Dhifaf Sarhan, Stephan Meinke, Natalio Garbi, Günter Hämmerling, Evren Alici, Klas Kärre, Benedict Chambers, Petter Höglund*, Nadir Kadri*
Continuous presence of dendritic cells is required to maintain responsiveness and homeostasis of NK cells under non-inflammatory conditions
Submitted

Rossana Tallerico, Laura Conti, Stefania Lanzardo, Rosa Sottile, Cinzia Garofalo, **Arnika K. Wagner**, Maria H. Johansson, Costanza Cristiani, Klas Karre, Ennio Carbone, and Federica Cavallo
NK cells control the breast cancer and related cancer stem cells hematological spreading
Submitted

Stefanie Hiltbrunner*, Pia Larssen*, Maria Eldh, Maria Jose Martinez Bravo, **Arnika K. Wagner**, Mikael Karlsson, and Susanne Gabrielsson
Exosomal cancer immunotherapy is independent of MHC molecules on exosomes
Oncotarget, in press

Hanna Brauner, Stina L. Wickström, **Arnika K. Wagner**, Marjet Elemans, Ramit Mehr, Maria H Johansson* and Klas Kärre*
MHC class I dependent shaping of the NK cell repertoire takes place already early during maturation in the bone marrow
Manuscript

* denotes equal contribution

CONTENTS

1	Introduction.....	1
1.1	Cancer immunotherapy.....	1
1.2	Immune cells Relevant for Immunotherapy.....	2
1.2.1	T cells.....	2
1.2.2	NKT cells	4
1.2.3	Dendritic Cells	5
1.2.4	Macrophages and other Myeloid Cells	5
1.3	NK cells and other innate lymphoid cells.....	6
1.3.1	Innate lymphoid cells.....	6
1.3.2	NK cell biology.....	7
1.3.3	Missing self recognition	8
1.3.4	NK cell development.....	9
1.3.5	Activating receptors.....	10
1.3.6	Inhibitory receptors.....	12
1.3.7	NK cell education	17
1.3.8	Adaptive features of NK cells.....	19
1.3.9	NK cells in immunotherapy.....	21
2	Aims.....	25
3	Discussion	27
3.1	Preserved anti-cancer response despite retuning of NK cell education	27
3.2	DNAM-1 in education of NK cells	33
3.3	Surface receptors that change upon retuning.....	41
3.4	NK cell-mediated killing of Dendritic cells and the impact of paired receptors	43
3.5	Exosomes as anti-cancer vaccine	47
3.6	Concluding remarks	52
4	Acknowledgements	55
5	References	57

LIST OF ABBREVIATIONS

ADCC	Antibody-dependent cell-mediated cytotoxicity
APC	Antigen presenting cell
alphaGalCer	alpha-galactosylceramide
B6	C57BL/6 mouse strain
BM	Bone marrow
BMDC	Bone marrow-derived dendritic cell
BiKe	Bispecific killer cell engager
CAR	Chimeric antigen receptor
cDC	Conventional Dendritic cell
CD	Cluster of differentiation
CMP	Common myeloid progenitor
CMV	Cytomegalovirus
CLP	Common lymphoid progenitor
CTL	Cytotoxic T Lymphocyte
CTLA-4	Cytotoxic T Lymphocyte-associated protein-4
DAP12	DNAX activating protein of 12 kDa
DC	Dendritic cell
DNAM-1	DNAX accessory molecule-1
FcR	Fc receptor
FasL	FAS ligand
Flt3L	Fms-like tyrosine kinase 3 ligand
GvL	Graft versus Leukemia effect
GvHD	Graft versus Host Disease
G-CSF	Granulocyte colony-stimulating factor
GM-CSF	Granulocyte macrophage-colony-stimulating factor
HSC	Hematopoietic stem cell
HSCT	Hematopoietic stem cell transplantation
HCMV	Human Cytomegalovirus
IFN	Interferon
Ig	Immunoglobulin
IL	Interleukin
ILC	Innate lymphoid cell
ITAM	Immunoreceptor tyrosine-based activation motif
ITIM	Immunoreceptor tyrosine-based inhibition motif

ITSM	Immunoreceptor tyrosine-based switch motif
KIR	Killer cell immunoglobulin-like receptor
KLRG1	Killer cell lectin like receptor G1
LAK	Lymphokine activated killer
LN	Lymph node
LTi	Lymphoid tissue inducer
mAb	Monoclonal antibody
MCMV	Murine Cytomegalovirus
MDSC	Myeloid derived suppressor cell
MFI	Mean fluorescence intensity
MHC-I	Major histocompatibility complex class I
NCR	Natural cytotoxicity receptor
NK	Natural killer
NKC	NK gene complex
NKP	NK cell precursor
PAMP	Pathogen-associated molecular pattern
PD-1	Programmed cell death protein-1
pDC	Plasmacytoid dendritic cell
PRR	Pattern recognition receptor
R	Receptor
SH2	Src homology region 2
SHIP-1	SH2 domain-containing inositol-5 phosphatase 1
SHP-1/2	SH2 domain-containing phosphatase 1/2
TCR	T cell receptor
TIGIT	T cell immunoreceptor with Ig and ITIM domains
TIL	Tumor infiltrating lymphocyte
Tim-3	T cell immunoglobulin mucin-3
TLR	Toll like receptor
TNF	Tumor necrosis factor
TRAIL	TNF-related apoptosis-inducing ligand
wt	wildtype
XLP	X-linked lymphoproliferative disease

1 INTRODUCTION

1.1 CANCER IMMUNOTHERAPY

Cancer immunotherapy strategies use the inherent ability of the immune system to recognize and kill tumor cells. This effect is mediated primarily by T cells, NK cells, NKT cells, B cells, dendritic cells (DC) and macrophages [1]. Therapy strategies that are based on the immune system include hematopoietic stem cell transplantation (HSCT) and adoptive transfer of specific immune cells, treatment with immune activating cytokines, vaccination, monoclonal antibodies (mAb) specific for antigens primarily expressed by tumor cells, blockade of natural inhibitory receptors, so called checkpoint blockade, and more recently, the use of engineered substances to specifically target cancer cells.

One of the first immune-based cellular therapies was the use of bone marrow (BM) stem cells in HSCT, which has provided long-term disease-free survival to many patients with hematologic cancers [2]. In HSCT, the patient's BM cells are replaced by donor hematopoietic stem cells (HSC) which give rise to a new immune system. Furthermore, cytotoxic lymphocytes within the graft can attack and eliminate cancer cells by a mechanism referred to as the graft-versus-leukemia (GvL) effect. This treatment however, can also cause attack of the patient's normal cells, a major drawback known as graft-versus-host disease (GvHD).

To refine cell-based procedures and reduce GvHD, one approach was to isolate blood lymphocytes, activate them *in vitro* with interleukin (IL)-2 to generate "lymphokine activated killer (LAK) cells". When transferred back to the patient in conjunction with IL-2 treatment, these LAK cells were capable of killing autologous tumor but not normal cells, which lead to complete tumor regression in some of the patients with metastatic cancers [3]. Much later it was appreciated that the majority of LAK cells were NK cells [4]. After these initial achievements with LAK cells, tumor-infiltrating lymphocytes (TILs), which are mainly T cells, were used with some promising results in the treatment of solid tumors [5] and likewise, syngeneic and allogeneic NK cells have been used for adoptive therapy of blood-borne cancers [6]. Isolation of certain subsets of immune cells has been further refined, and many different approaches have been or are tested in clinical trials.

Another approach to harness the immune system's anti-tumor effect was the administration IL-2, an immune-stimulatory cytokine, which activates NK cells and T cells and lead to regression of some solid tumors [7]. IL-2 also induces the generation of suppressive mechanisms, primarily by stimulating regulatory T cells (Tregs) which can counteract the beneficial effects. Recently, the use of IL-15 in the clinic has been approved [8], to circumvent the suppressive and other side effects of IL-2. Furthermore, engineered variants that combine IL-15 with its high-affinity receptor have been shown to activate specifically NK cells and cytotoxic T cells [9].

Antibodies that target molecules on cancer cells have been used for some years now. They work via several mechanisms, e.g. by blocking the function of the targeted molecule on the surface of the tumor cell, induction of apoptosis, or by labeling the targeted cell for attack by immune cells. The efficacy of many monoclonal abs used in therapy (anti-GD2 for neuroblastoma, cetuximab for metastatic colorectal cancer, trastuzumab for breast carcinoma, rituximab for several leukemias) have been shown to be at least partly dependent on NK cells [10, 11]. The Fc portion of many mAbs can be recognized and bound by Fc receptors (CD16) expressed on NK cells [12, 13]. Upon binding of the mAb, the Fc receptors transmit an activating signal that ultimately leads to antibody-dependent cell-mediated cytotoxicity (ADCC) [11, 14]. Ideal targets for mAb therapy are neo-antigens, molecules that are expressed on tumor tissue (e.g. GD2 on neuroblastoma cells, HER2 on breast carcinoma and other types of cancer) with restricted expression on normal tissues. To include the benefit of T cells, and to increase specificity of antibody-therapy, bi- and tri-specific antibodies, that target molecules on cancer cells and on immune cells at the same time, have been engineered and successfully used in pre-clinical studies [15]. Furthermore, engineered chimeric antigen receptors (CARs) for NK or T cells or fusion proteins of pro-inflammatory cytokines with tumor-specific antigens are being introduced into clinical therapy [16].

A crucial part of the immune system is to distinguish between self and non-self, and to restrict activation of immune cells against healthy self cells. Inhibitory immune checkpoints are negative regulators expressed by antigen-presenting cells (APCs) that normally deliver inhibitory signals to limit effector T cell and NK cell responses and maintain self-tolerance during immune responses. In the tumor microenvironment, these inhibitory checkpoint ligands can suppress responses of cytotoxic lymphocytes. Blockade of these natural immune breaks with antibodies directed against cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death-1 (PD-1) and its ligands, or inhibitory NK cell receptors, have been developed and approved for use in patients [17-19]. The emerging role of host immunity and the tumor-immunogenicity in the efficacy of cancer treatments has just started to become appreciated.

1.2 IMMUNE CELLS RELEVANT FOR IMMUNOTHERAPY

1.2.1 T cells

T cells play a central role in cellular immunity, and as such, in recognition of tumor cells. T cells have T cell receptors (TCRs) consisting of alpha and beta chains ($\alpha\beta$ T cells), that are produced from re-arranged genes which creates a diverse T cell repertoire. A fraction of T cells have invariant gamma delta TCRs ($\gamma\delta$ T cells) with limited diversity. $\alpha\beta$ T cells recognize antigenic peptides in complex with major histocompatibility complex (MHC). $CD4^+$ T helper cells bind to MHC-II on the surface of APCs, while $CD8^+$ cytotoxic T lymphocytes recognize peptide presented by MHC-I on the surface of most cells of the body. The different subsets of T cells each have distinct functions; $CD8^+$ cytotoxic T cells (CTLs) kill target cells, $CD4^+$ helper T cells produce cytokines and provide stimulation to other lymphocytes and antigen-presenting cells (APCs), regulatory T cells (Tregs) can

suppress effector responses and mediate tolerance and $\gamma\delta$ T cells are considered to be part of innate immunity with incompletely understood effects on healthy and diseased tissues. During an immune response, $CD4^+$ T helper cells can differentiate into several different functional classes. The most studied are Th1 cells, which secrete pro-inflammatory cytokines such as $IFN\gamma$, and orchestrate cell-mediated immunity, and Th2 cells, which secrete primarily IL-4, IL-5 and IL-13 and provide protection against many extra-cellular infections. Depending on the type of inflammation, Th1 or Th2 responses may be required for successful immune reactions [20]. In the context of a tumor, Th1 responses appear to be beneficial. Most immune-therapeutical approaches using T cells involve activation, modification or transfer of $CD8^+$ CTLs, but the effect of the therapy, including the pre-conditioning of the patients, may also affect $CD4^+$ cells and the balance of Th1 vs Th2 responses.

One of the first immunotherapies was infusion of autologous T cells with anti-tumor properties, which are isolated from resected tumor tissue and expanded *in vitro*. These tumor infiltrating T lymphocytes (TILs) are a heterogeneous population and only a fraction express a TCR specific for unique tumor-associated antigens. After infusion, TILs exert anti-tumor functions for a limited time, as they are unable to persist *in vivo*. Despite this apparent obstacle the response appears to be durable, and overall response rate for treatment of metastatic melanoma are 20-50% [5]. However, the efficacy of TILs seems to be restricted to melanoma, probably due to the high immunogenicity of this type of cancer. Furthermore, to obtain TILs, the tumor has to be surgically removed which limits the applicability of TILs to solid resectable cancers. Recently, infusion of autologous or heterologous unmodified selected T cells has been used for treatment of virally associated cancers and disorders [21].

Of late, new approaches to genetically modify T cells are being developed to redirect T cell specificity to tumor antigens. Two approaches have shown promising results in clinical studies and mouse models: (i) the use of bi-specific or tri-specific mAbs (BiKEs or TriKEs), and (ii) the introduction of a transgenic TCR or chimeric antigen receptor (CAR) [15, 16]. Since T cells do not express Fc receptors [15], they are unable to detect tumor cells that are bound by mAbs and do not perform ADCC as NK cells. BiKEs and TriKEs are fusion proteins composed of two or three different mAbs and are engineered to simultaneously bind to tumor cells and cytotoxic lymphocytes. By combining mAbs directed against tumor antigens with mAbs specific for CD3, T cells can be directed to kill tumor cells [15].

T cells can be transfected with a genetically modified TCR or a CAR with specificity against a tumor antigen [16]. These T cells can be isolated from the peripheral blood, transfected with a TCR specific for the desired antigen, expanded *in vitro* and then infused into the patient. Antigens that can be used for this type of therapy are molecules primarily expressed by tumor cells, so-called neo-antigens, viral antigens, or tissue-specific differentiation antigens, which are detected in many tumors but not in healthy tissues. An obstacle with using tumor-antigen-specific T cells is the appearance of MHC-I loss variants. To overcome this limitation, CAR T cells have been developed and are now being tested in clinical trials [16]. CARs are fusion proteins of the variable fragment of an antibody fused to intracellular signaling domains of

TCRs. The resulting modified T cells do not depend on proper antigen processing and presentation, and recognize the antigen in an MHC-I-unrestricted fashion. T cells with modified TCRs and CAR technology offers many advantages, but toxicity and the appearance of cytokine release syndrome warrant further studies. Malignancies of the B cell lineage, which displays restricted expression of CD19, have been successfully treated with CD19 CAR T cells [16].

Vaccination with antigenic peptides to treat cancers have been tested with limited success. Tumor-peptide, injected together with adjuvants or activated APCs, were thought to generate anti-tumor-specific immune responses. One such vaccination strategy lead to the approval of peptide-pulsed blood-derived monocytes for the treatment against advanced prostate cancer, however, treatment increased survival time of patients by only 4 months [22, 23]. Perhaps in the future, it will be possible to combine this approach with checkpoint blockade, thereby increasing the activation of effector cells.

T cells are activated via their TCR and co-stimulatory molecules. To control T cell responses and to prevent activation of potentially autoreactive T cells, APCs express molecules that inhibit T cell activation, so-called inhibitory immune checkpoint molecules. Among the most known are CTLA-4 and PD-1. CTLA-4 is the inhibitory counter-receptor to the co-activating receptor CD28. Both are expressed on T cells and recognize CD80 and CD86 on APCs. CD28 delivers a co-activation signal to T cells, while CTLA-4, which is upregulated on activated T cells, transmits an inhibitory signal to the T cell, thereby providing a mechanism to terminate the response. PD-1 is expressed by activated T cells, B cell precursors and has been found on NK cells. It binds to PD-L1 and PD-L2 which are expressed on many cell types, and prevents activation of the lymphocyte. This discovery has led to the development of checkpoint blockade antibodies, such as anti-CTLA-4, anti-PD-1 or anti-PD-L1 to restore T cell anti-tumor immunity [17, 18].

1.2.2 NKT cells

NKT cells are a distinct population of T cells with features and receptors of both the T cell and the NK cell lineage. They express an invariant TCR encoded by V α 14J α 18 in mice and V α 24J α 18 in humans, and several NK cell receptors, both activating and inhibitory. NKT cells recognize lipid antigens presented by the non-classical MHC class Ib molecule CD1d [24]. Upon recognition, they are rapidly stimulated and can in turn activate both innate and adaptive immune responses. NKT cells can be activated directly by tumor cells presenting lipid antigens, or indirectly by cross-presentation of antigens by DCs. NKT cells can kill tumor cells and rapidly produce high levels of cytokines, such as IL-4 and IFN γ , which influence the microenvironment and regulate responses of other immune cells [25]. With the discovery of α -Galactosyl-Ceramide (α GalCer) as an antigen that induces strong NKT cell activation, the critical role of NKT cells in activity against cancer cells could be demonstrated. Pre-clinical and clinical studies have demonstrated the potential for therapeutic use of NKT cell agonists, such as α GalCer [26]. In mouse models of melanoma, activation of

NKT cells and subsequent activation of NK cells lead to tumor protection. Production of IFN γ by both NKT and NK cells was required for the protective effect [26].

1.2.3 Dendritic Cells

Dendritic cells (DC) are antigen-presenting cells (APC) that belong to the myeloid lineage and originate from the BM. They populate the periphery as immature DCs where they take up substrates from the environment, e.g. dying or infected cells or proteins and scan the periphery for potential dangers via pathogen recognition receptors (PRRs) such as the Toll like receptors (TLRs) [20]. Cytokines important for DC differentiation and maturation are fms-like tyrosine kinase three ligand (Flt3L) and granulocyte-monocyte colony stimulating factor (GM-CSF). In the mouse, there are two major subsets, conventional DCs (cDC) and plasmacytoid DCs (pDC). cDCs (also known as myeloid DCs) are further subdivided into CD8 α^+ or CD8 α^- populations, the former is involved in cross-priming CTLs via MHC-I, while the latter drive adaptive immune responses via MHC-II [27]. Immature DCs are particularly proficient in capturing and processing of antigen. Furthermore, immature DCs can induce tolerance through induction of regulatory T cells (Tregs) or deletion of potentially autoreactive T cells. DCs mature when they encounter microbial peptide antigens or sense conserved pathogen-associated molecular patterns (PAMPs). Upon maturation, DC up-regulate co-stimulatory molecules such as CD40, CD80, CD83 and CD86, and express high levels of MHC-I and MHC-II and express CCR7 which induces migration to the lymph node (LN) where antigen presentation to T cells occurs [28, 29]. Mature DCs become highly efficient in antigen presentation and secrete cytokines, such as IL-12, which drives Th1-type immunity and enhance NK cell and CTL responses [30-32]. Due to their role in both innate and antigen-specific immunity, and their potential to control both tolerance and immune responses, DCs are sentinels of the immune system [29]. With the capacity to present antigen and provide co-stimulation, DCs appear to be an optimal vaccine against cancer [33]. DCs can be generated *in vitro* from BM or circulating precursor cells and activated and matured with tumor-specific antigens. The antigens are obtained from the patient, or from other sources such as cancer cell lines. With the molecular identification of many tumor-antigens, these molecules can be generated and used to stimulate DC. When transferred to the patient, DCs may home to the LNs, recruit T cells and NK cells and activate tumor-specific immune responses [22, 23, 33-37]. Vaccine strategies using antigenic peptide alone work in a similar fashion; the tumor-antigen is combined with an adjuvant to activate autologous DCs, which in turn can process and present the peptide and thereby inducing anti-tumor responses [22, 23, 38].

1.2.4 Macrophages and other Myeloid Cells

Macrophages are leukocytes of the myeloid lineage that recognize diseased cells and pathogens by PRRs such as TLRs. Upon recognition, the target cell is eliminated via phagocytosis or by direct killing via the production of nitric oxide (NO) [20]. Furthermore, macrophages can act as APCs and thereby initiate and regulate adaptive immune responses. Macrophages also play a role in anti-inflammatory responses as in wound healing [20]. Based on this functional diversity, macrophages are classified as M1/kill-type which directly kill

target cells and stimulate Th1 responses, and M2/repair-type, which stimulate Th2 responses [39]. Macrophages that are found in high numbers in tumors usually belong to the M2-type where they participate in the generation of the immune suppressive tumor microenvironment, which is in part, responsible for the failure of cytotoxic lymphocytes to kill tumor cells [40]. On the other hand, M1 macrophages may directly recognize tumor antigens and facilitate tumor clearance [41]. Macrophages exhibit great plasticity and conversion from the immunosuppressive M2 to the M1 may prove beneficial for cancer therapy [42, 43]. Notably, while M2 macrophages can suppress anti-tumor responses by T cells and NK cells, they can be killed by NK cells via DNAM-1 and 2B4 [41]. Furthermore, IFN γ released by NK cells can induce a shift from M2 to M1 macrophages [41], thereby shaping the tumor microenvironment. Some macrophage developmental intermediates may be part of a heterogeneous group of cells sometimes referred to as myeloid-derived suppressor cells (MDSCs), to which also some developmental and functional subsets of granulocytes can contribute. MDSCs expand in pathological situations and possess strong immunosuppressive properties. They can interact with other cell types, thereby influencing immune-therapeutical approaches [44]. A high infiltration of many tumors has been associated with a poor prognosis. Further studies on MDSCs and their impact on tumor- and immune cells are needed.

1.3 NK CELLS AND OTHER INNATE LYMPHOID CELLS

1.3.1 Innate lymphoid cells

Until recently NK cells were thought to be the only innate lymphocytes, but in recent years it has become apparent that additional innate lymphoid cells (ILC) exist. ILCs differ from T and B cells in that they do not have receptor gene rearrangement and lack antigen-specific receptors. ILCs are found in tissues that have close contact to commensal microorganisms, such as the skin, the gut, the blood, mucosal sites of lung and urogenital tract. They rapidly produce effector cytokines upon stimulation and are thought to help fight infections at these barrier sites, but also to help the microbiota to return back to normal conditions after an inflammation [45, 46]. Furthermore, ILCs have a role in lymphoid tissue development, tissue repair and homeostasis and in regulating adaptive immune responses [47]. ILCs include cytotoxic or killer ILC (conventional NK cells) and helper ILCs (ILC1, ILC2, ILC3) [48]. ILCs are a heterogeneous group of cells, but based on dependency on transcription factors and similarities in effector cytokine secretion, they can be divided into 3 main groups, which resemble T helper subsets in terms of differentiation and key cytokine secretion [45, 46, 48-50]. Functional plasticity of and between the different ILCs are starting to emerge [45, 51].

Group 1 ILCs are characterized by the dependency on the transcription factor T-bet for lineage specification and the ability to produce IFN γ upon stimulation. They can be further subdivided into Eomes⁻ ILC1 and Eomes⁺ ILC1, the latter are known as conventional NK cells and will be called NK cells throughout this thesis. Eomes⁻ ILC1 have phenotypic resemblance to NK cells, but differ in expression of certain markers that can be used to distinguish the two. ILC1 express CD127 (IL-7R α), NCRs (NKp46 in the mouse, NKp44 and

NKp30 in human), lack expression of MHC-I-specific inhibitory receptors and CD49b (DX5), express CXCR3 and CXCR6, and are positive for $\alpha 1\beta 1$ integrin (CD49a) and TNF-related apoptosis-inducing ligand (TRAIL), which allows ILC1 to eliminate target cells without the use of granzymes and perforin and they secrete high levels of IFN γ and TNF α [45-47, 52]. ILC1 have been identified in liver, intestine, tonsils, and the peritoneal cavity and in limited numbers in the spleen [45, 47, 50].

The key signature transcription factors for ILC2 are GATA3 and ROR α [45, 50]. ILC2s produce large amounts of Th2-type cytokines such as IL-5 and IL-13, but can also express amphiregulin, IL-4, IL-9 and IL-6 in response to IL-25, IL-33 or thymic stromal lymphopoietin (TSLP). ILC2 have been found in mesenteric fat-associated lymphoid clusters, mesenteric LN, lung, intestinal lamina propria, BM, liver and skin. ILC2 are critical for innate protection against helminths and nematode infections, by supporting epithelial barrier integrity and recruitment of eosinophils through secretion of IL-5 and IL-13. They can activate Th2 cell directly through MHC-II or indirectly through early type 2 cytokine secretion and recruitment of DCs, thereby initiating type 2 adaptive immune responses [45, 50].

Key transcription factors of all group 3 ILCs are TCF1 [53] and ROR γt , which is expressed already by precursors committed to the ILC3 lineage both in human and in mouse [54-56]. These ILC3 committed precursors seem to leave the BM and develop into the different ILC3 subsets locally in other tissues [45]. Other transcription factors, e.g. T-bet, TOX or AHR and Notch signaling are required for the development of some ILC3 subsets [45, 50]. Some ILC3 subsets secrete type 17 cytokines, such as IL-17A or IL-22, and GM-CSF. IL-22 is required in certain intestinal infections in mice, extracellular bacteria and fungal infections at mucosal barriers. Lymphoid tissue inducer (LTi) cells constitute a subpopulation of ILC3 and have been identified in human and mouse. LTi cells are important for lymphoid organogenesis, as in absence of LTi cells (as in ROR γt -deficiency) there is no development of peripheral LN and Peyer's patches. Furthermore, in adult mice, LTi cells produce IL-17A and IL-22 in the lamina propria of the intestine. Other ILC3 subsets can express classical NK cell markers such as NKG2D or NCRs (and CD56 in human), they secrete either IL-17A or IL-22 or both. Some NCR⁺ILC3 subsets produce IFN γ . ILC3s are found in tonsils, intestinal lamina propria, while LTi cells are mainly found in fetal liver and lymphoid organs [45, 46, 50].

1.3.2 NK cell biology

NK cells are innate lymphocytes that can kill virally infected or transformed cells by natural killing, i.e. without prior sensitization [57-60]. NK cells can kill tumor cells and they are important for the control of many virus and intracellular infections and thus have a critical role in immune surveillance [57-62]. They are rapidly recruited to sites of inflammation, where they participate in early defenses. While NK cells can kill target cells without prior sensitization, they do need priming by DCs via type I IFNs and IL-15 [63]. Upon activation, NK cells can kill target cells by releasing preformed granules that contain cytotoxic proteins such as perforin and granzyme or by transmitting death signals via Fas ligand (FasL) and

TRAIL to the target cell [64-68]. Furthermore, NK cell may recognize and kill antibody-covered cells with their Fc-receptor CD16, a process usually referred to as antibody-dependent cell-mediated cytotoxicity (ADCC) [12, 69]. Additionally, activated NK cells can rapidly secrete cytokines, such as IFN γ or TNF α , chemokines such as MIP-1 α/β and growth factors such as GM-CSF and G-CSF [70, 71].

NK cells functions are controlled by integration of a multitude of signals from germline-encoded activating and inhibitory receptors, co-activation and adhesion molecules [72]. Some of the ligands for NK cell activating receptors are expressed at low levels on normal cells, and upregulated on infected or transformed cells. Most inhibitory receptors on NK cells bind to MHC-I. Normal cells are spared from NK cell attack when signals from activating receptors are balanced by inhibitory signals emanating from inhibitory receptors recognizing their cognate MHC-I ligand. Target cells that lack expression of MHC-I, are killed due to lack of inhibition, a concept termed recognition of “missing self” [73-75]. NK cells can also kill cells which express MHC-I if these cells express high levels of activating receptor ligands, a mechanism termed “induced self recognition” [76, 77] .

NK cells are found in many tissues, such as liver, peritoneal cavity, placenta, uterine mucosa, lungs, lymph nodes (LN), tonsils, spleen and blood [78]. They comprise 5-15% of lymphocytes in human peripheral blood and 3-5% of mouse spleen cells. NK cells are characterized as CD3⁻CD56⁺NKp46⁺ cells in human and CD3⁻NK1.1⁺ or CD3⁻NKp46⁺ in mice, however, also other ILCs can express NKp46. About 90% of human NK cells in blood or spleen are CD56^{dim}CD16⁺, which are potent killer cells. NK cells in LNs and tonsils on the other hand are CD56^{bright}CD16^{dim/-} and are characterized by production of cytokines such as IFN γ , in response to type I IFNs, IL-12, IL-15 or IL-18 [78-80].

In addition to their function in control of tumors and protection against infections, NK cells have a role in maintenance of homeostasis in the lymphoid system and in reproduction [81, 82].

1.3.3 Missing self recognition

Soon after the initial description of NK cells, the relationship between NK cells and a phenomenon called “hybrid resistance” became acknowledged [83-85]. “Hybrid resistance” refers to a situation where BM grafts from either inbred parent are rejected in F1-generation offspring, while solid organ transplants are not [83]. This and other observations led to the hypothesis that NK cells search for self MHC-I on target cells and that expression of sufficient levels of self MHC-I would inhibit NK cell-mediated attack [73-75]. Further indications for such a recognition strategy were provided by studies showing that wildtype (wt) mouse NK cells attack cells from mice with mutations that result in low/absent MHC-I surface expression [86-89]. Similar results came from studies with human NK cells [90]. Furthermore, introduction of a transgene H2-D^d, enables NK cells to reject cells lacking this MHC-I, demonstrating that MHC-I genes themselves control how NK cells see missing self [91, 92]. The identification of inhibitory receptors specific for MHC-I in mice and humans has lent support to the missing self hypothesis [93-96].

1.3.4 NK cell development

NK cells arise from hematopoietic stem cells (HSC) that reside in the BM, where hematopoiesis, the generation of hematopoietic cells, takes place. Development of the different lineages occurs through several differentiation steps, guided by cytokines, transcription factors and interactions with BM stromal cells [20]. One of the first critical steps in hematopoiesis is fate decision between the myeloid and the lymphoid lineage to either common myeloid progenitor (CMP) or common lymphoid progenitor (CLP), which give rise to the myeloid lineages and lymphoid lineages respectively. T cells, B cells, NK cells and ILCs develop from CLPs, as well as some DC subsets [97, 98]. Early stages of NK development occur in the BM throughout life, and the presence of proper BM microenvironment is necessary for NK cell function, as agents that affect BM destroy support of NK maturation, e. g. ^{89}Sr [99] or estradiol [100, 101]. Some of the early papers describing NK cells show that BM is an important source of NK cells [84, 102] and NK cell progenitors could be transferred by BM graft [84, 103]. The CLP can give rise to progenitor cells that have been termed pre-pro NK cells by one group and pre-NK precursor (pre-NKP) by another and have lost the capacity to give rise to T, B, DCs [104, 105]. This progenitor cell lacks expression of most canonical NK cell markers, is characterized by a high expression of IL-7R, NKG2D and 2B4 and the transcription factor Id2, and lack of CD135 (Flt3) and CD122 (IL-2R β ; component of the IL-15R), suggesting that commitment to the NK cell lineage does not require IL-15 [104, 105]. In the next step, the pre-pro NK/pre-NKP differentiates in NK cell precursors (NKP)s which start to express the IL-15R complex (IL-15R α , IL-2R β , IL-2 γ chain) [106], by upregulating CD122, enabling this progenitor to respond to IL-15 [107]. Furthermore, NKPs express the transcription factors Ets-1, Id2 and GATA-3 [107]. NKPs progress into immature NK cells which express NK1.1 and NKG2D, but are not functionally mature [108, 109]. As they start to acquire expression of NK cell lineage markers such as DX5 and Ly49 receptors (Ly49r), they become immature NK cells, which are functional and egress from the BM into the periphery [108-110]. In the periphery, e.g. the spleen, immature NK cells develop via several intermediate stages, defined by expression of cell surface markers. NK1.1⁺DX5⁺ NK cells can be further subdivided using expression of CD27 and CD11b as markers, where immature NK cells (double negative DN) start to express CD27, then acquire CD11b (double positive, DP), and then down-regulate CD27 again [111, 112]. During the CD27^{high}CD11b^{low} stage, immature NK cells experience a proliferative burst and Ly49r expression commences [111]. The CD27^{high}CD11b^{high} subset is the most potent when it comes to effector functions such as cytokine production and cytotoxicity *in vitro* [111]. After down-regulation of CD27, expression of killer cell lectin-like receptor-1 (KLRG1) commences, resulting in CD11b^{high}KLRG1⁺ terminally mature NK cells, with low proliferation and poor cytokine production capacity [113]. However, these terminally mature CD27^{low}KLRG1⁺ NK cells have been shown to be the predominant effector cells that migrate to and perform cytotoxic functions against colon carcinoma cells and are necessary for the clearance of pulmonary metastases in mice [114, 115]

Different cytokines and contact with stromal BM cells appear to be necessary at different stages of NK cell development and maintenance [116-118]. Mice deficient for any component of the IL-15 signaling (IL-15 or IL-15R complex) are unable to generate NK cells, but the finding that NKPs lack CD122 suggest that IL-15 may be more important for proliferation and survival of NK cells than commitment to the NK cell lineage [105, 116]. It was recently demonstrated by fate mapping that all NK cells progress through an IL-7R α^+ intermediate stage [119]. Signaling through the common IL-2 and IL-15 receptor pathway is pivotal for the maturation and the acquisition of effector functions of NK cells [120]

Similarly, different transcription factors regulate the progression through the distinct developmental stages. Functional development of NK cells is reliant of key transcription factors such as Ikaros (commitment to the lymphoid lineage) [121], PU.1 [122] and Id2 [123, 124], as well as the T-box transcription factor T-bet [125, 126] and eomesodermin (Eomes) [127]. GATA-3 is required for NK cell maturation, Ly49r expression and functional development [128]. T-bet is necessary for the differentiation into terminally mature CD27^{low}KLRG1⁺ NK cells [111, 112, 125, 127, 129, 130].

1.3.5 Activating receptors

Each NK cell expresses several different activating receptors that can recognize ligands on target cells. Some of these ligands are stress-induced molecules that are up-regulated on the cell surface during transformation or infection, while others are constitutively expressed by healthy self cells. Some activating receptors specifically recognize pathogen-encoded ligands. Induction of NK cell cytotoxicity by resting NK cells requires engagement of several activating receptors, while NK cells activated in vitro with IL-2 do not need synergy of multiple receptors [131]. Activating receptors contain short cytoplasmic domains and require association with adaptor molecules to transduce a signal. Signaling results in cytoskeletal reorganization, secretion of cytokines and chemokines and release of preformed cytotoxic granules [72].

Signaling via Immunoreceptor tyrosine-based activation motifs

Most activating receptors either contain immunoreceptor tyrosine-based activation motifs (ITAM) within their cytoplasmic domain, or associate with adaptor molecules that harbor an ITAM. Upon recognition of its ligand, the ITAM becomes phosphorylated by Src family kinases [132]. In NK cells, three ITAM-containing adaptor molecules are expressed: FcR γ , CD3 ζ and DAP12. Phosphorylated ITAMs serve as docking stations for the kinases Syk and Zap70, both of which are expressed in NK cells [133]. Syk and ZAP70 transmit downstream signaling involving activation of LAT, PI3K, PLC γ , PKC and VAV. These signaling molecules in turn trigger down-stream signaling events. [72, 132].

CD16

CD16 is a low-affinity receptor on NK cells which binds the Fc part of antibodies (IgG1 and IgG3 in human, IgG1 and IgG2 in mouse) [69] and induces ADCC [134]. Human CD16 can signal via FcR γ or CD3 ζ , while mouse CD16 can only bind FcR γ [72]. CD16 is the only

activating receptor on resting NK cells that mediates killing of targets without engagement of another activating or co-activating receptor [131].

NK1.1

NK1.1 (NKR-P1C, KLR-B1C) is an activating receptor expressed on all NK cells in B6 mice, and is commonly used to identify NK cells in this strain [135-137]. It belongs to a family of C-type lectins that encompasses both activating and inhibitory members, and is encoded within the NK gene complex (NKC) [137-139]. NK1.1 associates with FcR γ for signal transduction [140]. To date, no ligand for the activating member NK1.1 has been identified, while the inhibitory members bind to Ocil/Clrb, another C-type lectin encoded in close proximity to the NKR-P1 genes [138, 141].

NKp46 and NCRs

The activating receptor NKp46 belongs to the natural cytotoxicity receptors (NCRs), a group of receptors primarily studied in human NK cell biology [142-144]. NKp46 is the only member of the NCRs that is also found in mouse, where it is expressed on almost all NK cells and commonly used for NK cell detection [145]. The NCRs NKp46, NKp44 and NKp30 trigger cytotoxicity against tumor targets [144]. The NCRs bind to intracellular proteins that may be expressed on the surface of stressed, proliferating or otherwise activated cells [144, 146-148], and recognition of viral hemagglutinins has been reported [147, 149, 150].

Activating Ly49rs, Ly49D and Ly49H

Ly49D is an activating member of the Ly49r family. It binds to H2-D^d and mediates rejection of D^d-positive BM or cell grafts [151-153]. The activation signal is transduced via DAP12 and crosslinking leads to cytotoxic granule release and cytokine production [154]. The affinity of Ly49D to D^d is lower than the affinity of the inhibitory Ly49A to the same ligand [155, 156]. NK cells expressing only Ly49D without inhibitory Ly49rs are disfavored and more prone to apoptosis in an H2-D^d mouse strain, probably to reduce the frequency of potentially autoreactive NK cells [157]. However, when NK cells are strongly stimulated by cytokines the inhibitory receptors are overridden and Ly49D⁺ NK cells become activated even in the presence of the inhibitory receptor [158]. A physiological role for activating receptors that recognize MHC-I has been suggested in pregnancy [81, 159].

The activating Ly49H receptor, expressed in some mouse strains such as B6, directly binds m157 protein of murine cytomegalovirus (MCMV) and is responsible for the genetic resistance to the virus [160-165]. Ly49H associates with DAP12 for signaling [166, 167].

NKG2D

NKG2D is a heterodimer of the C-type lectin family. It is expressed by all NK cells and a subset of T cells. NKG2D associates and signals via DAP10 and DAP12 [168, 169]. NKG2D binds to structures that are rarely expressed by healthy cells, but induced upon cellular stress such as DNA damage, heat shock response or excessive proliferation and it thus recognizes cells that are infected or undergoing cellular transformation [170]. The ligands of NKG2D are

MICA/B and ULBP1-6 in human, and Rae1, Mult1 and H60 in the mouse, which share structural similarities with MHC-I molecules [170-173]. Most primary tumors express NKG2D ligands. Tumors can evade NK cell recognition by shedding their NKG2D ligands, a mechanism that not only reduces the level of ligands on the target cell, but also the soluble portions can desensitize NK cells and induce downregulation of the NKG2D receptor on NK cells [174-176]. However, an enhanced anti-tumor activity has been reported recently in response to shed NKG2D ligands [177, 178].

DNAM-1

DNAM-1 (DNAX accessory molecule-1; CD226) is a molecule that functions both as activating receptor and as adhesion molecule through interactions with CD155 and CD112 [179-181]. Expression of CD112 and CD155 is regulated by cellular stress [182, 183]. The DNAM-1 signal can be transduced via intracellular recruitment of the serine-threonine kinase PKC and the tyrosine kinase Fyn [184-187]. More recently, DNAM-1 mediated cytotoxicity was also found to be involved directly via Grb2 [188]. Both in mouse and man, the ligands for DNAM-1 are CD112/Nectin-2 and CD155/PVR which are members of the Nectin/Nectin-like family of adhesion molecules [180, 189, 190]. Nectins and nectin-like proteins mediate cell-cell adhesion, migration, cell polarization and formation of adherence junctions by binding to each other in *cis* or *trans* via homotypic and heterotypic interactions [191]. NK cells have three receptors that can recognize CD155, the co-activating receptors DNAM-1, the inhibitory receptor T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD96, for which both activating and inhibitory functions were reported [179]. DNAM-1/CD155 recognition is critical for NK-mediated tumor cell killing of several human cancers and DNAM-1-deficient mice have increased susceptibility for tumor cells or chemically induced tumor development [192-196].

1.3.6 Inhibitory receptors

Most NK cell inhibitory receptors recognize MHC-I molecules. Three families of MHC-I-specific inhibitory NK cell receptors exist, Ly49 receptors (Ly49r) in mouse, Killer-cell immunoglobulin-like receptors (KIR) in human and NKG2A in both species. The Ly49rs and KIRs are structurally different and belong to different receptor families, but they are expressed in a similar manner. Both gene families are polygenic and polymorphic, i.e. there are many genes with many allelic variants for the Ly49rs in mouse and the KIRs in humans [197-199]. Other species use either Ly49rs or KIRs, although independent evolution of KIR genes in different species has been suggested [198]. This is an example of convergent evolution, where different species have developed distinct recognition systems for MHC-I, thereby enabling NK cell recognition and inhibitory function [199, 200]. The diversity of genes and alleles has most likely arisen through gene duplication and gene conversion [198].

Signaling

Signaling by inhibitory receptors is mediated by an immunoreceptor tyrosine-based inhibitory motif (ITIM), a conserved sequence in the cytoplasmic domain of the receptors. Each Ly49r heterodimer contains two ITIMs (one in each molecule), which are phosphorylated at the

tyrosine upon receptor engagement. The phosphorylated ITIMs of Ly49rs recruit phosphatases, preferentially src homology region 2 (SH2) domain-containing phosphatase 1 (SHP-1) or SHP-2, but also SH2 domain-containing inositol-5 phosphatase 1 (SHIP-1) can bind via the SH2 domain [201]. SHP-1/2 function by dephosphorylating key signaling molecules needed for optimal transduction of activating signals, such as Vav-1, ZAP70, Syk, PLC γ 1 and PLC γ 2, LAT, SLP76 and the JAK kinases necessary for type I IFNs and cytokine-mediated activation [72]. SHIP-1 dephosphorylates signaling molecules necessary for sustained Ca²⁺ signaling [201]. Furthermore, engagement of inhibitory Ly49rs and NKG2A induces phosphorylation of Crk, a small adaptor protein, which leads to its dissociation from a multiprotein complex that connects Crk to the components of the cytoskeleton and prevents remodeling of the F-actin network [202, 203]. Remodeling of the cytoskeleton is important in granule polarization, NK cell-target cell conjugate formation and cytotoxicity [204].

NKG2A

The heterodimer CD94/NKG2A, which is encoded in the NKC, is expressed by both human and mouse NK cells and interacts with non-classical class Ib molecule Qa-1^b in mouse or HLA-E in human. Both are dependent on β 2m and present conserved leader peptides from the cleaved signal sequences of certain classical class Ia molecules [205-209]. This allows NK cells to probe the entire pathway involved in MHC-I synthesis, since either absence of the heavy chain, defects in the transport into the endoplasmic reticulum and peptide loading, defects in transport to the cell surface or β 2m light chain availability and expression impact on the expression of QDM-loaded Qa-1^b [205, 208, 210]. NKG2A is expressed on some T cell subsets and about 50% of NK cells in a mono-allelic fashion [211-213]. During NK cell development, NKG2A is the earliest expressed MHC-I-specific inhibitory receptor and provides developing NK cells with the means to recognize MHC-I-deficient target cells [214].

KIRs

In humans, most MHC-I-specific inhibitory receptors belong to the KIR family. KIRs consist of a family of approximately 15 closely related Ig-like receptors expressed on human NK cells containing two (KIR2D) or three (KIR3D) Ig-like domains. Most KIRs have long (L) intracellular domains that contain ITIMs and are inhibitory, while the activating KIRs have a short (S) cytoplasmic region without signaling motifs [72, 215]. The ITIM of inhibitory KIRs, once phosphorylated, enables recruitment of SHP-1 and interference with activating signaling. Inhibitory KIRs recognize the HLA-I ligand groups HLA-C1, C2 and Bw4. Similar to the Ly49rs, some inhibitory and activating KIRs share the same ligand, but the affinity of the inhibitory version is superior. Each individual has different KIR profile (genes) and within an individual, not all NK cells have the same receptor expression profile, not all NK cells express even express a KIR that is specific for self-MHC-I [216]. KIR haplotype (group of 5-10 specific alleles in the KIR locus), and KIR expression is highly diverse among the population. Furthermore, the KIR locus is among the most polymorphic regions of the human

genome [72, 199]. The haplotypes are classified into two main categories, haplotype A, which consists of mostly inhibitory KIRs and is common in the Caucasian population, and haplotype B, which consist of inhibitory and activating KIRs and is common in Africa [217]. However, some KIR genes are shared by all haplotypes [72, 217].

Ly49rs

The Ly49 C-type lectin family of receptors (now also known as killer cell lectin-like receptors subfamily A, Klra) recognize MHC-I or related molecules [153, 155, 218]. Several closely related Ly49rs have been identified, all of which are encoded in the NKC on mouse chromosome 6 [93, 219, 220]. The Ly49rs and NKG2A are expressed on individual NK cells in a partly stochastic variegated fashion, i.e individual NK cells may express a random number of inhibitory receptors, so that each individual NK cell can end up with none, one, or any combination of inhibitory receptors. In a B6 mouse that is MHC-I⁺, NK cells can express 0-6, but most cells express one or two inhibitory receptors [109, 157, 221-226]. Most Ly49rs have overlapping specificity to different MHC-I alleles [155, 222, 227]. It is noteworthy, that the Ly49rs and their ligands, MHC-I molecules, are located on different chromosomes, and thus inherited independently. As a result, NK cells can lack expression of inhibitory receptors that are specific for self-MHC-I [224]. A similar pattern of expression is seen for KIRs on human NK cells [216, 228]. A mechanism termed NK cell education ensures that only NK cells with inhibitory receptor for self-MHC-I can react to cells lacking MHC-I expression (but otherwise normal) (section 1.3.7).

During NK cell development, the Ly49rs are expressed in an orderly fashion, although distinct expression sequences have been determined by different experimental approaches. Surface detection after transfer of immature NK cells suggests expression in the order Ly49A, -G2, -C/I [110]. A study using *in vitro* BM stromal cell culture experiments corroborated this order [229]. However, when transcription was assessed by RT-PCR in NK cells generated *in vitro* from progenitor cells, inhibitory receptors were expressed in the order NKG2A and Ly49B, then Ly49G2, -C/I, and much later Ly49A, -D,-E, -F [109]. These results are not necessarily in conflict, they could rather suggest that transcription and surface expression are not linked. It has been shown by several studies that once expression of a certain inhibitory receptor has started, it remains stable over time [110, 218, 230, 231]. Ly49r⁺ NK cells appear gradually during ontogeny and the appearance is concurrent with NK cell activity [110].

Most inhibitory Ly49rs are usually expressed in a mono-allelic fashion and transcriptional termination of the second allele is regulated by methylation [232-235]. Cessation of transcription affects each Ly49r gene independently and appears to a certain degree to be stochastic process [234, 236, 237]. An influence of MHC-I on mono-allelic expression could be demonstrated; in the presence of a cognate MHC-I molecule, bi-allelic expression of those Ly49rs that could bind has been reduced [236]. Expression of the activating receptors Ly49D and Ly49H on the other hand is bi-allelic [238]. Furthermore, Ly49D and Ly49H often appear together and are preferentially expressed on NKG2A- NK cells [239, 240].

MHC-I-dependent skewing of the Ly49r repertoire

Even though inhibitory receptors appear to be expressed in a seemingly random fashion, there is a striking influence of MHC-I expression on the distribution of Ly49rs. In the presence of MHC-I, NK cells with one or two inhibitory receptors are over-represented (as approximated by the product rule, which predicts frequencies by multiplying the frequency of NK cells expressing each receptor), while NK cells with many self-specific inhibitory receptors are scarce. This phenomenon is referred to as “skewing of the repertoire” and creates a diverse repertoire of NK cells with distinct receptors [157, 241, 242]. Using mouse models with different MHC-I alleles it has become evident that there is a reduction in total expression of each Ly49r in the presence of the cognate MHC-I molecule. This is apparent both in terms of frequency of Ly49r⁺ NK cells (i.e. NK cells expressing the particular Ly49r), and the average expression level per cell (usually measured as mean fluorescence intensity [MFI]) [242-245]. It has to be noted that most of the reduction in MFI results from interactions of Ly49rs with their cognate MHC-I molecules in *cis*, i.e. on the same cell, which is described further below [246]. However, the frequency of NK cells expressing only one particular Ly49r recognizing host MHC-I, and none of the other inhibitory receptors, increases [157, 243, 247]. A skewed repertoire (an NK cell pool where many cells express only few self-specific inhibitory receptors) is potentially more useful in detecting loss or down-regulation of a certain MHC-I, which is a hallmark of both infection and tumor transformation. In humans, MHC-I-dependent shaping of the inhibitory receptor repertoire has been described for peripheral blood NK cells but not for cord blood-derived NK cells, while other studies report little or no influence by the presence of cognate MHC-I [228, 248].

Specificity of Ly49rs for different MHC-I alleles

Most Ly49rs recognize several MHC-I alleles with variable affinity [92, 155, 227, 249]. Depending on the method to determine recognition (e.g. MHC-I-tetramers for staining, inhibition of cytotoxicity, degree of receptor-downregulation, NK cell education), different studies suggest different receptor-ligand interactions. In B6 mice, the Ly49C and Ly49I receptors interact strongly with K^b, while Ly49A appears to interact weakly with D^b [155, 227, 249]. In mice transgenic for D^d, it is primarily the Ly49A⁺ NK cells that can strongly interact with its ligand [157, 218, 249].

Mode of binding

NK cells and T cell both bind to MHC-I, yet both the result of this interaction, as well as the mode of binding, differ. The T cell receptor touches both germline-encoded components of the MHC-I as well as the peptide. Ly49rs, on the other hand require the presence of a bound peptide, but they do not directly bind to the peptide [250]. Some degree of peptide selectivity has been reported for Ly49C and Ly49I [155, 227], whereas Ly49A binds to the complex with any peptide tested [251, 252]. Ly49rs bind multiple H-2D and H-2K alleles underneath the peptide-bonding platform which is formed by β_2m and mainly non-polymorphic amino-acids of the heavy chain $\alpha 3$ domain [253]. Furthermore, different modes of binding have been reported for the distinct Ly49rs [254]. KIRs bind MHC-I molecules by engaging mostly

invariant (but polymorphic) amino-acid residues of the $\alpha 1$ and $\alpha 2$ helices with minimal interactions with the bound peptide [250]. Peptide-selectivity for KIR2D binding to HLA-C has been reported [72, 255]. In addition to binding to MHC-I in on other cells (in *trans*), some Ly49rs can also bind MHC-I molecules on the same cell (in *cis*) [256]. *Cis* binding reduces the availability of Ly49rs to binding in *trans*, thereby lowering the threshold for inhibition [256, 257]. *Trans* and *cis* binding is mediated by the same binding site [256]. *Cis* binding of KIRs has not been reported [258]

Non-MHC-I-specific inhibitory receptors

NK cells may express inhibitory receptors recognizing other ligands than MHC-I. Within the NKC on mouse chromosome 6 there are genes encoded belonging to three families of C-type lectin-like glycoproteins [94, 259]. Similar to the Ly49r and the NKG2 family, the NKR-P1 family contains activating and inhibitory members as well. NKR-P1A, -C, and -F are activating, while NKR-P1B and -D are inhibitory and recognize Ocil/Clr-b. Ocil/Clr-b is encoded in close proximity to the receptors within the NKC and is expressed on many hematopoietic cells. this receptor-ligand system can provide additional MHC-I-independent regulation of self-tolerance [259]. In humans, several additional inhibitory NK cell receptors exist, which have not been identified in the mouse.

The SLAM family member 2B4

Receptors of the SLAM family are expressed on hematopoietic cells and have important immune-modulatory functions. Most SLAM family members are self-ligands, except 2B4 which binds to CD48, a molecule expressed on all hematopoietic cells [260]. 2B4 has four immunoreceptor tyrosine-based switch motifs (ITSM) in its cytoplasmic domain, which become phosphorylated and recruit the small adaptor molecules SAP, EAT2 and ERT (ERT only in mice)[261]. These adaptor molecules mediate activation of NK cells via the Src family kinase Fyn and Vav-1, which results in cytokine secretion and cytotoxicity [262]. In the absence of SAP, as in immature NK cells or X-linked lymphoproliferative disease (XLP), the ITSM motifs bind to the phosphatases SHP-1, SHP-2 and SHIP1 instead, which leads to NK cell inhibition [261, 263-265]. In mice, 2B4 appears to mediate both inhibitory and activating signals, depending on the context and the model system [266, 267].

KLRG1

Killer cell lectin-like receptor 1 (KLRG1) is an adhesion molecule expressed by about 50% of naïve mouse and human NK cells and by activated and memory T cells [268, 269]. KLRG1 is a marker for mature NK cells and activated T cells, as expression on NK cells starts at the CD27⁺CD11b⁺ late maturation stage in NK cells and is induced on T cells after contact with virus-infected cells [130, 269-271]. KLRG1 binds to cadherins which are expressed on epithelial and endothelial cells, as well as some hematopoietic cells such as DCs [272-274]. KLRG1 contains an ITIM within its cytoplasmic domain which can recruit SHIP-1 and SHP-2, but inhibitory function under physiological conditions has only been demonstrated in human NK cells [271, 275, 276]. In mouse NK cells, KLRG1 form

multimers, while on human NK cells it exists predominantly as a homo-dimer, which appears to be crucial for inhibitory function [277]. An inhibitory function of KLRG1 for mouse NK cells could only be demonstrated with transfected KLRG1 at very high levels, but not under physiological conditions [277]. An association between KLRG1 expression and education had been suggested [157, 278].

1.3.7 NK cell education

NK cells need to determine whether a cell is harmful to the body or not, i.e. they need to distinguish healthy cells from cells that are infected or transformed. Reactivity of NK cells is controlled by the balance of signals received by activating and inhibitory receptors. NK cell inhibitory receptors (Ly49 receptors in mouse, KIRs in human, CD94/NKG2A in both species) and their ligands (different MHC-I alleles) are located on different chromosomes, and consequently inherited independently from each other [279]. Furthermore, expression of inhibitory receptors is seemingly random (although there are some patterns connected to host MHC-I), so that NK cells lacking a receptor that can bind to self MHC-I do exist [216, 224, 228]. This suggests that there must be other means than shaping the repertoire of inhibitory receptors to ensure self-tolerance. Both deletion and induction of anergy of potentially auto-reactive NK cell subsets have been discussed [86, 280-282]. To remain self-tolerant, NK cells need to undergo an *in vivo* education process, so that only those NK cells which have an inhibitory receptor specific for self MHC-I, acquire the capacity to kill cells based on missing self as the only or major phenotype alteration [216, 223, 224, 283, 284]. NK cells lacking expression of an inhibitory receptor specific for self-MHC-I remain in the population but display a reduced responsiveness MHC-I-deficient, but otherwise healthy cells [224, 228]. Education is dependent on the functional interaction of inhibitory receptors with a cognate MHC-I and the resulting phosphorylation of the Ly49r-ITIM, but not necessarily recruitment of SHP-1 [223, 285, 286].

Different models have been proposed for how NK cells adapt their responsiveness during development. The licensing model postulates that NK cells with self receptors acquire responsiveness due to MHC-I interactions with surrounding cells. Only NK cells that encounter and bind a cognate MHC-I molecule via its Ly49r will develop functionally [223]. In contrast, the disarming model assumes that initially responsive NK cells lacking self receptors acquire a hypo-responsive phenotype and become self-tolerant in situations where overstimulation by activating receptors in the absence of inhibitory signals are perceived [224]. The main argument for an active mechanism of tolerance in induction is that wt NK cells in chimeric or mosaic mice (mix of MHC-I⁺ and MHC-I⁻ cells) acquire a hypo-responsive phenotype, i.e., they are less responsive and do not attack surrounding MHC-I⁻ cells [282, 287, 288]. In recent years, our group has proposed the “Rheostat model” for tuning of NK activation thresholds [283, 284], which postulates that NK cells are not just in an “on-” or “off-state” – but that there rather is a continuum of different degrees of responsiveness at the single cell level. Furthermore, the rheostat model suggests that the degree of responsiveness, at the single cell level, will depend qualitatively and quantitatively on inhibitory MHC-I input. According to the rheostat model, NK cell education is a continuous

process in which the responsiveness of an individual cell is set according to the amount of inhibitory input (interaction with MHC-I) they receive, and the combined strength of the resulting interactions, i.e. the number of inhibitory receptor-MHC-I interactions and the affinity of the individual inhibitory receptor for their cognate MHC-I ligands [283, 284]. Consequently, it should be possible to fine-tune responsiveness also in mature NK cells by changing the inhibitory input at the NK/receptor level, which we tested (paper I) [289].

As a result of this education process, only NK cells which express inhibitory receptors for self MHC-I, and consequently are inhibited from killing healthy self cells, have gained the functional capacity for effector functions when encountering a target cell which has too low MHC-I levels to prove that it is a healthy non-dangerous self cell. This inhibitory interaction during the effector phase, when the NK cell integrates activating and inhibitory signals and decides whether to kill or not to kill, is mediated by the same inhibitory receptor-MHC-I as the preceding education. Importantly, the threshold for education appears to be higher than that for inhibition so that weak interactions could lead to inhibition even if they do not impose education, most likely to establish a safety margin against auto-reactivity [249].

NK cells with multiple inhibitory receptors for self MHC-I respond better, and the different MHC-I molecules have distinct impact on responsiveness [92, 157, 284]. Similarly, also the MHC-I expression levels on encountering cells seems to play a role in education. This is exemplified by a study in mice where the impact of homo-versus hemizygoty of MHC-I expression was assessed [290], and could also be shown in humans [291, 292]. Any higher organism usually has multiple MHC-I alleles, each of which can bind to different inhibitory receptors with distinct affinity and avidity and thus educate different NK cells. NK cells can express individual Ly49rs in a seemingly random order, some express none, one, two or up to the number of MHC-I genes [293] (ranging from 0-6 in B6 mice).

Different MHC-I alleles have a different impact on education of an individual NK cell via a certain inhibitory receptor, i.e. there is a hierarchy of education impact [92, 283]. In the mouse the interaction of H2-D^d with the Ly49A results in a more responsive NK cell than interaction of H2-D^d with Ly49G₂ and interaction of H2-K^b with Ly49C has a stronger impact than H2-K^b on Ly49I-expressing NK cells [223, 284]. Similar hierarchy of educating impact of the different HLA-I alleles have been reported for human NK cells [228, 294]. Overall, when it comes to functional readouts of education, the most clear-cut results can be obtained by comparing Ly49A⁺ with Ly49A⁻ NK cells in a mouse that expresses a strong ligand for Ly49A, e.g. H2-D^d [157, 249, 284].

Recently, it has been proposed by several groups, that not only the inhibitory input an NK cells receives but also the activation signals are important for education and set the threshold for responsiveness [157, 289, 295-297]. As interactions via inhibitory receptors decreases the threshold, and thereby increases responsiveness to subsequent stimuli, the interactions via activating receptors may increase the threshold for responsiveness. This is to assure that every individual NK cell has the appropriate threshold to respond to changes in the levels of both MHC-I (and other inhibitory ligands) and ligands for the activating receptors.

Overstimulation via activating receptors thus leads to hypo-responsive NK cells [291, 296, 298-303].

In this thesis, education of NK cells via inhibitory interactions is studied and discussed. NK cell education by other inhibitory receptors such as 2B4, KLRG1 or inhibitory NKR-P1 receptors has been suggested [138, 267, 304]. The term “educated” in this thesis refers to an NK cell that has experienced MHC-I and can react to loss of the same, while an “uneducated” or “hypo-responsive” NK cell has not and thus does not kill a target solely on the basis of MHC-I down-regulation.

Uneducated, hypo-responsive NK cells are not useless. As they are not inhibited by MHC-I molecules, in case of a strong activation, their reduced responsiveness could be compensated by reduced inhibition during an effector phase. Indeed, during infection, it is mainly the uneducated NK cells that respond with proliferation and IFN γ production to MCMV [305], influenza [306], or *Listeria monocytogenes* [224]. Similarly, uneducated NK cells can respond quite well to stimulation by cytokines. Furthermore, NK cells do not need to have experienced education by MHC-I in order to kill MHC-I- targets. The balance of activating and inhibitory signals is what determines whether a target cell is killed or not. This quite counter-intuitive notion has been demonstrated by *in vitro* killing assays [88], and also *in vivo* (paper I) [289].

1.3.8 Adaptive features of NK cells

Interplay with other cells

An immune response in mammals is mediated by two broad systems, innate immunity which provides a first-line defense against many pathogens, and adaptive immunity, which is antigen-specific and displays immunological memory [20]. NK cells were described to respond rapidly and non-specifically to infection, and therefore classified as being part of the innate immune system. However, NK cells can direct immune responses to a more pro-inflammatory, Th1 type response, they can help T cell responses by secretion of IFN γ and other pro-inflammatory mediators, and by early killing of target cells, thereby reducing antigenic load. The resulting cell debris may promote antigen presentation by APCs [307]. NK cells can also directly communicate with other immune cells, such as DCs, NKT cells and T cells and thereby shift adaptive immune responses [71, 308, 309]. NK cells kill recently activated CD8⁺ T cell in a perforin- and NKG2D-dependent manner, which may be important for termination of an immune response but can also lead to a reduction in T cell memory responses [310]. A vast body of literature describes cross-talk of NK cells with DCs [32, 35, 311-317]. The reciprocal activation of NK cells and DCs leads to polarization of the immune response, NK cells may release IFN γ , while DCs acquire the capacity to prime T cells towards Th1 responses. Furthermore, DCs provide tonic stimuli which are necessary for NK cell priming [63].

Memory NK cells

NK cells, with their limited repertoire of germ-line encoded receptors, are part of the innate immune system, and as such, have been thought to lack immunological memory (acquired immunity). However, recent studies suggest that NK cells can respond better to secondary stimulation, a feature that has been attributed to immunological memory. The first report illustrating NK cell memory functions, describes contact hypersensitivity responses against 2,4-dinitrofluorobenzene and oxazolone haptens in RAG γ mice, which are devoid of T and B cells. These responses were acquired, antigen-specific, persisted for up to four weeks and depended on Ly49C/I⁺ NK cells, (educated in these mice) [318]. Later, it was shown that NK cells from liver, but not spleen, could develop enhanced responses to a secondary challenge, against antigens from several different viruses [319]. Furthermore, NK cells activated *in vitro* with IL-12, -18, and low dose IL-15 could be detected for up to 22 days after transfer to naïve mice. These transferred NK cells were phenotypically indistinguishable from naïve NK cells, but responded better to subsequent stimulation with cytokines and receptor-crosslinking [320]. Memory NK cells have been further characterized in a mouse model for MCMV infection. In B6 mice, it is NK cells with the activating Ly49H receptor that specifically recognize m157, a MCMV-encoded protein, and respond by proliferation and effector functions. After the infection is cleared, most NK cells disappear again during a so-called contraction phase. Some NK cells, however, persist for several months in lymphoid and non-lymphoid organs. Upon a second challenge with MCMV, these long-living, self-renewing NK cells respond with enhanced cytokine production and degranulation which results in protective immunity against higher doses of virus [321].

Similar to the expansion of the Ly49H⁺ NK cell subset during MCMV infection, HCMV seems to drive the expansion of certain NK cell subsets as well and selectively shapes the repertoire of NK cells. HCMV seropositive humans have an increase of NK cells expressing certain KIRs and NKG2C, which recognizes HLA-E [322]. These NKG2C⁺ NK cells displayed an increased responsiveness when challenged with HLA-E-expressing target cells or crosslinking of activating receptors. Furthermore, these *in vivo* expanded NKG2C⁺ NK cells had acquired the maturation marker CD57 and expressed KIRs specific for self-HLA-I [323-327]. Changes in signaling molecules have been detected which may facilitate stronger effector responses by these adaptive NK cells when encountering infected cells. Furthermore, adaptive NK cells have been shown to spare activated T cells thereby further influencing adaptive immune responses [133].

The generation of memory NK cells in MCMV mouse model is dependent on the pro-inflammatory cytokine IL-12 and the expression of Ly49H and DNAM-1 on the NK cell [321, 328, 329]. Furthermore, memory NK cells predominantly arise from KLRG1⁻ NK cells, even though memory NK cells generated in response to MCMV infection are KLRG1^{high} [330, 331]. Human memory-like NK cells generated *in vitro* with IL-12, -15 and -18 up-regulate CD25, the high affinity receptor for IL-2, which enables them to respond to picomolar concentrations of this cytokine with expansion and increased cytotoxicity [332]. All these reports indicate that NK cells, in certain situations and in response to certain stimuli,

can acquire the ability to respond more robustly against a secondary stimulus with the same antigen. The results from mouse studies using hapten-induced memory, and the human studies indicate that NK cell education may be helpful in the generation of memory cells.

1.3.9 NK cells in immunotherapy

As one of the first immune-based cellular therapies, allogeneic (from a donor to a patient) hematopoietic stem cell transplantation (HSCT) has provided disease-free survival to many patients with hematological malignancies. The usual conditioning with irradiation and chemotherapy already reduces the tumor burden substantially, while it allows stable engraftment of the new immune system. Mature lymphocytes in the graft, and cells arising from the new BM can eliminate remaining tumor cells, a process referred to as the graft versus leukemia (GvL) effect. A major drawback is graft versus host disease (GvHD), based on the recognition of the patient's healthy cells by mature T cells of the graft, which become activated by the recipients APCs presenting peptides of the patient to the donor T cells. However, a certain degree of GvHD appears to be beneficial in terms of long-term survival, most likely because the cytotoxic lymphocytes mediate both GvHD and GvL and a complete suppression of GvHD may also hamper anti-tumor responses.

The first clinical evidence that NK cell alloreactivity played a major role in tumor surveillance came in 2002 [333]. In a cohort of AML patients that received HSCT, the risk of relapse was substantially reduced if the patient received a KIR-HLA mismatched graft. For a long time, donors have been selected so that their MHC setup matches that of the patient. This can be achieved through sibling donors (25% chance for a complete match) or via BM donor registries (usually for a strong but not complete match). Due to lack of such optimal donors, different additional strategies have been launched, e.g. the use of haplo-identical (half of the MHC loci are matched) has been started. To avoid T cell-mediated GvHD, these haplo-identical grafts are extensively depleted of T cells. Optimal donors in such a situation are biological parents and most siblings, as their MHC setup display the condition of haplo-identical, i.e. that half of the MHC genes are identical to the patient's. Extensive T cell depletion before transplantation, and immune suppressive treatment after the procedure result in a situation where the patient is quite susceptible to infections. However, the mature donor NK cells in the graft have been shown to be protective and to boost the anti-tumor response without causing GvHD [333]. In those donor-recipient-pairs where the NK cells display a KIR ligand mismatch in the donor vs recipient direction, donor-versus-recipient NK cell alloreactivity decreased leukemia relapse and protected from GvHD. The transferred NK cells attacked the patients remaining tumor cells (GvL) and the patients activated DCs, thereby preventing the induction of GvHD responses [333]. The reason for why donor NK cells killed the patient's tumor cells and DCs, but no other tissues of the patient, is probably the balance of activating and inhibitory signals provided by the cells. As all patient cells were haplo-identical, i.e. they lacked some of the MHC-I molecules that the donor's NK cells regard as self, there is low inhibition. Coupled with the high levels of activating ligands on tumor cells and on activated DCs, this would tip the balance towards NK cell activation and killing of such target cells.

These reports triggered the field of mismatched or haplo-identical transplantation and adoptive transfer of allogeneic mature haplo-identical NK cells. Many transplant centers around the world have started to study the outcome based on stratification of both HLA and KIR genotype in donors and recipients, albeit with varying results [334-343]. The conclusions that can be drawn from these studies are the following: (i) a KIR-HLA-I-ligand mismatch, where the donor has the HLA-ligand for the KIRs expressed by the NK cells, but the patient lacks these HLA-I genes, are preferable and lead to overall better outcome [333, 344-346], (ii) donor-recipient combinations where the donor had at least one group B haplotype (more activating KIR genes), had a better outcome [347, 348], and (iii) patients receiving NK cells with certain activating KIRs (e.g. KIR2DS1) where the donor was positive for the ligand (e.g. HLA-C2) had a reduced risk of relapse [291, 349]. Some, if not all of these observations may be explained by NK cell education and the search for missing self, as discussed in section 3.1 (Paper I).

As donor NK cell alloreactivity correlates with improved outcome in several studies, investigators started to use allogeneic mature NK cells for adoptive transfers to boost the NK alloreactivity effect after HSCT, or to reduce tumor burden before HSCT. Additionally, adoptive NK cell transfer has been used outside of HSCT in conjunction with IL-2 activation, and complete remission could be achieved in 5/19 AML patients [350]. This outcome could be increased to 50% complete remission by depleting the patient of Tregs, which appear to hamper NK cell expansion and activation [351]. With the clinical approval of IL-15, this treatment may be further enhanced by replacing IL-2 with IL-15, thereby limiting the activation of Tregs. Multiple groups are now investigating alternative sources of NK cells, such as differentiation from progenitors, *ex vivo* expansion, and immortalized NK cell lines [352].

NK cell effector functions are negatively regulated by inhibitory receptors such as KIRs and NKG2A, as well as induced co-inhibitory receptors PD-1 and T cell immunoglobulin mucin-3 (Tim-3). Anti-KIR mAbs are used with the aim of blocking the inhibitory KIR-HLA-I signal and thereby enhancing NK cell function [353]. While pre-clinical studies in mice have given promising results, initial clinical studies have shown that this treatment did not demonstrate major responses when used as single agent [19, 354-358]. However, combining anti-KIR mAb with lenalidomide, which increases the expression of stress molecules such as ligands for NKG2D or DNAM-1 on tumor cells, has increased the response rate in a recent study [359].

Shortly after the discovery of NK cells, the ability to kill syngeneic and allogeneic tumor cells *in vivo* and thereby providing natural resistance against cancer was recognized [360]. Ever since, there have been numerous studies in mice on effector functions of NK cells and their role in host protection [72].

As for T cell immunotherapy discussed above, engineered BiKes and TriKes, and CARs for NK cells are being developed and tested in pre-clinical studies [352, 361, 362]. Targets for BiKes and TriKes include CD33⁺ cells which is expressed on many hematopoietic

malignancies such as AML, or CD133, which is an antigen specifically expressed by colorectal cancer [361, 362]. NK cell CARs currently under investigation are anti-CD19 (B cell malignancies) and anti- EGFR targeted for breast cancer and brain metastasis [352]. The field of engineered receptors has just started, and it will be interesting to see what the future may hold.

2 AIMS

This thesis aims to study NK cell education, whether it can be modulated *in vivo* and how this impacts immunotherapy.

Specific Aims:

Paper I

To investigate if education of mature NK cells can be retuned by altered inhibitory input from normal cells in the environment and how this may affect tolerance to self and activity towards tumor cells.

Paper II

To characterize the expression of DNAM-1 on NK cells with respect to education imposed by MHC class I molecules.

Paper III

To assess the impact on inflammation on NK cell – DC cross-talk, and to study which molecules are involved.

Paper IV

To modulate NK cell missing self- responses by *in vivo* activation of iNKT cells and to compare soluble α GalCer versus α GalCer administered in the context of exosomes.

3 DISCUSSION

3.1 PRESERVED ANTI-CANCER RESPONSE DESPITE RETUNING OF NK CELL EDUCATION

The rheostat model for NK cell education postulates that responsiveness is set according to the strength of the net signal resulting after balancing activating and inhibitory input, so that killing of normal healthy cells is avoided. As a consequence, the number of inhibitory MHC-I interactions and the affinity of the individual inhibitory receptor for their cognate MHC-I ligands will strongly influence the development of an activation threshold, i.e. more inhibitory input sensed by an individual NK cell will result in a stronger responsiveness [283, 284]. Furthermore, the model suggests that responsiveness is tuned continuously and it predicts that retuning of responsiveness should be possible. This was tested in studies performed in mouse, where mature NK cells were adoptively transferred from B6 mice (MHC-I⁺) to $\beta_2m^{-/-}$ mice (MHC-I⁻) and vice versa [363, 364]. NK cells transferred from B6 to $\beta_2m^{-/-}$ mice displayed reduced responsiveness when triggered via crosslinking of activating receptors *in vitro*, and against MHC-I-deficient target cells *in vivo*. The decrease in capacity to degranulate and to produce IFN γ was specific to NK cells that expressed inhibitory receptors sensing the relevant MHC-I [364]. When mature hypo-responsive NK cells from $\beta_2m^{-/-}$ mice were adoptively transferred to an MHC-I-positive mouse strain, the ability to degranulate and produce IFN γ in response to *in vitro* receptor-crosslinking was increased [363]. These results advocate that mature NK cells can adapt their responsiveness according to the MHC-I environment, which is in support of the rheostat model of NK cell education. The results from these two mouse studies would predict that in a clinical setting, adoptively transferred NK cells from an HLA-mismatched donor to a patient where KIR ligands (HLA-I) are missing, would adapt and lose their capacity to kill the patient's tumor cells. However, in adoptive transfer or BM transplantation therapies, the KIR haplotype of the donor, and the relationship between the donor's inhibitory KIR expression and the patient's HLA genotype, do have an impact on clinical outcome in allogeneic settings. A longer progression-free survival post-transplantation is observed in leukemia patients that lack the HLA-I (KIR-ligand) for the donor's inhibitory KIRs [333, 343-346, 348, 365]. In the same studies it was shown that donor NK cells did not induce GvHD, in fact, the risk of GvHD after mismatched transplantations of HSC was reduced [333]. The donor's NK cells seem to kill the mismatched tumor cells but not the equally mismatched healthy tissues. This was explained by the finding that the transferred NK cells could kill the patient's DCs, thereby preventing activation of allogeneic T cells of the graft, which would attack the patient's tissues and cause GvHD. Furthermore, ongoing clinical trials use anti-KIR antibodies to block the inhibitory interaction of KIRs with MHC-I on tumor cells. The approach tested in these clinical trials, as well as results from pre-clinical studies, suggest increased killing of MHC-I-positive tumors by NK cells [19, 354-356, 366].

The strategies of these clinical studies are encouraging, but the sometimes limited effect of treatment could potentially be explained by retuning as demonstrated in mouse studies, where

transferred NK cells adapt and become tolerant to MHC-I-mismatched cells [364]. After transfer of mature NK cells from B6 to $\beta_2m^{-/-}$ mice, NK cell reactivity *in vivo* was tested only against spleen cells (MHC-I) and the *in vivo* killing capacity of NK cells after transfer from $\beta_2m^{-/-}$ to MHC-I⁺ mouse strains was not tested at all [363, 364]. The results of both studies therefore only show that the activation threshold is altered after a change in MHC-I sensing. How this translates to killing of tumor cells, MHC-I⁺ or MHC-I⁻, was the starting point of paper I. We transferred mature splenic NK cells from B6 mice (MHC-I⁺) to $\beta_2m^{-/-}$ mice (MHC-I⁻), and tested the capacity to kill MHC-I target cells after 7 days. This time-point was chosen after initial kinetic experiments using spleen cells as targets. We found a variable induction of tolerance towards MHC-I spleen cells as early as day 4 (data not shown), which was very robust at day 7 (paper I, Fig. 3). NK cell responsiveness was down-tuned both when cell suspensions made from entire spleens were transferred, and when we isolated the NK cells prior to transfer (paper I, Fig. 3A). We then tested how well these NK cells could kill tumor cells, by using a pair of H-2^b (syngeneic to B6) T cell lymphoma lines, RMA (MHC-I⁺) and RMA-S (MHC-I⁻). RMA-S was generated by mutagenesis of the parental lymphoma line RBL-5 (later identified as a subline of the EL-4 cell line[367, 368]) followed by repeated selection for low binding of MHC-I antibody, while the RMA line underwent mutagenesis but not selection [73, 75]. The two cell lines have been cultured separately and could have acquired different mutations. We therefore tested a panel of ligands for NK cell activating receptors and detected no difference between RMA and RMA-S (Paper I, Suppl. Fig. 2). Notably, while B6 NK cells transferred to $\beta_2m^{-/-}$ mice became tolerant to MHC-I spleen cells, they were still able to recognize and efficiently kill MHC-I RMA-S tumor cells (paper I, Fig. 3D). This suggests that these NK cells were not simply exhausted by the multitude of interactions with MHC-I cells but actually tolerant. After all, educated NK cells fully capable of performing missing self-rejection, were placed into an environment full of cells representing the missing self phenotype, i.e. cells lacking MHC-I. We did not see any signs of auto-aggression or toxicity. This does not exclude the possibility that the transferred NK cells killed the first couple of MHC-I cells they encountered. But ultimately, these NK cells adapted and became tolerant to healthy MHC-I cells while still being able to kill tumor targets with low MHC-I expression.

The previous studies showed that hypo-responsive NK cells, transferred from $\beta_2m^{-/-}$ mice to MHC-I⁺ recipients can respond better to stimulation *in vitro* [363, 364]. We wanted to test if this could translate to an *in vivo* situation, i.e. whether NK cells could up-tune their capacity to kill MHC-I target cells *in vivo*. As MHC-I⁺ recipients we used RAG γ -double knockout mice. These mice lack T and B cells due to their defect TCR and BCR generation, and they lack NK cells since NK cell development requires functional IL-15 signaling and the common gamma chain is part of the IL-15R complex [116, 369]. We needed a mouse strain that would not reject the transferred NK cells because we wanted to avoid the use of a “mega-dose” of NK cells [363] to generate a more physiological and clinically relevant setting. NK cells transferred from an MHC-I donor to an MHC-I⁺ recipient did not kill spleen cells that lack MHC-I expression, rather, they remained tolerant (paper I, Fig. 4A+C). This may be in

apparent contrast with the *in vitro* data obtained by Elliot et al. and Joncker et al., as well as the predictions of the rheostat model [363, 364]. One possibility, however, was that the NK cells had been retuned but that this was not sufficient to kill cells with low MHC-I but otherwise healthy phenotype and hence not detectable using spleen cells as targets. We therefore wondered how these NK cells would perform when challenged with tumor targets. Again we used the lymphoma cell lines RMA and RMA-S, and observed that NK cells transferred from MHC-I mice could kill RMA-S better when exposed to MHC-I⁺ surrounding cells (paper I, Fig. 4B+D). $\beta_2m^{-/-}$ NK cells were even better in RMA-S killing than B6 cells when transferred to RAG γ mice and just as efficient as naïve B6 NK cells (paper I, Fig. 4B). These results show that mature NK cells can adapt their responsiveness to their surroundings, but also that self-tolerance is very robust. In both settings, NK cells tolerate the lack of MHC-I on healthy (spleen) cells, while they vigorously react to tumor cells that lack the same MHC-I molecules.

As mentioned before, blocking inhibitory receptors to decrease MHC-I-dependent inhibition of NK cells and thereby inducing killing of (MHC-I⁺) tumor cells, has given encouraging results both in a clinical trial for safety and in mouse studies [19, 354-356, 358, 366]. Importantly, killing of MHC-I normal cells has not been reported in these studies. We therefore wanted to test the effect of blocking Ly49C and Ly49I (self-specific inhibitory Ly49rs in B6 mice) on the killing of MHC-I target cells. Similar to the adoptively transferred NK cells, mature educated NK cells in B6 mice altered their behavior and became tolerant towards MHC-I spleen cells. Paper I is the first report of a change in NK cell behavior towards MHC-I cells after blockade of inhibitory NK cells receptors. The decrease in responsiveness seen *in vivo* was also observed after crosslinking activating receptors *in vitro*. Importantly, in the *in vitro* assay we could monitor the function of specific NK cell subsets by staining for functional markers and inhibitory receptors. To our surprise, only NK cells expressing Ly49I showed a significant decrease in IFN γ production and degranulation (paper I, Fig. 2A+C) even though the antibody can bind both Ly49I and Ly49C [358]. We speculate that either the binding efficiency of the antibody to the two receptors may differ, or that the two receptors respond differently to the blockade. A direct comparison on binding affinity has not been performed. However, it is known that Ly49I is more accessible to the antibody than Ly49C, which, in a B6 mouse (H2-K^b) is mostly bound in *cis* [370]. After establishing that after blockade of Ly49C/I by antibody binding, NK cells reset their responsiveness to MHC-I spleen cells, we wondered how these cells would perform when challenged with tumor targets. In this approach, we tested two MHC-I tumor cell lines, the previously described RMA-S and a recently generated MHC-I variant of C1498 [371]. Similar to the B6 NK cells that were adoptively transferred to MHC-I hosts, the blocked NK cells responded efficiently to MHC-I tumor cells (Paper I, Fig. 1D-F). Whether continuous blockade of inhibitory KIRs affects NK cell responsiveness has not been studied in humans. However, in a mouse model transgenic for a KIR and the cognate HLA-I molecule, *in vivo* blockade with anti-KIR mAb for up to 21 days did not affect *in vitro* responses to stimulation with α NK1.1 or tumor cells. *In vivo* rejection of healthy cells has however not been tested

[366]. As more clinical trials are undertaken with the anti-KIR mAb lirilumab, further studies may elucidate whether KIR blockade also leads to retuning in treated patients.

We suggested a model to explain our and other groups' findings (paper I, Fig. 6). We propose that the activation threshold is set according to the integration of activating and inhibitory input NK cells perceive. This is set at the single cell level, i.e. every NK cell senses a different extent of activation signals and inhibitory signals which are integrated into a net signaling that is perceived as normal and healthy/non-dangerous. Only target cells with ligands providing sufficient activating potential (signals from activating ligands exceeding the net activation signal that was perceived as normal/healthy) will make the NK cell react.




Figure 1: Model for retuning of NK cell responsiveness after a change in MHC-I-dependent inhibitory input. NK cells integrate inhibitory and activating signals they receive from surrounding cells. Based on this integrated signal, a net signaling threshold is set for each individual NK cell. This net signaling threshold needs to be overcome by the activation potential of target cells for killing to NK cell activation to occur. Adoptive transfer to an MHC-I-disparate environment or blockade of inhibitory receptors alters the inhibitory input. Activating and inhibitory signals are re-integrated which causes an adaptation of the net signaling threshold. Individual NK cells can still respond to cells where the activating ligands exceed inhibitory ligands, such as cancer cells. Signals provided by MHC-I-deficient tumor cells are above the net signaling threshold, while MHC-I-deficient healthy cells are not.

Reduction of inhibitory input, e.g. by blocking interactions of inhibitory Ly49rs or by adoptive transfer from an MHC-I⁺ to an MHC-I⁻ environment, increases the net signaling threshold, i.e. the same activation signals with less inhibition are now perceived as normal. This can explain the induction of tolerance towards MHC-I⁻ spleen cells, as they provide exactly what is after retuning perceived as normal: less inhibition, but the same amount of activation. Tumor cells are still efficiently killed since they express more ligands for NK cell activating receptors (paper I, suppl. Fig. 2 and [171]) and their activation potential therefore overcomes the net signaling threshold of NK cells (paper I, Fig. 6). Additionally, tumor cells could potentially produce cytokines that activate NK cells. While RMA and RMA-S do not express IL-12 or IL-18 [372], they produce IL-2, a cytokine known to activate NK cells (Kritikou et al, manuscript under revision).

Our model can also explain the increased ability of $\beta_2m^{-/-}$ NK cells to kill MHC-I tumor cells after transfer to MHC-I⁺ mice, while at the same time tolerance towards MHC-I spleen cells is observed. By being able to receive MHC-I-dependent inhibitory signals, the net signaling threshold is reduced, meaning that less net activation provided by ligands on target cells is required for an NK cell to kill the target (Fig. 1: Model for retuning of NK cell responsiveness after a change in MHC-I-dependent inhibitory input). Translated to the clinical setting with human NK cells, this would implicate that when NK cells are transferred from a donor that lacks the cognate HLA-I for some of the expressed KIRs to a patient where the particular HLA-I is present, these NK cells could gain responsiveness and start to kill the patient's tumor cells, while being tolerant to the healthy cells, that are equally mismatched.

Interactions of Ly49rs with cognate MHC-I give rise to strong inhibitory signals, but they are not the only source of inhibition and therefore non-MHC-I-dependent inhibitory interactions may also be involved in fine-tuning the net activation threshold [138, 267, 304]. However, since we interfered with sensing of MHC-I via Ly49rs, we can show that MHC-I-dependent inhibition is a major contributor in setting the net signaling threshold. Similarly, not only stress-induced activating ligands can be a source of activation, also MHC-I-specific activating interactions may contribute to the increase the net activation threshold. As described in section 1.3.7, recent studies report an impact of activating Ly49rs/KIRs on NK cell education. In clinical studies it was reported that patients receiving NK cell allografts from donors expressing activating KIRs (e.g. KIR2DS1) but lacking the ligand (e.g. HLA-C2), had less relapse than patients who received grafts where both KIR and KIR-ligand were expressed [291, 349, 373]. These studies suggest that NK cells with activating KIRs interacting with cognate ligand in the donor are hypo-responsive. The effect is even stronger, when two copies of the HLA-I gene are present, for example KIR2DS1⁺ NK cells in donor's that are homozygous for HLA-C2 [349]. However, when the patients were homozygous for the ligand (HLA-C2/C2), the KIR2DS1-induced NK alloreactivity was gone and these patients had a higher risk of relapse [349]. This finding could be interpreted as a down-tuning in net activation threshold induced by increased activation input via recognition of C2 by KIR2DS1.

To date it is not known which cells provide the educating signal to NK cells. It could be a specific cell type, e.g. DCs or BM stromal cells or any hematopoietic cell expressing a certain molecule or secreting a necessary factor, or it could be any encounter with another cell, including fellow NK cells and even target cells, i.e. cells that are killed. It could also be so that every cell can provide the educating signal, but that NK cells are only responsive to that in a certain environment/niche, e.g., in a certain organ (lymphoid organs as the BM) or under specific conditions (cytokines, growth factors). A recent study performed in mice suggested that even MHC-I tumors can alter the activation threshold and induce hypo-responsiveness in NK cells locally [372]. Initially it has been postulated that NK cells are educated in the BM [99, 100]. More recent data, including my own (paper I), have shown that education is not fixed, that mature NK cells can be re-educated and adjust their responsiveness according to the MHC-I input they receive throughout their life span and also in the periphery [289, 363,

364, 372, 374]. It has been proposed that interactions of Ly49rs with MHC-I in *cis*, i.e. on the same cell, influence NK cell education [375]. The data on adoptively transferred NK cells presented in paper I however, indicate that *trans* interactions are necessary to adapt to the new environment. If *cis* interactions were the sole cause for education, the transferred NK cells would not retune and change their net signaling threshold, as B6 NK cells transferred to $\beta_2m^{-/}$ mice could still sense MHC-I in *cis*, and $\beta_2m^{-/}$ NK cells transferred to MHC-I⁺ mice would not sense MHC-I in *cis*. However, NK cells can acquire MHC-I from the surface of other cells, a process termed trogocytosis [376]. When we assessed the expression of K^b on transferred $\beta_2m^{-/}$ NK cells 7 days after transfer, we could see a small increase in K^b MFI when the recipients were MHC-I⁺, but not MHC-I⁻ (data not shown). The levels of K^b expression on transferred $\beta_2m^{-/}$ NK cells only reached about 1-2% of wt B6 levels, but we therefore cannot exclude trogocytosis and *cis* interactions entirely. However, transferred B6 NK cells adapted to the changed ability to interact with MHC-I in *trans* as well without a measurable reduction of MHC-I expression (data not shown), strongly suggesting that *trans* interactions are required for the observed retuning.

In the clinic, NK cells from haplo-identical (partly HLA-I mismatched) donors either as mature NK cells or as HSCs, are experimentally used to treat patients with several blood-borne cancers, such as acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS). However, variable success rates have been reported. Some studies describe a beneficial effect when patients lack the HLA-I (KIR-ligand) for the donor's inhibitory KIRs [333, 340, 343, 346, 348, 365], while others see no such effects [377-379]. Differences in conditioning regimen, T cell depletion or immunosuppressive treatment may influence the net signaling threshold of educated donor cells which could provide an explanation for the differences in observed outcome. Furthermore, a difference in residual disease of different patients could have an impact on the killing capacity of transferred NK cells. The data from tumor outgrowth experiments, (paper I, table I) indicate that the increased net signaling threshold also affects tumor rejection. Treatment with anti-Ly49C/I antibody increased killing of the MHC-I⁺ tumor cells (paper I, table I and [356, 358]). We interpret this as a result of reduced inhibition at the effector-target interaction phase where the tumor cells are not able to inhibit the NK cells from killing and fewer mice develop tumors. As described previously, killing of MHC-I⁻ tumor cells was not affected (Paper I, Figs. 1, 3, 4). However, when we challenged the system with a higher dose of MHC-I tumor cells, more mice in the group that received the anti-Ly49C/I treatment developed MHC-I tumors (paper I, table 1). This suggests that missing self-rejection of tumor cells is also affected, as the net signaling threshold of blocked NK cells is increased. Our results show that the window where the treatment is beneficial might be narrow, which could explain the divergent outcome in clinical studies. To increase the positive effects of antibody blockade, we suggest discontinuous treatment so that NK cells will have the time to set their net activation threshold back to default and be able to respond efficiently to MHC-I tumor cells. Furthermore, combining inhibitory receptor blockade with another treatment, such as immune-modulating cytokines or other mAbs specific for tumor

antigens, or adoptive transfer of donor NK cells might be successful. In fact, the study performed by Ardolino et. al. could recently show that the hypo-responsiveness induced by MHC-I tumors could be reversed by treatment with IL-2 or IL-12 and IL-18 [372]. Furthermore, in clinical trials for treatments of a broad range of solid and hematological tumors, the anti-KIR antibody lirilumab is tested in combination with several other anti-cancer drugs. These drugs include the newly approved anti-PD-1 mAb, anti-CTLA-4, an anti-SLAMF7 mab, the anti-CD20 mAb, and the demethylating agent 5-azacytidine (clinicaltrials.gov, as of 2016-05-05). Combining anti-KIR blockade with a mAb against the neo-antigen GD2, has already given promising results in the treatment of neuroblastoma. To improve therapy with adoptively transferred NK cells, we suggest similar strategies to enhance NK cell functions and to counter-act the adaptation processes. Pre-treatment with cytokines before transfer (e.g. IL-2 or IL-15), and *in vivo* activation with IL-15 are being used recently. It will be interesting to see the developments in the field in the coming years.

Taken together, our data in paper I demonstrate that retuning of MHC-I dependent education of mature NK cells can be achieved in both directions. We can furthermore show that despite induction of tolerance towards healthy MHC-I cells, tumor cells representing the same missing self phenotype are efficiently rejected. We suggest that this is because tumor cells, due to their higher expression of activating ligands, overcome the net activation threshold of NK cells even after retuning.

3.2 DNAM-1 IN EDUCATION OF NK CELLS

DNAM-1 is expressed on NK cells, T cells, DCs, monocytes and a subset of B cells [181]. It binds to CD155 and CD112, which are broadly expressed by hematopoietic, epithelial and endothelial cells [189, 190], upregulated on some tumor cells [380, 381] and modulated in response to infection [329, 382]. DNAM-1 contributes to various innate and adaptive immune responses, which include lymphocyte migration, activation, proliferation and differentiation of NK and T cells and polarization towards the Th1 type of CD4 T cells [181, 187, 194, 383, 384]. A physical and functional association with LFA-1 has been reported [185, 187, 385, 386], with a coordinated expression of DNAM-1 and LFA-1 in educated human NK cells [386]. Previous reports established that DNAM-1^{high} NK cells can produce more IFN γ , degranulate more upon stimulation and are superior in killing CD155-bearing tumor target cells [239, 386, 387]. Additionally, DNAM-1⁺ NK cells respond better to IL-15 stimulation and express genes involved in cell cycle and survival [387]. Most of these traits have been associated with educated NK cells [157, 223, 224]. Furthermore, in humans, where all NK cells are all positive for DNAM-1, educated NK cells have higher levels of DNAM-1 [216, 386]. Based on these observations, we sought to determine a possible role of DNAM-1 in NK cell education.

Based on the hypothesis that DNAM-1 is connected to NK cell education, we started with three predictions which we could test using different strains of mice and looking at different NK cell subsets based on inhibitory receptor expression. In contrast to human NK cells, NK

cells in laboratory mice have a bimodal expression of DNAM-1, resulting in DNAM-1⁺ and DNAM-1⁻ NK cells. For this reason, we assessed both the frequency of DNAM-1⁺ NK cells, and the average expression level of DNAM-1 on NK cells that were positive for DNAM-1 (measured as DNAM-1 MFI). The two parameters correlated in all mouse strains with different combinations of MHC-I alleles (paper II, Suppl. Fig. 1).

The first prediction was that DNAM-1 should be higher in wt B6 mice and lower when mice lacked MHC-I surface expression. Indeed, in B6 wt mice, about 60% of NK cells express DNAM-1, while in $\beta_2m^{-/-}$, TAP-1^{-/-} and K^{b/-}D^{b/-} only 35-45% of NK cells are positive for DNAM-1 (paper II, Fig. 1 and data not shown). The second prediction was that expression of DNAM-1 should correlate to the educating impact of specific MHC-I alleles. Individual MHC-I alleles educate NK cells to different degrees, which results in different strength of responsiveness *in vitro* as well as of rejection capacity *in vivo* of cells that lack the particular MHC-I molecule [92, 284]. The educating impact correlates to differential binding strength and affinity between inhibitory receptors and the respective MHC-I ligand [249, 283, 284]. Indeed, the frequency of DNAM-1⁺ NK cells, and the DNAM-1 MFI of DNAM-1⁺ NK cells correlated positively with the educating impact of the particular MHC-I allele (paper II, Fig. 1) in a panel of mouse strains expressing one single MHC class I gene.

The third prediction was that DNAM-1 should be higher on NK cells that can bind to MHC-I versus NK cells that do not express an inhibitory receptor for self-MHC-I within the same mouse, and NK cells with several self-specific inhibitory receptors should have more DNAM-1 than NK cells with one receptor. We tested this by studying different NK cell subsets based on the expression of inhibitory Ly49rs and NKG2A in mice with different MHC-I alleles. In accordance with our prediction, in all mouse strains, NK cells expressing self-specific inhibitory receptors had higher levels of DNAM-1. The highest levels of DNAM-1 were observed on NK cells expressing NKG2A, as described previously [239]. For NKG2A⁻ NK cells, the more Ly49rs were expressed, the more DNAM-1⁺ NK cells were within that subset. In accordance to our prediction, NK cells with self-specific Ly49rs had higher levels of DNAM-1 in all mouse strains (paper II, Fig. 2 and Suppl. Fig. 2). NK cells with two self-MHC-I-specific Ly49rs had higher DNAM-1 levels than NK cells expressing either of the two Ly49rs alone, i.e. Ly49C⁺Ly49I⁺ NK cells had more DNAM-1⁺ cells than Ly49C⁺ or Ly49I⁺ cells in a B6 mouse (paper II, Fig. 2A) and Ly49A⁺Ly49G₂⁺ cells than Ly49A⁺ or Ly49G₂⁺ NK cells in a D^d-single mouse (data not shown). This was true also when NK cells were divided based on the number of inhibitory Ly49rs (paper II, Fig. 3), most likely because with increasing number of receptors, the chance of expressing one that educates also increases.

Furthermore, we could show that DNAM-1⁺ NK cells can detect the absence of MHC-I on tumor target cells and can perform missing self-reactions *in vitro* (paper II, Fig. 5). This could simply indicate that DNAM-1 is involved in tumor cell recognition and killing, however, we could show that the MHC-I⁺ and MHC-I⁻ tumor cells used have low and similar levels of CD155 and do not express CD112 (paper II, Suppl. Fig. 5). This is in line with recently

published results showing that even target cells devoid of any known DNAM-1 ligands are killed better by the DNAM-1^{high} human NK cells and indicates that DNAM-1 may serve as an intrinsic sensor for cytotoxic potential of NK cells [386].

We furthermore found that DNAM-1 expression is an early event during NK cell development, which precedes expression of NKG2A, the earliest NK cell inhibitory receptor expressed, and that the expression levels decrease upon NK cell development (paper II, Fig. 7). This is in line with a recent study showing that DNAM-1 expression decreases upon NK cell maturation [387]. However, DNAM-1 does not only appear early, the expression is also the same in MHC-I⁺ and MHC-I⁻ mice early in life (data not shown), and is then calibrated to the levels seen in adult mice after the onset of Ly49r expression, again suggesting a link between DNAM-1 and education. In addition, the expression levels are re-calibrated to the levels seen in the host after adoptive transfer of mature splenic NK cells. In our transfer experiments we could see down-regulation of DNAM-1 when mature educated NK (Ly49C⁺ or Ly49I⁺) cells were transferred to $\beta_2m^{-/-}$ recipients, but not when transferred to syngeneic MHC-I⁺ mice. Uneducated NK cells from $\beta_2m^{-/-}$ mice, on the other hand, up-regulated DNAM-1 slightly when transferred to an environment expressing MHC-I (paper II, Fig. 8 and Suppl. Fig. 7). It has been shown that DNAM-1⁻ NK cells develop from DNAM-1⁺ NK cells when transferred into lymphopenic hosts, but not vice versa [387]. Furthermore, DNAM-1 is not essential for maturation [192, 239, 387]. Whether it is required in order to become educated has not been tested so far. NK cell education is tunable and can be changed even in mature NK cells [283, 289, 297, 363, 364]. To test the possibility that interactions via DNAM-1 are constantly needed to maintain the educated state, we blocked DNAM-1 for 2 days or 2 weeks, and then challenged NK cells with MHC-I target spleen cells to assess killing due to missing self recognition. DNAM-1 blockade had no effect on missing self responses, even though complete blockade was achieved (paper II, Fig. 6 and Suppl. Fig. 6), showing that DNAM-1 is not needed to sustain education. Furthermore, this result shows that DNAM-1 is not involved in killing of MHC-I spleen cells, at least not as a cell surface receptor recognizing cognate ligand. Whether DNAM-1 is necessary to reach the educated state could not be tested with this experiment. For this, the missing self rejection assay would need to be performed with DNAM-1^{-/-} mice, which to my knowledge has not been done.

Three simplistic interpretations

There are at least three possible interpretations of our data offering simplistic models. Firstly, DNAM-1 expression on NK cells may be a prerequisite for education to occur *in vivo*, marking NK cells that are “educate-able”. Secondly, DNAM-1 may be a major functional determinant of education, similar as proposed by Enqvist et. al.[386], i.e. induced by education and required to maintain that state. The third interpretation is that DNAM-1 does not induce or control education, but rather is a down-stream correlate of education. According to this interpretation, expression of DNAM-1 could simply be a passive marker for educated NK cells, but it could also endow NK cells with additional features that provide the educated

NK cells with increased functional capabilities, although these are not essential for the educated state (capacity to recognize and eliminate MHC-I-deficient cells) *per se*.

If DNAM-1 is indeed a pre-existing marker for “educate-able” NK cells, DNAM-1 should be present on NK cells before the education process imposed by MHC-I begins, i.e. before NK cells express inhibitory receptors specific for MHC-I. This is indeed what we observed; appearance of DNAM-1 expression is an early event during NK cell development, that precedes expression of the counter-receptor TIGIT as well as NKG2A, the earliest MHC-I-specific NK cell inhibitory receptor expressed. The surface levels then decrease upon NK cell maturation. While this is consistent with the idea that DNAM-1 may be required for NK cell education, the observation that the correlation between education and DNAM-1 expression is not absolute argues against this interpretation. Additionally, in humans all NK cells express DNAM-1, but not all NK cells are educated [216, 386].

The second possibility is that the DNAM-1 level is what makes NK cells more capable of detecting and reacting to lack of MHC-I on otherwise normal cells, i.e. act as “educated” by MHC-I. DNAM-1 might for example function in educated NK cells by inducing a tight attachment to a target cell and delivering an activating signal. This would be necessary for NK cells to scan a potential target cell for the presence of self-MHC-I. Our data on adoptively transferred mature NK cells lend some support to this interpretation, since DNAM-1 expression was indeed reversible according to the inhibitory input on individual cells, which could indicate that DNAM-1 is in fact what defines and maintains education. However, this model would predict induction of DNAM-1 expression as a result of education, i.e. after expression of Ly49rs during development in the bone marrow. The very early expression of DNAM-1 in developing NK cells that we observed thus argues against this interpretation. Furthermore our results with blockade of DNAM-1 *in vivo* argue against DNAM-1 as being the deterministic molecule for NK cell education, at least in a model where cognate interactions involving cell surface DNAM-1 would be required to allow NK cells attack of MHC-I-deficient target cells, or to maintain education. Finally, we note that if DNAM-1 were the functional determinant, then all educated NK cells should express DNAM-1. However, within the NK cell subsets carrying a self-specific Ly49r, there was always a population that was DNAM-1⁻.

The third interpretation is that DNAM-1 is a down-stream consequence of education rather than a functional requirement. Again, the very early onset of DNAM-1 expression during NK cell development argues against this. The fact that DNAM-1 is expressed on NK cells of mice deficient for MHC-I^{-/-}, $\beta_2m^{-/-}$ or TAP-1^{-/-}, is also difficult to reconcile with this possibility, but it is intriguing that all NK cell subsets in these mice express lower levels of DNAM-1 and that the preferential expression on certain Ly49r-positive subsets is abolished. It could still be so that all NK cells express a certain baseline level of DNAM-1, whether they are educated via MHC-I or not, and the education process adds to that via interactions with MHC-I and signaling through Ly49rs. Alternatively, education by non-MHC-I-dependent mechanisms such as 2B4 [138, 267, 304] could account for the baseline levels of DNAM-1 in mice

lacking surface expression of MHC-I or NK cells in wt mice that lack inhibitory Ly49rs for self-MHC-I.

An integrated model

Neither of the simplistic interpretations fits all the data, we therefore propose a model in which DNAM-1 is expressed on NK cells independently of education, and is gradually down-regulated during maturation, although this process is modulated by education. Our data on the early onset of DNAM-1 expression on NK cell precursors before any inhibitory receptors specific for MHC-I are expressed fits with this model, and so does the observation that DNAM-1 levels generally decrease during maturation (paper II, Fig. 7 and [387]). The notion that DNAM-1 is high on “young” NK cells is true during ontogeny (NK cells in young mice), and in developmentally immature NK cells (young NK cells in adult mice). During development and maturation, DNAM-1 levels decrease, and in some instances decrease so much that in mice individual NK cells become DNAM-1⁻. Superimposed on this gradual decline are other events, such as education or infection, that maintain DNAM-1 at higher levels and “rescue” NK cells from losing DNAM-1 expression altogether. The correlation between DNAM-1 expression and NK cell education observed in mouse (paper II) and human [216, 386], is in accordance with this model. So is the observation that DNAM-1 levels increase in response to viral infection [329]. One may even speculate that the reason why all NK cells in humans are DNAM-1⁺ is the many infections that humans are subjected to. To this end, it would be interesting to assess DNAM-1 expression in feral mice, which have been shown to have a more similar immune system to humans than laboratory mice [388]. The assumption that DNAM-1 levels are increased due to constant infections could explain the finding that in human NK cells, it is the more mature CD57⁺ population that has the highest levels of DNAM-1 [386, 389], which is in contrast to the situation in the mouse (paper II, Fig. 7 and [387]).

Education may in some instances even increase DNAM-1 levels. We could observe an increase of DNAM-1 levels in two distinct experimental setups. By staining for maturation markers CD27 and CD11b, we could show that at the transition from the CD27⁻CD11b⁻ to the CD27⁺CD11b⁻ stage, expression of DNAM-1 increases. This could reflect a factual increase in DNAM-1 gene transcription, or it could be so that the CD27⁻CD11b⁻ NK cells transcribe the same amount of DNAM-1 but that it is down-modulated due to interactions with the ligands [381, 390, 391], e.g. during migration to the spleen. Additionally, transfer of mature NK cells from $\beta_2m^{-/-}$ mice to MHC-I⁺ recipients lead to an increase of DNAM-1 levels on DNAM-1⁺ NK cells.

We suggest that DNAM-1 is not a pre-requisite for MHC-I-dependent education to occur, nor is it what defines the educated, responsive state. Rather, DNAM-1 endows NK cells with functional advantages, during different stages of an NK cell’s life. Early in development, it provides immature NK cells with a means to interact with surrounding cells to receive growth and survival and possibly education signals. In paper II, we discuss interactions with DCs, as DCs are important for providing tonic stimuli for NK cells under steady state conditions [63].

However, interactions with other cells in the BM may also be of importance, and DNAM-1 ligands are expressed by many cell types. Furthermore, NK cells may use adhesion via DNAM-1 while they egress from the BM. DNAM-1⁺ cells respond better to IL-15 signaling and express more genes connected to cellular survival [387], both traits may be of importance for developing NK cells.




Figure 2: The gradual decline in DNAM-1 levels is rescued by expression of inhibitory NK cell receptors and interaction with MHC-I. Expression of DNAM-1 is initiated by NK cell precursors in the BM, before the onset of MHC-I-specific inhibitory NK cell receptors. During development, NK cells gradually decrease DNAM-1 levels, which may result in DNAM-1-negative NK cells. NK cells that start to express either NKG2A or inhibitory Ly49rs specific for self-MHC-I are rescued from maturation-induced loss of DNAM-1. Continuous interactions between inhibitory Ly49rs and MHC-I retain DNAM-1 expression and prevent complete loss of DNAM-1. DNAM-1 may be important for NK cell development and beneficial for educated NK cells during distinct maturation stages and in interactions with surrounding cells. Infection with a virus, e.g. MCMV induces expression of DNAM-1 in all NK cell subsets.

In the next step of an NK cells life, DNAM-1 may contribute to interactions with cells that provide educating signals. Many studies report the bi-directional crosstalk between NK cells and DCs, which result in enhanced effector functions of both cell types [35, 63, 311, 313-317]. We speculate that these continuous interactions may be facilitated by adhesion via DNAM-1 and its ligands, and furthermore may provide NK cells with a possibility to interact with MHC-I via their inhibitory receptors. As discussed in paper I, education is now considered to be a continuous process, and frequent interactions with MHC-I⁺ cells are necessary to maintain the educated state.

During effector responses of NK cells, DNAM-1 provides advantages as well. NK cells need to migrate to inflamed tissues and lymph nodes to interact with infected cells and DCs. A role for DNAM-1 and CD155 during monocyte transendothelial migration through endothelial junctions, specifically in the diapedesis step of extravasation has been shown [392]. DNAM-1 and CD155 may take part in the regulation of NK extravasation into the underlying tissues as well, similar as for monocytes. Healthy endothelial and epithelial cells express DNAM-1

ligands [393], which in this context might help the NK cell to migrate to inflamed tissues. Recirculation of leukocytes from blood to lymphoid organs or sites of inflammation is crucial for the induction of inflammatory responses. DNAM-1 may regulate the migration of NK cells, the interaction of NK cells with DCs, and the NK cell-mediated lysis of target cells, depending on the surface expression of MHC-I on the interacting cells. Additionally, DNAM-1 enables NK cells to efficiently dock to ligand-expressing target cells. Many tumor cells and MCMV-infected cells up-regulate DNAM-1 ligands, allowing DNAM-1⁺ NK cells to engage and possibly kill these cells [194, 329, 381, 383, 394-396]. Upregulation of CD155 is mediated by the DNA damage response and induced by therapeutic agents [182, 183, 397], and therefore is expressed by many tumors and acts as a danger signal alerting educated NK cells to cellular stress. In the absence of effective MHC-I inhibition, the engagement of DNAM-1 and other triggering receptors results in induction of cytotoxicity. It has recently been shown that education of NK cells alters the signaling of activating receptors after they have bound to their ligands on target cells [398]. Educated NK cells both in mouse and in human have increased inside-out signaling to LFA-1 upon cross-linking of activating receptor, which increases the frequency of conjugation and the strength of the NK cell adhesion to the target cell [398]. Furthermore, DNAM-1 crosslinking increases inside-out signaling to LFA-1 in T cells [185] and engagement of LFA-1 with ICAM-1 on target cells induces co-localization of DNAM-1 and LFA-1 at the immune synapse independent of expression of DNAM-1 ligands [386]. These data can explain the fact that co-engagement of DNAM-1 and LFA-1 by the ligands expressed on transfected insect cells triggered IFN γ production while expression of either ligand alone had no effects [399]. The synergistic effects of many activating receptors that are required for optimal NK cell activation [131] validate the idea that higher levels of DNAM-1, and other activating receptors and adhesion molecules, can provide educated NK cells with a means to overcome the inhibition mediated by the educating inhibitory receptors.

During infection with MCMV or influenza virus, NK cells without self-specific inhibitory Ly49rs dominate the response and are critical in protection against the respective virus [305, 306]. However, DNAM-1 is essential for optimal differentiation of memory NK cells during MCMV infection [329], thus having high DNAM-1 levels on educated NK cells may be an advantage for protection against secondary infections.

DNAM-1 and NKG2A

A tight correlation between DNAM-1 and NKG2A has been reported before [239], however, by staining for all relevant inhibitory receptors simultaneously, we could detect that almost all NK cells expressing only NKG2A (and no other inhibitory receptor) were positive for DNAM-1 in all MHC-I backgrounds. While this observation fits with our prediction, it was surprising that this correlation was seen in all strains of mice (paper II, Suppl. Fig. 2B). NKG2A is an inhibitory receptor which binds non-classical class Ib MHC-I molecules in complex with leader peptides of certain classical class Ia MHC-I molecules, Qa-1^b in mouse and HLA-E in human [205, 206]. Qa-1^b is predominantly loaded with a QDM-peptide (Qa-1

determinant modifier) from H2-D or H2-L alleles, and NK cells via NKG2A, can discriminate Qa-1^b complexes with substituted peptides [207]. Consequently, in a mouse that lacks H2-D alleles, as in K^b-single or K^b-D^b- mice, Qa-1^b is not correctly loaded. Transfection of TAP-deficient RMA-S cells with a Qa-1^b-QDM construct protects these cells from NK cell attack [400], showing that recognition via NKG2A is sufficient to mediate NK cell inhibition. However, how this affects NK cell education has not been studied. Assuming that DNAM-1 is correlated to education, the observation that expression of NKG2A and DNAM-1 correlate even in the absence of QDM-loaded Qa-1^b indicates that either, the high expression of DNAM-1 on NKG2A⁺ NK cells is independent of education, or that NK cells are educated via NKG2A even when Qa-1^b is loaded with other peptides than QDM. At present, we cannot distinguish between the alternatives and conclude that DNAM-1 expression is connected to NKG2A expression in a manner independent of MHC-I. This is emphasized by the observation that NKG2A is associated with DNAM-1 expression also in NK cells from $\beta_2m^{-/-}$ mice.

CD155 and Dap12

In mice that lack expression of CD155, the main ligand for DNAM-1 and TIGIT, DNAM-1 expression is slightly elevated. However, the pattern of DNAM-1 expression does not change, still the highest levels of DNAM-1 cells are found within the Ly49C⁺ and/or Ly49I⁺ subsets, when NKG2A-positive NK cells are excluded. The frequencies of DNAM-1⁺ NK cells were only marginally elevated, showing a deviation from the correlation between frequency of DNAM-1⁺ cells and MFI of DNAM-1⁺ that we observed for all strains of mice that differed only in MHC-I expression (paper II, Suppl. Fig. 1 and manuscript on CD155^{-/-} NK cells in preparation). Interaction between DNAM-1 and CD155 on other cells leads to down-regulation of DNAM-1 [381, 396] and this seems to be the reason for the increase in DNAM-1 levels in CD155^{-/-} mice [401]. Interestingly, another exception from the observation (paper II, Suppl. Fig. 1) was seen in DAP12^{-/-} mice, where the frequencies of DNAM-1⁺ NK cells were elevated (paper II, Suppl. Fig. 3D), while the average expression level was not (data not shown). This supports our tentative conclusion that signaling by other activating receptors, such as Ly49D, may decrease the number of NK cells expressing DNAM-1 by counteracting the inhibitory signals during education. The DAP12^{-/-} mice used in this study express a DAP12 with mutated ITAM which is signaling deficient, therefore Ly49D is expressed but the activating signals is not transmitted. In paper II we are quite cautious about this finding, as the DAP12^{-/-} mice are on H-2^b background. There is only one study showing that Ly49D binds to an MHC-I molecule in this background, and that was done using non-glycosylated Ly49D [402]. Other than that there is no published evidence that D^b can serve as a ligand for Ly49D. However, this study and other unpublished results of our group argue for an interaction between Ly49D and D^b, albeit weaker than that of Ly49D with D^d. In paper II we propose that DNAM-1 levels are up-regulated by education via inhibitory Ly49rs. Further assuming that signals from activating receptors contribute to education by decreasing the net signaling threshold of NK cells, one can hypothesize that activating receptor signaling decreases DNAM-1 levels. The finding that NKG2D^{-/-}NKp46^{-/-} double

knockout mice [403] and DAP12^{-/-} mice (paper II, Suppl. Fig. 4D) have elevated frequencies of DNAM-1⁺ NK cells lend some support to tuning of DNAM-1 levels by education.

The DNAM-1-TIGIT-CD96-CD155-CD112 network

Two additional adhesion molecules, CD96 and the inhibitory molecule TIGIT, are both expressed on NK and T cells and also bind to CD155 [404-407]. The receptors TIGIT and CD96 which bind to the same ligands as DNAM-1 but with distinct affinities could aid in fine-tuning NK cells responses reminiscent of the CD28-CTLA-4-CD80-CD86 network, which tightly regulates activation of T cells and thus ensures T cell activation only under appropriate circumstances [408]. TIGIT exerts inhibitory functions on NK cells by limiting granule polarization and thereby inhibiting the cytotoxicity against CD155-expressing target cells [405, 409, 410]. In addition, the phosphatases SHP-1, SHP-2 and SHIP-1 can be recruited by an ITIM in the cytoplasmic domain of TIGIT and contribute to inhibition of effector responses [409, 410]. For CD96 both activating and inhibitory functions have been described [410, 411], and in CD96^{-/-} mice it has been shown that CD96 limits NK cell function competing with DNAM-1 for binding of CD155 [412]. When we analyzed CD96 and TIGIT on NK cells, we found that CD96 is expressed at similar levels on all NK cell subsets, and that TIGIT expression is inversely regulated to that of DNAM-1, with the highest levels on NK cells that express neither Ly49 inhibitory receptors nor NKG2A and similarly, higher levels in MHC-I-deficient mice than wt B6 mice (data not shown). The higher levels of DNAM-1 and lower levels of TIGIT on educated NK cells, combined with constant levels of CD96, may be a means to regulate effector functions of educated NK cells. The DNAM-1-TIGIT-CD96-CD155-CD112 network of positive and negative signaling receptors might regulate the threshold of NK cell activation and may thus be involved in maintenance of tolerance to self, while allowing for vigorous effector functions against infected or transformed cells [412]. It therefore does not seem astonishing that several groups could show that inhibitory interactions between TIGIT and CD155/CD112, very much like inhibitory Ly49 receptor interaction with MHC-I are dominant over the combined activating potential of the activating receptors including DNAM-1 [404, 405]. In cases of paired receptors sharing the same ligands, often the inhibitory receptor has a higher affinity for the shared ligand which implies that the activating receptor needs to out-compete the inhibitory receptor to signal. Blocking immune checkpoints with mAbs is proving successful as therapies against multiple types of cancers. Similarly, blocking the inhibitory interaction of CD96 with CD155 leads to increased anti-tumor responses of NK cells in a mouse model [412, 413]. Combination of anti-CD96 with anti-PD-1 has shown even greater responses in controlling lung metastasis [413]. Upregulation of DNAM-1 ligands by genotoxic drugs or irradiation therapy, combined with checkpoint blockade, e.g. anti-PD-1 or anti-KIR or possibly anti-CD96 may increase NK cell responses and reactivity against human tumors.

3.3 SURFACE RECEPTORS THAT CHANGE UPON RETUNING

In paper I, we employed several experimental models for retuning of NK cells. This allowed us to search for surface markers that would change during the re-tuning process, i.e. markers

that might be used to distinguish educated from hyporesponsive NK cells. Which changes occur during education are to date not known. How does education work at the molecular and mechanistic level? What are the molecular changes? What has been observed so far are very subtle changes, e.g. down-regulation of Ly49 per-cell-levels in the presence of the cognate MHC-I, small increases of those NK cell subsets that express only the particular Ly49r specific for self MHC-I, a general increase of cells expressing 1-2 and a decrease in cells expressing 3 or more inhibitory receptors. While these subtle differences may explain how the frequency of “potentially useful” NK cells increases, they do not explain what is so fundamentally different between an educated and a hypo-responsive NK cell. Several groups, including my own, have tried to determine changes in expression of genes on a global level, using microarrays to quantify mRNA. Most of these studies were inconclusive, which suggests that the difference may not be a matter of expression level of molecules, but rather their localization within the cell or within the cell membrane. Cell surfaces are compartmentalized into distinct regions, which differ in membrane composition. Some of these regions, so called membrane-rafts, attract specific proteins which results in signaling clusters. In fact, one group recently showed that the distribution of activating receptors is different, and that on non-MHC-I-educated NK cells, activating receptors are confined together with inhibitory receptors. In educated NK cells on the other hand, the activating receptors became dynamically compartmentalized in functional microdomains [414]. Furthermore, signaling via inhibitory KIRs leads to dissociation of the small adaptor protein Crk from cytoskeletal scaffold complexes, which enables subsequent activation events by activating receptors [202]. A possible conclusion from these and other studies is that education does not change the amount of certain receptors or adaptors, but rather the localization or availability or signaling complexes. Furthermore, education appears to induce changes that are close to the membrane, as changes in responsiveness induce alterations in the phosphorylation state of signaling molecules Akt and Erk [372].

There is no one single molecular marker that can be used to distinguish educated from non-educated NK cells. By stimulating NK cells *in vitro* with plate-bound mAb or tumor cells, and staining for inhibitory receptors in addition to the degranulation marker CD107 and intracellular cytokines, e.g. IFN γ , we can determine which cells are more responsive and can correlate this to the MHC-I alleles these NK cells have been educated against [415]. This knowledge can then be transferred to different situations, where we assess another marker, in my case DNAM-1 or KLRG1, together with inhibitory receptors in different mouse strains with known MHC-I expression. This approach allows the researcher to correlate markers with NK cell education. But it does not provide an answer as to the reason for the correlation, not to mention the possible mechanism. Finding such a molecular marker for educated NK cells would enable clinicians to sort and enrich these cells before using them in therapeutic approaches.

Of all surface markers we assessed, only expression of KLRG1 changed in all three settings in which we observed an adaptation of responsiveness. The surface expression of KLRG1 was reduced after blockade of inhibitory receptors (paper I, Fig. 2D-E) and after transfer of

B6 NK cells to $\beta_2m^{-/-}$ mice, while it was increased after transfer of $\beta_2m^{-/-}$ NK cells to an MHC-I⁺ environment (paper I, Fig. 5C-D). This was detectable as an increase in NK cells that expressed KLRG1 (frequency of KLRG1⁺ NK cells), and as an increase of average expression per cell (MFI). Furthermore, in the transfer settings, NKG2D surface levels were increased when NK cells gained responsiveness, and decreased when tolerance was induced (paper I, Fig. 5A-B). This could be seen only when MFI was analyzed, as still most NK cells were positive for NKG2D. Additionally, the surface expression of DNAM-1 behaved in a similar way after transfer in both directions (paper II, Fig. 8). The change in surface levels were marginal, but we could see an increase in average DNAM-1 levels per cells (MFI) when $\beta_2m^{-/-}$ NK cells were placed into an MHC-I⁺ environment and a decrease when the cognate MHC-I interaction was removed, which, similar to KLRG1, suggests that the cells expressing the respective marker adjust the levels of it.

KLRG1 and DNAM-1 are both adhesion molecules expressed by 50-60% of NK cells in wt B6 mice. While DNAM-1 is activating, KLRG1 has an ITIM in the cytoplasmic domain that can transmit an inhibitory signal upon engagement. However, due to the low affinity of KLRG1 to its ligands, it has been suggested that physiological levels of KLRG1 are not sufficient for inhibition [277]. The higher level observed on educated NK cells could therefore have a functional impact. DNAM-1 is expressed early during NK cell development, and the levels decrease during maturation ([387] and paper II). KLRG1 expression on the other hand, is initiated on terminally mature cells [130]. While both molecules are induced upon infection with MCMV [270, 271, 329], presence of DNAM-1 but absence of KLRG1 are beneficial for generation of MCMV-specific memory cells [329, 331]. Despite these opposing functions of the two markers, they are both preferentially expressed by educated NK cells (paper I, paper II and [157, 216, 278, 386]). One hypothesis is that it is primarily their function as adhesion molecules, and secondarily the activating/inhibitory function, that endows educated NK cells with a functional advantage. The ligands for both adhesion molecules are expressed on many cell types, including hematopoietic cells, which could provide educated NK cells with a means for interaction with surrounding cells.

3.4 NK CELL-MEDIATED KILLING OF DENDRITIC CELLS AND THE IMPACT OF PAIRED RECEPTORS

Education provides NK cells with a means to strongly react to dangerous and non-self cells, while at the same time robust tolerance to healthy self cells is achieved. One exception is the interaction with autologous DCs. NK cells can bi-directionally communicate with DCs, which can lead to an increase in the function of both cell types, but can also result in killing of the DC [32, 35, 63, 312-314, 316, 317, 416-418]. DCs produce cytokines such as IL-12 and IL-15 that are important for NK cell development and function [63, 417], and activated NK cells can secrete GM-CSF, TNF α and IFN γ cytokines which affect differentiation and maturation of DCs under inflammatory conditions [419]. Furthermore, NK cells can kill DCs in certain situations, which may help to modulate adaptive immune responses. It was proposed that during an infection, NK cells kill some DCs to select for those DC with the

propensity for potent stimulation of T cells and NK cells [311]. This model was later termed DC editing [418]. Most studies that have investigated the NK cell-mediated killing or activation of DCs involved DCs generated under inflammatory conditions [309, 314, 382, 420] or NK cells activated by MHC-I- deficient cells [421, 422]. It is still unclear which NK cell subsets are involved in the DC editing effect, although involvement of NKG2A⁺KIR⁻ or DNAM-1⁺NK cells has been suggested [314, 423]. Both cell-to-cell interactions and various cytokines released by both cell types have been suggested to play a role during the early phases of innate immune responses [314].

In paper III we have investigated the effect of inflammatory conditions on the sensitivity of DCs to NK-mediated killing. We could show that DCs generated from BM (BMDC) in the presence of Flt3L or isolated from mouse spleen were relatively resistant to NK cell-mediated cytotoxicity. However, DCs became more susceptible in the presence of the inflammatory cytokine GM-CSF both *in vitro* and *in vivo* (paper III, Figs. 1+2). GM-CSF is produced by NK cells upon stimulation with IL-18, and this is partly responsible for the increase in sensitivity of DCs. Culture of DCs with GM-CSF, or treatment of mice with IL-18, resulted in an increase in the surface markers ICAM-1 (CD54), CD80, CD86, PD-L1 and the DNAM-1-ligands CD112 and CD155 (paper III, Fig. 3). Classical and non-classical MHC-I molecules and CD40 were also slightly up-regulated. In an attempt to find the receptor-ligand interactions that are responsible for the observed increase in susceptibility, we used knock-out mice for CD80, CD86, PD-1, CD112 or CD155 for generation of BMDCs, or blocked CD40, ICAM-1 or PD-L1 during the *in vitro* killing assay. A reduction in NK-mediated killing of the DCs was observed only in two situations; firstly, when interactions of ICAM-1 on DCs with LFA-1 on NK cells were blocked, and secondly, when DNAM-1 on NK cells was blocked from binding to its ligands on DCs (paper III, Fig. 5). Further we could show that it is a specialized subset of NK cells, expressing DNAM-1 but not NKG2A, which is superior in killing DCs. However, CD155^{-/-} BMDCs were even more susceptible to killing by NK cells (paper III, Fig. 5).

These data suggest that under inflammatory conditions, such as in the presence of GM-CSF or IL-18, expression of CD155 and ICAM-1 are induced on DCs which makes them more vulnerable to NK cell attack. It has been previously hypothesized, that NK cell killing of DCs is a way of terminating an inflammatory response induced by DCs [311, 418, 421]. Along these lines, it has been shown that also IFN γ and TNF α produced by NK cells can cause up-regulation of ICAM-1 and induce conjugate formation and target cell cytolysis [424]. In support of this, GM-CSF has been used in combination therapy together with the anti-GD2 mAb (dinutuximab) in a phase II clinical trial for neuroblastoma [425, 426].

Previous studies have mainly focused on inflammatory DCs [309, 314, 382, 420]. Our study shows that BMDCs generated under non-inflammatory conditions or isolated from mouse spleen, are relatively resistant to NK cell killing, and that the levels of ligands for both activating and inhibitory receptors are lower. Once DCs are matured, and NK cells activated, the balance of activating and inhibitory ligands is shifted and the expression of activating

receptors (such as DNAM-1) and inhibitory receptors (such as NKG2A) determines the outcome of that interaction. It is noteworthy, that the DNAM-1⁺NKG2A⁻ NK cell subset represent a small percentage of NK cells, probably because expression of NKG2A appears to maintain high levels of DNAM-1 (paper II). However, this subset is efficient in killing, as it is not inhibited by non-classical MHC-I, which is also higher on DCs in inflammation (paper III, Fig. 5).

Similar to DNAM-1⁺ mouse NK cells, DNAM-1⁺ human NK cells are involved in killing of human monocyte-derived DCs [314, 382, 420]. Furthermore, killing of pDCs has been shown to depend on expression of CD155, but not CD112 [314], which is similar to our results showing that CD112 does not play a role in NK cell-mediated killing of DCs. During HCMV infection, DNAM-1 ligands and HLA-E are reduced over time, making these cells more susceptible to DNAM-1⁻NKG2A⁺ NK cells [382]. In contrast, a mouse study shows that both CD155 and CD112 are rapidly upregulated on infected DCs and macrophages upon infection with MCMV [329]. Additionally, it has been shown that anti-DNAM-1 could inhibit CD86 upregulation on DCs, and simultaneous inhibition of NKp30 and DNAM-1 completely abrogated maturation of human DCs [309]. It is therefore reasonable to assume that both in mouse and man, different subsets of NK cells play a role both in controlling DCs and in providing maturation stimuli at different time-points during an inflammation.

NK cells with inhibitory receptors specific for MHC-I can detect DCs which, during an immune response or under homeostatic conditions, do not reach sufficient levels of MHC-I expression. NK cells could favor DCs that have high levels of MHC-I but also co-stimulatory receptor ligands and are thus good for T and NK cell priming and eliminate those that fail to undergo maturation [311, 421, 423]. This of course requires that the NK cells have inhibitory receptors able to recognize autologous MHC-I, which we could show in paper II is correlated to expression of DNAM-1. Additionally, NK cells with Ly49r for self-MHC-I have higher levels other adhesion molecules, such as KLRG1 (paper I and [157]). The ligands, cadherins are expressed by DCs and may contribute to binding to NK cells and some T cell subsets that express KLRG1. Expression of MHC-I-specific inhibitory receptors and DNAM-1 enables NK cells to mediate the “editing program”. We could show that DNAM-1⁺NKG2A⁻ NK cells are superior in killing DCs under inflammatory conditions (paper III, Fig. 5). However, when we tested killing of non-inflammatory DCs, we hardly observed any killing by this subset (unpublished results). DCs provide tonic stimuli needed to keep NK cells in a primed state [63] and Luu et al, manuscript submitted), possibly even providing NK cells with the opportunity to interact with MHC-I⁺ cells to maintain education.

These data together with our findings that DCs were killed under inflammatory but not non-inflammatory conditions could be interpreted in such a way that in the absence of inflammation, there are interactions of the two cell types which do not result in killing of DC, but rather in a productive communication between DCs and NK cells which may result in enhancement of functions of both cell types such as education of NK cells. A recent report has shown that DNAM-1⁺ NK cells respond better to IL-15 signaling and express more cell-

cycle and survival-related genes [387]. The lower IL-15 reactivity of DNAM-1⁻ NK cells might be a result of insufficient crosstalk between NK cells and DCs.

DCs generated from CD155^{-/-} BM were killed better by NK cells. This result was at first surprising, but can be explained by the complex nature of paired receptors that share the same ligands [427]. Besides DNAM-1, NK cells have two additional receptors that can recognize CD155, the inhibitory receptor TIGIT and CD96, for which both activating and inhibitory functions have been described [405, 410-412]. CD155 and CD112 are up-regulated on many tumor cells [189, 428], and it has been shown that the interaction of DNAM-1 with its ligands leads to destruction of the target cell, but on the other hand both molecules are expressed on healthy epithelial or endothelial cells and cells of the hematopoietic lineages. It would be detrimental should NK cell attack these normal healthy cells. It therefore does not seem astonishing that several groups could show that inhibitory interactions between TIGIT and CD155/CD112, very much like inhibitory Ly49 receptor interaction with MHC-I are dominant over the combined activating potential of the activating receptors including DNAM-1 and CD96 [404, 405, 410]. The DNAM-1-TIGIT-CD96-CD155-CD112 network of positive and negative signaling receptors might regulate the threshold of NK cell activation and may thus be involved in maintenance of tolerance to DCs under steady state conditions, while allowing for vigorous effector functions against DCs under inflammatory conditions [412]. This system may provide NK cells with a means of appropriate self-tolerance before the regulation by MHC-I-specific activating and inhibitory receptors during development. Our data on the early expression of DNAM-1, TIGIT (paper II, Fig. 7) and CD96 (manuscript in preparation) supports this hypothesis.

Fascinatingly, of the molecules that were increased on GM-CSF-treated DCs, only ICAM-1 and CD155 appeared to play a role in NK cell-mediated killing of inflammatory DCs. ICAM-1 is recognized by LFA-1, and this interaction is necessary for polarization of cytotoxic granules when NK cells interact with target cells [429]. LFA-1 and DNAM-1 are physically and functionally associated in lipid rafts [185-187] and engagement of LFA-1 and subsequent inside-out signaling recruits DNAM-1 to the immunological synapse and this is increased when both LFA-1 and DNAM-1 are engaged with ligands on the target cell [386]. Furthermore, educated NK cells are more prone to recruitment of DNAM-1 and activation-induced conformational changes of LFA-1 upon encounter with a target cell [386].

The bi-directional crosstalk between NK cells and DCs, which can result in increase of functions of both cell types, and in a selection for Th1-promoting DCs, should be taken into account for cell-based therapies. Moreover, studies in mice show that mature DCs could induce a Th1 polarization during the early phase of T cell priming which is defective in NK-deficient infection models [35, 430, 431].

Both NK cells and DCs are used in the clinic as cellular therapy for treatment of leukemia and solid tumors. It has been shown that in haplo-identical HSCT, donor NK cells kill the patient's DCs, thereby preventing the development of GvHD [333]. Additionally, DNAM-1⁺ NK cells can lyse activated T cells which express high levels of CD155 in response to

proliferation, thereby limiting GvHD [183]. This effect could be even mediated by autologous DNAM-1⁺NKG2A⁻ or DNAM-1⁺Ly49r⁻ NK cells, as they are not inhibited by the expression of MHC-I on DCs or T cells. The interactions between the two cell types could also have an impact on transferred DCs generated *ex vivo*. Different clinical centers use different protocols to generate and activate the DCs. Our results in paper II demonstrate that the *in vitro* culture conditions have a profound impact on the outcome of the interaction.

Inflammatory conditions may influence NK cell immune surveillance. NK cells react upon infection with many pathogens, and kill cells with low or no MHC-I. It is however less clear how NK cells react to developing tumor cells. At the beginning of tumor development, NK cells most likely kill most cells with aberrant MHC-I expression. But once the number of MHC-I- cells overwhelms NK cells, they seem to become retuned and functionally impaired to kill MHC-I- tumor cells [372]. Acute inflammation as in MCMV infection, can revert anergy and break tolerance towards MHC-I- deficient cells [303]. The low levels of inflammation within many tumors may therefore diminish NK cell responses. On the other hand, it has been suggested that low grade inflammation is a driver for tumor development, but it has not been studied how this affects NK cells. Initiation of an inflammatory response may alert NK cells to the imminent danger of transformed cells. The differential expression of DNAM-1 and inhibitory receptors for MHC-I may ensure responsiveness under inflammatory conditions.

3.5 EXOSOMES AS ANTI-CANCER VACCINE

DCs regulate NK cell functions via cell-cell contacts and by release of cytokines and chemokines. In addition, DCs can secrete exosomes, 30-100 nm small vesicles consisting of a lipid bilayer that derive from multivesicular bodies (MVB) within the late endosomal compartment. In this thesis exosomes were used to study NK cell responses induced by stimulation of iNKT cells using α GalCer. Activation of iNKT cells by soluble α GalCer has been used successfully in mouse studies and clinical trials for cancer [25, 26]. However, iNKT cells become anergic after the first treatment with α GalCer, while α GalCer-loaded exosomes do not induce iNKT cell anergy [432]. Exosomes are shed from different cell types, such as DCs, B cells, mast cells, platelets, erythrocytes, and tumor cells during physiological and pathological conditions. The composition of lipids and membrane-proteins depends on the cell type which secretes the vesicle. Exosomes also contain mRNA and microRNA molecules and cytosolic proteins, which after fusion with another cell, can immediately regulate transcription of different genes.

Exosomes usually contain a narrow range of different proteins and lipids, which suggests a non-random enrichment and loading into the exosome [433]. The surface proteins of exosomes can mediate co-activation, antigen-presentation, adhesion and fusion to other cells and are usually enriched in components necessary to present antigens, such as MHC-I, MHC-II and CD1. They were originally described as a mechanism for reticulocytes to release proteins that were no longer required. An immune modulating role has later been appreciated

with the discovery that APC-derived exosomes activate other cells and even can be taken up by other cells. On the other hand, exosomes released by tumor cells can suppress T cells and NK cells and promote a general immune-suppressive environment by enrichment of suppressive factors [433, 434].

Using DC-derived exosomes without additional antigen-loading in a mouse model, tumor growth could be suppressed and established tumors were eradicated [435]. After this first success, DC-derived exosomes were specifically loaded with tumor-specific antigens, e.g. MAGE, which is expressed on many melanoma cells and by other tumors. These exosomes elicited partial responses in phase I studies for melanoma and non-small cell lung cancer [436, 437]. Importantly, while no antigen-specific T cells could be detected, NK cell infiltration into the tumor and activation of NK cells with increased *in vitro* responses towards tumor targets could be observed [436, 437]. Assessment of surface molecules of DC-derived exosomes revealed the presence of IL-15R α on exosomes from both human and mouse DCs, which stimulated NK cell proliferation [438]. Furthermore, ligands for the activating receptor NKG2D were detected on human DC-derived exosomes. Soluble ligands for NKG2D have been proposed to desensitize NKG2D on NK cells, but when presented in the context of an exosomal membrane, NK cells were activated via NKG2D [438].

In an experimental approach aiming to modulate exosome composition, mouse DCs have been cultured in the presence of peptide and α GalCer. Exosomes harvested from these cultures have the potential to stimulate antigen-specific T cell responses and activate iNKT cells via α GalCer presented on CD1d *in vivo*. Treatment of mice with exosomes loaded with both the peptide and α GalCer have been shown to elicit B and T cell responses superior to those after simultaneous treatment with exosomes loaded with either peptide or α GalCer, showing that the immunogenicity of DC-derived exosomes can be further enhanced when several cell types are targeted simultaneously [432].

In paper IV we addressed NK cell activation after treatment of mice with α GalCer, either soluble or exosome-bound. The exosomes we used were loaded with α GalCer to activate iNKT cells and the model peptide antigen OVA to provide stimulation for T cells. These exosomes were produced similarly to the ones used in the study by Gehrman et al. where synergistic induction of adaptive antitumor responses by co-delivery of peptide antigen and lipid antigen has been demonstrated [432]. The tumor used in that study, B16/OVA stably expresses the antigen and can thereby be recognized by OVA-specific T cells. However, since B16 naturally has only very low levels of MHC-I, it is also recognized by NK cells [439]. In paper IV, we therefore addressed NK cell anti-tumor functions and missing self recognition when activated in an iNKT cell-dependent manner. We could show that iNKT cells activated with α GalCer, either soluble or exosomal, mediate activation and proliferation of NK cells and induce up-regulation of KLRG1 (paper IV, Figs. 1 and 6). *Ex vivo* NK cell responses measured by degranulation and IFN γ production were augmented and this could be further increased by stimulation with YAC-1 tumor cells or crosslinking of the activating receptors NK1.1 or NKp46 (paper IV, Fig. 2 and data not shown). Interestingly, mainly the

KLRG1⁺ NK cells responded with IFN γ production and degranulation. Previous studies on KLRG1 have demonstrated a rather weak inhibitory effect of KLRG1 at physiological level on mouse NK cells [277]. The observed drastic increase after iNKT cell activation may increase the inhibitory potential of this receptor and may thus allow KLRG1^{high} NK cells to functionally interact with cadherin-expressing cells, e.g. DCs without killing them. Furthermore, KLRG1 physically associates with the transferrin receptor in *cis*, sequestering KLRG1 from interacting with its ligands, which limits the inhibitory effect of KLRG1. Notably, transferrin receptor expression is induced on activated and proliferating cells, making KLRG1 available for binding to cadherins in *trans* [440].

Given the importance of educated NK cells in anti-tumor immunity, we determined whether proliferation and activation were different between NK cells that could recognize self-MHC-I and those that could not. Treatment with either soluble or exosomal α GalCer led to activation of all NK cell subsets (data not shown), but induced proliferation predominantly of educated NK cells (paper IV, Fig. 4). To confirm that it is specifically educated NK cells that preferentially proliferate, we used mouse strains expressing different MHC-I alleles. Indeed, the Ly49C⁺Ly49I⁺NKG2A⁺ subset had a higher proliferation index in B6 mice, where Ly49C, Ly49I and NKG2A can bind to self MHC-I, while the Ly49A⁺Ly49G₂⁺ NK cell subset proliferated more in a mouse expressing D^d, which is recognized by Ly49A and Ly49G₂.

In a recent study it has been shown that during a response to MCMV infection, uneducated, hypo-responsive NK cells primarily proliferate and dominate the response to the infection [305]. However, in the MCMV model of infection, the virus is specifically recognized by the activating Ly49H receptor, which binds to the MCMV-encoded surface protein m157. About 50% of NK cells in B6 express Ly49H. Orr et al show that among the Ly49H⁺ NK cells, the ones with self-specific Ly49C or Ly49I are inhibited due to recognition of self MHC-I and therefore respond less well. While the study clearly demonstrates that Ly49C/I NK cells respond better and dominate the response, it does not show that educated NK cells do not respond to viral infection or that they are useless. Activation via Ly49H is such a strong cue, which activates both educated and hypo-responsive NK cells. However, since educated NK cells are “inhibit-able” because they express Ly49rs specific for self-MHC-I, they respond less. The “gain in function” inflicted by education does not reach the unimposed activation of Ly49C/I NK cells. Experiments with Ly49H-deficient mice or Δ m157-MCMV could provide information on whether educated or uneducated NK cells can do better during infection. However, another recent study analyzing influenza virus infection in mice confirms the dominant role of uneducated, hypo-functional NK cells in the response [306]. It is not known how NK cells interact with influenza-infected cells, but a specific recognition of influenza hemagglutinin by activating receptor NKp46 has been suggested [150]. In contrast, by using α GalCer-induced iNKT cell-dependent mechanism for NK cell activation, we could show that educated MHC-I-recognizing NK cells proliferate better. The difference may be explained by the different mode of stimulation, receptor-mediated versus cytokine-mediated, or it may be that the specific mixture of cytokines has different influence on educated versus

hypo-responsive NK cells. One hypothesis is that in our system, exosomes are taken up by host DCs, which in turn provide stimulation of NK cells, possible via surface-bound IL-15 [63, 417]. As educated NK cells can respond better to stimulation by IL-15 [157], these NK cell subsets would then proliferate preferentially in our system. Our findings support the notion that distinct NK cell subsets are useful in different physiological and pathological situations.

Previous studies have suggested that the functions of exosomes are mediated by uptake of injected DC-derived exosomes by host DCs [435]. In fact, in a recently accepted paper my collaborators can show that the whole proteins in exosomes are degraded and presented by host DCs on the host MHC-I (Hiltbrunner & Larssen, in press), which corroborates the idea that the effects are mediated by host DCs which have taken up the injected exosomes. This finding is promising for the clinical applicability of exosome immunotherapy, as it implies that exosomes do not necessarily need to be generated from autologous (the patient's) DCs.

To test whether the increased proliferation of educated NK cells would lead to any functional responses, we used *in vivo* methods to determine missing self responses and anti-tumor responses. The *in vivo* target cell elimination assay, which I have used throughout my studies, is the only way to measure NK cell responses that are entirely dependent on recognition of missing self. By simultaneously using two target cell populations that differ only in their MHC-I expression, the differential killing of the MHC-I target cells, measured as preferential survival of the MHC-I⁺ cells, can be determined. This assay allows assessment of a functional increase of specifically educated NK cells, as only NK cells educated on MHC-I will detect missing MHC-I on the MHC-I target cells. Wt B6 mice treated with α GalCer, both soluble or exosomal, showed increased missing self responses (paper IV, Fig. 5-6). Importantly, the treatment did not induce killing of MHC-I target cells in MHC-I^{-/-} mice, despite comparable activation of NK cells in these mice (paper IV, Suppl. Fig. 1), which shows that tolerance is not broken and NK cells do not start to kill healthy autologous cells. Furthermore, this finding demonstrates that education is necessary for the α GalCer-enhanced missing self responses towards otherwise healthy cells.

When we tested the capacity to kill tumor cells, we used the same cells as in paper I, RMA and RMA-S. In this study however, the assay was somewhat modified. Spleen cells from NK1.1-depleted wt B6 mice were co-injected as reference cells together with the two tumor cells lines, as an increase in killing of both tumors was anticipated. Indeed, this reference population enabled us to detect an increase in killing of both tumors, MHC-I⁺ and MHC-I⁻. Interestingly, in this case, α GalCer-mediated iNKT cell activation lead to an increase of tumor killing in MHC-I^{-/-} mice as well.

Previous studies suggested a major role of NKG2D ligands in exosome-mediated NK cell activation [438]. NKG2D ligands were absent from exosomes used in our study. Furthermore, we did not detect any changes in NKG2D levels on NK cells. However, non-significant down-regulation of NKp46 could be detected (data not shown), which may indicate that NK cells encounter NKp46 ligands and the receptor levels are lower due to

ligand-induced receptor down-regulation. Whether ligands for activating receptors on exosomes have activating or desensitizing effects, as suggested for soluble NKG2D ligands, is unknown. The study by Viaud et al. however could show NK cell activation after encounter with exosomal NKG2D ligands [438].

Exosomes, with the abundant expression of MHC-I, MHC-II, co-stimulatory molecules, and possible activating receptor ligands, can function as an antigen-presenting entity, and can be used as vehicles for antigen-based anti-tumor vaccines. Similar to DC-based vaccines, they induce activation and proliferation of immune cells. However, in the tumor microenvironment, DCs may be subjected to suppressive mechanisms and may down-regulate co-stimulatory molecules, which impairs antigen presentation functions. Exosomes should be unaffected by such mechanisms. Furthermore, the membrane lipids of exosomes can have adjuvant functions and can further boost an immune response. In fact, the first study using exosome therapy against tumors in a mouse model, demonstrates that not only can exosomes substitute for DCs, they also display superior immune stimulation which leads to eradication of established tumors [435].

In paper IV we show that iNKT cell activation can enhance NK cell-mediated missing self responses towards healthy cells with aberrant MHC-I expression and tumor cells, which should be taken into account when designing vaccines against cancer. By including the innate arm of the immune system, adaptive responses can be shaped and fine-tuned by production of cytokines and early target cell elimination, which in turn increases antigen presentation. By induction of CTL responses against MHC-I⁺ tumors and NK cell responses against MHC-I⁻ tumors, NKT cell-targeted therapy thus offers the potential for a successful therapy against cancer.

3.6 CONCLUDING REMARKS

Protection against infected and transformed cells is vital for any organism to survive. NK cells, with their inherent ability to detect loss or down-regulation of MHC-I as well as molecules induced by cellular stress, are key players in immune surveillance. With the discovery of missing self recognition 30 years ago, and the continuously growing knowledge about NK cell biology, it does not seem surprising that these cells are considered in many immune therapeutically approaches for treatment of cancer. In fact, the first cell-based adoptive immunotherapy approach, infusion of *ex vivo* activated LAK cells, turned out to be NK cells. This and other approaches have been and are refined ever since, fueled by the increasing appreciation of NK cell missing self responses against tumor cells.

This thesis aimed to explore how NK cell education may impact immunotherapy against cancer. The data and conclusions from the papers presented show that a balance between activation and inhibition is crucial for NK cells to perform anti-tumor responses while at the same time being tolerant to healthy and non-dangerous cells. Tolerance to healthy cells is robust, even in the absence of cognate MHC-I. This fine-tuned balance between being active against potentially dangerous cells, and being tolerant to cells that, despite low levels of self-ligands, do not represent a threat, is mediated by a multitude of inhibitory receptors, activating receptors and adhesion molecules. A tight correlation between some of these molecules appears to be beneficial.

The main conclusions from each paper of this thesis are as follows:

- NK cells adapt their responsiveness according to the integrated net signaling input from interactions with surrounding cells. This can occur in different forms of immunotherapy based on missing self-recognition. The adaptation ensures both tolerance to non-dangerous cells, while reactivity towards malignant cells is maintained (**paper I**).
- Expression of the adhesion molecule DNAM-1 is correlated to NK cell education. Furthermore, there is a tight association between DNAM-1 and NKG2A expression, independent of education. DNAM-1 is expressed at high levels early during development and then decrease gradually during maturation so that it is eventually lost in some NK cells. We propose a model in which NK cell education can prevent the loss of DNAM-1 and in some cases even increase the expression, which may be useful for educated NK cells to perform their functions (**paper II**).
- Although NK cell education appears to result in robust tolerance to normal host cells it is clear that NK cells can kill autologous DCs. In **paper III** we show that depending on the context - normal or inflammatory conditions - NK cells may kill autologous DCs. Production of GM-CSF by NK cells induces up-regulation of surface molecules on DCs, such as ICAM-1 and CD155, which makes them susceptible to NK cell attack.

- Activation of iNKT cells via (exosomal) α GalCer induces activation and strong proliferation of educated NK cells and potentiates killing of normal as well as tumor cells with the “missing self phenotype” (**paper IV**).

These conclusions allude to the potential that NK cells offer in therapy against cancer, and also point out the need for further study. They emphasize that combination of different approaches to increase NK cell responses to tumor cells is advisable. Furthermore, careful stratification of donor and recipient MHC-I genotype and as well as receptor phenotype of donor NK cells seems to be key for the success of immunotherapy.

What has been considered basic research just some few years ago, has a major impact on development of clinical therapies today. I truly believe that gathering knowledge about biology and function of the different cell types of our immune system will help to develop new and to improve existing therapies and may one day lead to cure for cancer.

4 ACKNOWLEDGEMENTS

Many of you have helped throughout these years, and all of you have made an impression on me.

Klas, thank you for the tremendous support during those years. Thank you for laying your trust in me and for giving me the freedom to develop into an independent scientist. I have learned a lot through your expertise and I appreciate your contagious enthusiasm and curiosity for science.

Mia, thank you for your support and day-to-day discussions, and for sharing your expertise with me. Thank you for teaching me, and believing in me. It is a pleasure to complete this journey thanks to your always kind and helpful guidance and encouragement.

Petter, thank you for always asking the relevant questions, pointing out the weak parts of my data. Thanks for all the educational discussions and the invaluable suggestions on my work.

Benedict, thanks for always being there! Without trying, you taught me so much. Thanks for bringing DNAM-1 into my life, for sprinkling the days with humor, the history lessons, and for reminding me that not only NK cells can't do everything alone and sometimes need support.

Hanna, thanks for introducing me to the lab, the LSR and Aria, for teaching me different methods, and showing me how things are done at MTC. Thanks for sharing marzipan during late FACS nights.

To my collaborators: Thank you all for inspiring project discussion, early morning meetings, late FACS nights and full day lab sessions and meet-and-greets in the mouse house! **Ulf**, thanks for a great collaboration and for being a good friend! Your knowledge and your drive were highly inspiring to me. Superhard-working **Stina**, there is nothing you can't do! thanks for being a friend. **Rossana**, thanks for exploring Stockholm nightlife with me. Thanks for being as discouraged as I was when we got scooped with paper I. Thanks for helping me to get back on track! **Nadir** and **Thuy**, thanks for the great work together, I am looking forward to many more discussion. **Susanne**, thanks for the great collaboration, your help to my research is invaluable and you trust in my expertise very much appreciated! **Stefanie**, thanks for the collaborations, sharing data and sharing rooms at retreats. **Valentina**, thanks for the inspiration, your motivation and devotion to science are amazing! **Rosa**, **Pradeep**, **Ennio** and **Jonas**, we will finish that Old (and New) project too! **Lisa**, **Joanna**, **Carin** and **Marisa**, working with you Wasps has been great!

I would like to thank the current and previous members of the Kärre and associated groups: **Adil**, **Adnane**, **Ali**, **André**, **Anna-Maria**, **Arie**, **Arwen**, **Baltzar**, **Björn**, **Banu**, **Benedict**, **Danika**, **Elin**, **Elina**, **Ennio**, **Eva**, **Francesca**, **Giota**, **Hanna**, **Hannes**, **Huda**, **Jens**, **Jonas**, **Kanth**, **Karolin**, **Keerthana**, **Klas**, **Koen**, **Louise**, **Ludwig**, **Mantas**, **Mia**, **Micke**, **Nadir**, **Neha**, **Pedro**, **Per**, **Petter B**, **Petter H**, **Pradeep**, **Quentin**, **Ramit**, **Ranjana**, **Rosa**, **Rossana**, **Sarah**, **Sadia**, **Sofia B**, **Sofia J**, **Sridharan**, **Steph**, **Stephan**, **Stina**, **Suni**, **Susanne**, **Valentina**, **Thuy**, **Tim**, **Zsofia**. It was a great pleasure to work with you, I have learned a lot! Thanks for Christmas dinners too!

I wouldn't be here if it wasn't for the guidance and inspiration of my former supervisors: **Christian S**, **Christian K**, **Andrea** and **Jeanette**. With your ingenuity, enthusiasm, knowledge, and inspiration you have laid the foundation to my scientific career!

Thank you to my fellow board members at MSA: **Afrouz, Agata, Habib, Maria Lisa, Mariam, Marijke, Paola, Soazig, Samer, Suni** and DSA: **Arash, Agata, Emma, Hugo, Håkan, Jayesh, Ranjita, Sonal, Susanna, Yuan**. I really enjoyed our intercultural solution-finding-discussions to many problems, and working with you was inspiring!

I am thankful for the many friends I have made at MTC, KI and NK cell meetings. There are lots of memories I share with every single one of you. Thank you for sharing my life, work, coffee, chocolates, laughter, tears, stories, rooms, happiness and sadness, discussing life in general and life as a Ph.D. student and researcher. Without you it wouldn't have been such a great time. **Adil** and **Anna-Maria**, thank you for offering your couch when I most needed it, **Annika** and **Valentina**, thanks for getting my to crawl, **Berit**, thanks for the chats, the tips, the mAbs, **Carin**: thanks for “det finns inga hinder, bara utmaningar!”, **Cath**, thanks for all the laughs and cakes, **Jens** and **Fia**, what a great time I spent with you!, **Joanna**, for your never-give-up and always-have-fun attitude, **Marc** and **Maciej**, the best course-team, **Shady**, thanks for the spaghetti-story on pizza-night, **Marisa**, thanks for being such a nice travel companion and a true friend, all others that make up the MTC atmosphere: **Amanda, Anton, Anuj, Carina, Chris, Elena, Emilie, Francesca, Frank, Gabriel, Gao, Gerry, Gunilla, Hamid, Harsha, Hayrettin, Ingeborg, Jaime, Jonathan, Julian, Juan, Katja, Kiran, Laura, Mariana, Martin, Mattias, Mike, Noemi, Pontus, Qin, Robban, Sharesta, Shawon, Silke, Sonia, Speranta, Suman, Sylvie, Thomas, Vanessa, Vishnu** and KI: **Ali Z., Andreas, Anne-Laure, Alessandra, Ben & Marta, Cindy, David, Dhifaf, Edwin, Einar, Evelina, Florian, Janina, Jessica, Karin, Konrad, Kristina, Maarten, Milind, Nicole, Lara, Laura, Patricia, Pia, Sakthi, Veronika, Vivien, Tiiu**, and so many more... **Anna, Lune, Matt, Lars, Glòria, Anaïs, Athanasia, Julia, Mike, Malcolm, Cormac**, I am so happy to have met you!!! Conferences would be different without you.

My little Lübeck gang: **Michael, Luise, Susi & Peio, Anette, Jonathan** and **Benjamin**. I am grateful to have you in my life!!!

Marton, Elina, Berit, Annika, Stefanie, my running buddies, come sunshine, rain or snow, one of you was always eager, **Marijke, Rossana, Rozina, Sabrina, Sofia B**, thanks for training-dinner-gossip nights, **Anette, Carin, Janina, Jens, Ulf**, thanks for all the gym sessions together, **Carin, Stefanie** and **Tina**, thanks for Tjejvasan, what an experience!

Thank you everyone at MTC, who have helped me with my little and big problems. **Birgitta**, for help at the flow cytometers and FACS sorting and the chats. **Gesan**, thanks for taking a sincere interest in my Ph.D. studies! **Barbro** for financial and administrative support at any time, **Helene, Åsa, Lina, Anita, Mia** for help with regulations, the Swedish education system and encouraging talks, **Sándor, Magnus, Per, David, Thorbjörn, Susanne, Milina** (and many others) for fixing everything. Thanks for great help and invaluable technical support from **Kenth, Anna-Karin, Helene, Torunn, Susanne** and all the others that have contributed over the years.

I am fortunate to have many friends all over the world that I have encountered and that have made an impact on me during different stages in my life. I will not even try to name you all here, you know who you are!

Thank you to **my family** for always supporting me and believing in me.

Thank you **Thore**. You have supported this adventure from the beginning to the end, picking me up when I was down, sharing my happiness when things worked, and putting up with me when things didn't. You are my best friend and a true companion!

5 REFERENCES

1. Couzin-Frankel, J., *Breakthrough of the year 2013. Cancer immunotherapy*. Science, 2013. **342**(6165): p. 1432-3.
2. Jenq, R.R. and M.R. van den Brink, *Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer*. Nat Rev Cancer, 2010. **10**(3): p. 213-21.
3. Rosenberg, S.A., et al., *Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer*. N Engl J Med, 1985. **313**(23): p. 1485-92.
4. Phillips, J.H. and L.L. Lanier, *Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytotoxicity*. J Exp Med, 1986. **164**(3): p. 814-25.
5. Hinrichs, C.S. and S.A. Rosenberg, *Exploiting the curative potential of adoptive T-cell therapy for cancer*. Immunol Rev, 2014. **257**(1): p. 56-71.
6. Malmberg, K.J., et al., *NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy*. Cancer Immunol Immunother, 2008. **57**(10): p. 1541-52.
7. Rosenberg, S.A., *IL-2: the first effective immunotherapy for human cancer*. J Immunol, 2014. **192**(12): p. 5451-8.
8. Conlon, K.C., et al., *Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer*. J Clin Oncol, 2015. **33**(1): p. 74-82.
9. Rosario, M., et al., *The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas*. Clin Cancer Res, 2016. **22**(3): p. 596-608.
10. Alderson, K.L. and P.M. Sondel, *Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity*. J Biomed Biotechnol, 2011. **2011**: p. 379123.
11. Wang, W., et al., *NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy*. Front Immunol, 2015. **6**: p. 368.
12. Lanier, L.L., J.J. Ruitenberg, and J.H. Phillips, *Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes*. J Immunol, 1988. **141**(10): p. 3478-85.
13. Morel, P.A., L.K. Ernst, and D. Metes, *Functional CD32 molecules on human NK cells*. Leuk Lymphoma, 1999. **35**(1-2): p. 47-56.
14. Santoni, A., R.B. Herberman, and H.T. Holden, *Correlation between natural and antibody-dependent cell-mediated cytotoxicity against tumor targets in the mouse. II. Characterization of the effector cells*. J Natl Cancer Inst, 1979. **63**(4): p. 995-1003.
15. Zhukovsky, E.A., R.J. Morse, and M.V. Maus, *Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection*. Curr Opin Immunol, 2016. **40**: p. 24-35.
16. Essand, M. and A.S. Loskog, *Genetically engineered T cells for the treatment of cancer*. J Intern Med, 2013. **273**(2): p. 166-81.
17. Mavilio, D. and E. Lugli, *Inhibiting the inhibitors: Checkpoints blockade in solid tumors*. Oncoimmunology, 2013. **2**(9): p. e26535.
18. Pardoll, D.M., *The blockade of immune checkpoints in cancer immunotherapy*. Nat Rev Cancer, 2012. **12**(4): p. 252-64.
19. Benson, D.M., Jr., et al., *A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma*. Blood, 2012. **120**(22): p. 4324-33.
20. Murphy, K., et al., *Janeway's immunobiology*. 8th ed2012, New York: Garland Science. xix, 868 p.

21. Uhlin, M., et al., *A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation*. *Cancer Immunol Immunother*, 2010. **59**(3): p. 473-7.
22. Thomas, S. and G.C. Prendergast, *Cancer Vaccines: A Brief Overview*. *Methods Mol Biol*, 2016. **1403**: p. 755-61.
23. Bloy, N., et al., *Trial watch: Dendritic cell-based anticancer therapy*. *Oncoimmunology*, 2014. **3**(11): p. e963424.
24. Cardell, S.L., *The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice*. *Clin Exp Immunol*, 2006. **143**(2): p. 194-202.
25. Smyth, M.J., et al., *Differential tumor surveillance by natural killer (NK) and NKT cells*. *J Exp Med*, 2000. **191**(4): p. 661-8.
26. Robertson, F.C., J.A. Berzofsky, and M. Terabe, *NKT cell networks in the regulation of tumor immunity*. *Front Immunol*, 2014. **5**: p. 543.
27. Dudziak, D., et al., *Differential antigen processing by dendritic cell subsets in vivo*. *Science*, 2007. **315**(5808): p. 107-11.
28. Sallusto, F. and A. Lanzavecchia, *Mobilizing dendritic cells for tolerance, priming, and chronic inflammation*. *J Exp Med*, 1999. **189**(4): p. 611-4.
29. Banchereau, J. and R.M. Steinman, *Dendritic cells and the control of immunity*. *Nature*, 1998. **392**(6673): p. 245-52.
30. Moser, M. and K.M. Murphy, *Dendritic cell regulation of TH1-TH2 development*. *Nat Immunol*, 2000. **1**(3): p. 199-205.
31. Fernandez, N.C., et al., *Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo*. *Nat Med*, 1999. **5**(4): p. 405-11.
32. Gerosa, F., et al., *Reciprocal activating interaction between natural killer cells and dendritic cells*. *J Exp Med*, 2002. **195**(3): p. 327-33.
33. Palucka, K. and J. Banchereau, *Cancer immunotherapy via dendritic cells*. *Nat Rev Cancer*, 2012. **12**(4): p. 265-77.
34. Palucka, K., et al., *Dendritic cells and immunity against cancer*. *J Intern Med*, 2011. **269**(1): p. 64-73.
35. Martin-Fontecha, A., et al., *Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming*. *Nat Immunol*, 2004. **5**(12): p. 1260-5.
36. Timmerman, J.M. and R. Levy, *Dendritic cell vaccines for cancer immunotherapy*. *Annu Rev Med*, 1999. **50**: p. 507-29.
37. Gonzalez, F.E., et al., *Tumor cell lysates as immunogenic sources for cancer vaccine design*. *Hum Vaccin Immunother*, 2014. **10**(11): p. 3261-9.
38. Slingluff, C.L., Jr., *The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?* *Cancer J*, 2011. **17**(5): p. 343-50.
39. Mills, C.D., et al., *M-1/M-2 macrophages and the Th1/Th2 paradigm*. *J Immunol*, 2000. **164**(12): p. 6166-73.
40. Marchesi, M., et al., *HLA-dependent tumour development: a role for tumour associate macrophages?* *J Transl Med*, 2013. **11**: p. 247.
41. O'Sullivan, T., et al., *Cancer immunoediting by the innate immune system in the absence of adaptive immunity*. *J Exp Med*, 2012. **209**(10): p. 1869-82.
42. Mills, C.D., L.L. Lenz, and R.A. Harris, *A Breakthrough: Macrophage-Directed Cancer Immunotherapy*. *Cancer Res*, 2016. **76**(3): p. 513-6.
43. Mosser, D.M. and J.P. Edwards, *Exploring the full spectrum of macrophage activation*. *Nat Rev Immunol*, 2008. **8**(12): p. 958-69.
44. Poschke, I. and R. Kiessling, *On the armament and appearances of human myeloid-derived suppressor cells*. *Clin Immunol*, 2012. **144**(3): p. 250-68.

45. Serafini, N., C.A. Vosshenrich, and J.P. Di Santo, *Transcriptional regulation of innate lymphoid cell fate*. Nat Rev Immunol, 2015. **15**(7): p. 415-28.
46. Sanos, S.L. and A. Diefenbach, *Innate lymphoid cells: from border protection to the initiation of inflammatory diseases*. Immunol Cell Biol, 2013. **91**(3): p. 215-24.
47. Cortez, V.S., M.L. Robinette, and M. Colonna, *Innate lymphoid cells: new insights into function and development*. Curr Opin Immunol, 2015. **32**: p. 71-7.
48. Spits, H., et al., *Innate lymphoid cells--a proposal for uniform nomenclature*. Nat Rev Immunol, 2013. **13**(2): p. 145-9.
49. Murphy, K.M. and S.L. Reiner, *The lineage decisions of helper T cells*. Nat Rev Immunol, 2002. **2**(12): p. 933-44.
50. Diefenbach, A., M. Colonna, and S. Koyasu, *Development, differentiation, and diversity of innate lymphoid cells*. Immunity, 2014. **41**(3): p. 354-65.
51. Bjorklund, A.K., et al., *The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing*. Nat Immunol, 2016. **17**(4): p. 451-60.
52. Daussy, C., et al., *T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow*. J Exp Med, 2014. **211**(3): p. 563-77.
53. Mielke, L.A., et al., *TCF-1 controls ILC2 and NKp46+RORgammat+ innate lymphocyte differentiation and protection in intestinal inflammation*. J Immunol, 2013. **191**(8): p. 4383-91.
54. Montaldo, E., et al., *Human RORgammat(+)/CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells*. Immunity, 2014. **41**(6): p. 988-1000.
55. Cherrier, M., S. Sawa, and G. Eberl, *Notch, Id2, and RORgammat sequentially orchestrate the fetal development of lymphoid tissue inducer cells*. J Exp Med, 2012. **209**(4): p. 729-40.
56. Klose, C.S. and A. Diefenbach, *Transcription factors controlling innate lymphoid cell fate decisions*. Curr Top Microbiol Immunol, 2014. **381**: p. 215-55.
57. Kiessling, R., et al., *"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell*. Eur J Immunol, 1975. **5**(2): p. 117-21.
58. Kiessling, R., E. Klein, and H. Wigzell, *"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype*. Eur J Immunol, 1975. **5**(2): p. 112-7.
59. Herberman, R.B., et al., *Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells*. Int J Cancer, 1975. **16**(2): p. 230-9.
60. Herberman, R.B., M.E. Nunn, and D.H. Lavrin, *Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity*. Int J Cancer, 1975. **16**(2): p. 216-29.
61. Biron, C.A., *Activation and function of natural killer cell responses during viral infections*. Curr Opin Immunol, 1997. **9**(1): p. 24-34.
62. Vidal, S.M., S.I. Khakoo, and C.A. Biron, *Natural Killer Cell Responses during Viral Infections: Flexibility and Conditioning of Innate Immunity by Experience*. Curr Opin Virol, 2011. **1**(6): p. 497-512.
63. Lucas, M., et al., *Dendritic cells prime natural killer cells by trans-presenting interleukin 15*. Immunity, 2007. **26**(4): p. 503-17.
64. Zamai, L., et al., *Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells*. J Exp Med, 1998. **188**(12): p. 2375-80.
65. Kagi, D., et al., *Cytotoxicity Mediated by T-Cells and Natural-Killer-Cells Is Greatly Impaired in Perforin Deficient Mice*. Nature, 1994. **369**(6475): p. 31-37.

66. Hayakawa, Y., et al., *Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin*. J Immunol, 2002. **169**(10): p. 5377-81.
67. Smyth, M.J., et al., *Perforin is a major contributor to NK cell control of tumor metastasis*. J Immunol, 1999. **162**(11): p. 6658-62.
68. Smyth, M.J., et al., *Activation of NK cell cytotoxicity*. Mol Immunol, 2005. **42**(4): p. 501-10.
69. Biburger, M., A. Lux, and F. Nimmerjahn, *How immunoglobulin G antibodies kill target cells: revisiting an old paradigm*. Adv Immunol, 2014. **124**: p. 67-94.
70. Stetson, D.B., et al., *Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function*. J Exp Med, 2003. **198**(7): p. 1069-76.
71. Vivier, E., et al., *Innate or adaptive immunity? The example of natural killer cells*. Science, 2011. **331**(6013): p. 44-9.
72. Lanier, L.L., *NK cell recognition*. Annu Rev Immunol, 2005. **23**: p. 225-74.
73. Kärre, K., et al., *Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy*. Nature, 1986. **319**(6055): p. 675-8.
74. Ljunggren, H.G. and K. Kärre, *In search of the 'missing self': MHC molecules and NK cell recognition*. Immunol Today, 1990. **11**(7): p. 237-44.
75. Ljunggren, H.G. and K. Kärre, *Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism*. J Exp Med, 1985. **162**(6): p. 1745-59.
76. Diefenbach, A. and D.H. Raulet, *Strategies for target cell recognition by natural killer cells*. Immunol Rev, 2001. **181**: p. 170-84.
77. Raulet, D.H. and R.E. Vance, *Self-tolerance of natural killer cells*. Nat Rev Immunol, 2006. **6**(7): p. 520-31.
78. Carrega, P., et al., *CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph*. J Immunol, 2014. **192**(8): p. 3805-15.
79. Cooper, M.A., T.A. Fehniger, and M.A. Caligiuri, *The biology of human natural killer-cell subsets*. Trends Immunol, 2001. **22**(11): p. 633-40.
80. Caligiuri, M.A., *Human natural killer cells*. Blood, 2008. **112**(3): p. 461-9.
81. Hiby, S.E., et al., *Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2*. J Clin Invest, 2010. **120**(11): p. 4102-10.
82. Flodstrom-Tullberg, M., et al., *Natural killer cells in human autoimmunity*. Curr Opin Immunol, 2009. **21**(6): p. 634-40.
83. Cudkowicz, G. and M. Bennett, *Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice*. J Exp Med, 1971. **134**(6): p. 1513-28.
84. Kiessling, R., et al., *Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts*. Eur J Immunol, 1977. **7**(9): p. 655-63.
85. Hochman, P.S. and G. Cudkowicz, *Different sensitivities to hydrocortisone of natural killer cell activity and hybrid resistance to parental marrow grafts*. J Immunol, 1977. **119**(6): p. 2013-5.
86. Bix, M., et al., *Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice*. Nature, 1991. **349**(6307): p. 329-31.
87. Ljunggren, H.G., et al., *Altered natural killer cell repertoire in Tap-1 mutant mice*. Proc Natl Acad Sci U S A, 1994. **91**(14): p. 6520-4.
88. Höglund, P., et al., *Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains*. Eur J Immunol, 1998. **28**(1): p. 370-8.
89. Grigoriadou, K., et al., *MHC class Ia molecules alone control NK-mediated bone marrow graft rejection*. Eur J Immunol, 1999. **29**(11): p. 3683-90.

90. Zimmer, J., et al., *Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome)*. J Exp Med, 1998. **187**(1): p. 117-22.
91. Höglund, P., et al., *Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice*. J Exp Med, 1988. **168**(4): p. 1469-74.
92. Johansson, S., et al., *Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules*. J Exp Med, 2005. **201**(7): p. 1145-55.
93. Yokoyama, W.M., et al., *Chromosomal location of the Ly-49 (A1, YE1/48) multigene family. Genetic association with the NK 1.1 antigen*. J Immunol, 1990. **145**(7): p. 2353-8.
94. Yokoyama, W.M., et al., *cDNA cloning of mouse NKR-P1 and genetic linkage with LY-49. Identification of a natural killer cell gene complex on mouse chromosome 6*. J Immunol, 1991. **147**(9): p. 3229-36.
95. Colonna, M. and J. Samaridis, *Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells*. Science, 1995. **268**(5209): p. 405-8.
96. Wagtmann, N., et al., *Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains*. Immunity, 1995. **2**(5): p. 439-49.
97. Galy, A., et al., *Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset*. Immunity, 1995. **3**(4): p. 459-73.
98. Kondo, M., I.L. Weissman, and K. Akashi, *Identification of clonogenic common lymphoid progenitors in mouse bone marrow*. Cell, 1997. **91**(5): p. 661-72.
99. Kumar, V., et al., *Natural killer cells in mice treated with 89strontium: normal target-binding cell numbers but inability to kill even after interferon administration*. J Immunol, 1979. **123**(4): p. 1832-8.
100. Hackett, J., Jr., et al., *Origin and differentiation of natural killer cells. II. Functional and morphologic studies of purified NK-1.1+ cells*. J Immunol, 1986. **136**(8): p. 3124-31.
101. Pollack, S.B. and C. Rosse, *The primary role of murine bone marrow in the production of natural killer cells. A cytokinetic study*. J Immunol, 1987. **139**(7): p. 2149-56.
102. Haller, O., et al., *Generation of natural killer cells: an autonomous function of the bone marrow*. J Exp Med, 1977. **145**(5): p. 1411-6.
103. Hackett, J., Jr., et al., *Transplantable progenitors of natural killer cells are distinct from those of T and B lymphocytes*. Proc Natl Acad Sci U S A, 1986. **83**(10): p. 3427-31.
104. Carotta, S., et al., *Identification of the earliest NK cell precursor in the mouse bone marrow*. Blood, 2011.
105. Fathman, J.W., et al., *Identification of the earliest natural killer cell-committed progenitor in murine bone marrow*. Blood, 2011. **118**(20): p. 5439-47.
106. Kennedy, M.K. and L.S. Park, *Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex*. J Clin Immunol, 1996. **16**(3): p. 134-43.
107. Rosmaraki, E.E., et al., *Identification of committed NK cell progenitors in adult murine bone marrow*. Eur J Immunol, 2001. **31**(6): p. 1900-9.
108. Kim, S., et al., *In vivo developmental stages in murine natural killer cell maturation*. Nat Immunol, 2002. **3**(6): p. 523-8.
109. Williams, N.S., et al., *Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression*. Eur J Immunol, 2000. **30**(7): p. 2074-82.

110. Dorfman, J.R. and D.H. Raulet, *Acquisition of Ly49 receptor expression by developing natural killer cells*. J Exp Med, 1998. **187**(4): p. 609-18.
111. Hayakawa, Y. and M.J. Smyth, *CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity*. J Immunol, 2006. **176**(3): p. 1517-24.
112. Chiossone, L., et al., *Maturation of mouse NK cells is a 4-stage developmental program*. Blood, 2009. **113**(22): p. 5488-96.
113. Hayakawa, Y., et al., *Functional subsets of mouse natural killer cells*. Immunol Rev, 2006. **214**: p. 47-55.
114. Malaise, M., et al., *KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma*. J Immunol, 2014. **192**(4): p. 1954-61.
115. Renner, P., et al., *KLRG1 natural killer cells protect against pulmonary metastatic disease by immunosurveillance*. Oncoimmunology, 2014. **3**: p. e28328.
116. Vosshenrich, C.A., et al., *Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo*. J Immunol, 2005. **174**(3): p. 1213-21.
117. Suzuki, H., et al., *Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain*. J Exp Med, 1997. **185**(3): p. 499-505.
118. Puzanov, I.J., et al., *Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in?* Res Immunol, 1997. **148**(3): p. 195-201.
119. Schlenner, S.M., et al., *Fate mapping reveals separate origins of T cells and myeloid lineages in the thymus*. Immunity, 2010. **32**(3): p. 426-36.
120. Huntington, N.D., C.A. Vosshenrich, and J.P. Di Santo, *Developmental pathways that generate natural-killer-cell diversity in mice and humans*. Nat Rev Immunol, 2007. **7**(9): p. 703-14.
121. Georgopoulos, K., et al., *The Ikaros gene is required for the development of all lymphoid lineages*. Cell, 1994. **79**(1): p. 143-56.
122. Colucci, F., et al., *Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells*. Blood, 2001. **97**(9): p. 2625-32.
123. Yokota, Y., et al., *Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2*. Nature, 1999. **397**(6721): p. 702-6.
124. Ikawa, T., et al., *Commitment of common T/Natural killer (NK) progenitors to unipotent T and NK progenitors in the murine fetal thymus revealed by a single progenitor assay*. J Exp Med, 1999. **190**(11): p. 1617-26.
125. Townsend, M.J., et al., *T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells*. Immunity, 2004. **20**(4): p. 477-94.
126. Robbins, S.H., et al., *Direct effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation*. Eur J Immunol, 2005. **35**(3): p. 757-65.
127. Gordon, S.M., et al., *The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation*. Immunity, 2012. **36**(1): p. 55-67.
128. Samson, S.I., et al., *GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells*. Immunity, 2003. **19**(5): p. 701-11.
129. Jenne, C.N., et al., *T-bet-dependent SIP5 expression in NK cells promotes egress from lymph nodes and bone marrow*. J Exp Med, 2009. **206**(11): p. 2469-81.
130. Huntington, N.D., et al., *NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation*. J Immunol, 2007. **178**(8): p. 4764-70.
131. Bryceson, Y.T., et al., *Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion*. Blood, 2006. **107**(1): p. 159-66.
132. Watzl, C. and E.O. Long, *Signal transduction during activation and inhibition of natural killer cells*. Curr Protoc Immunol, 2010. **Chapter 11**: p. Unit 11 9B.

133. Schlums, H., et al., *Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function*. *Immunity*, 2015. **42**(3): p. 443-56.
134. Perussia, B., et al., *Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene*. *J Exp Med*, 1989. **170**(1): p. 73-86.
135. Carlyle, J.R., et al., *Evolution of the Ly49 and Nkrp1 recognition systems*. *Semin Immunol*, 2008. **20**(6): p. 321-30.
136. Giorda, R. and M. Trucco, *Mouse NKR-P1. A family of genes selectively coexpressed in adherent lymphokine-activated killer cells*. *J Immunol*, 1991. **147**(5): p. 1701-8.
137. Plougastel, B., et al., *Analysis of a 1-Mb BAC contig overlapping the mouse Nkrp1 cluster of genes: cloning of three new Nkrp1 members, Nkrp1d, Nkrp1e, and Nkrp1f*. *Immunogenetics*, 2001. **53**(7): p. 592-8.
138. Carlyle, J.R., et al., *Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors*. *Proc Natl Acad Sci U S A*, 2004. **101**(10): p. 3527-32.
139. Carlyle, J.R., et al., *Mouse NKR-PIB, a novel NK1.1 antigen with inhibitory function*. *J Immunol*, 1999. **162**(10): p. 5917-23.
140. Ljusic, B., et al., *Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptors*. *J Immunol*, 2005. **174**(8): p. 4789-96.
141. Plougastel, B., C. Dubbelde, and W.M. Yokoyama, *Cloning of Clr, a new family of lectin-like genes localized between mouse Nkrp1a and Cd69*. *Immunogenetics*, 2001. **53**(3): p. 209-14.
142. Sivori, S., et al., *p46, a novel natural killer cell-specific surface molecule that mediates cell activation*. *J Exp Med*, 1997. **186**(7): p. 1129-36.
143. De Maria, A., et al., *Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca fascicularis NK cells*. *Eur J Immunol*, 2001. **31**(12): p. 3546-56.
144. Kruse, P.H., et al., *Natural cytotoxicity receptors and their ligands*. *Immunol Cell Biol*, 2014. **92**(3): p. 221-9.
145. Biassoni, R., et al., *The murine homologue of the human NKp46, a triggering receptor involved in the induction of natural cytotoxicity*. *Eur J Immunol*, 1999. **29**(3): p. 1014-20.
146. Garg, A., et al., *Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor*. *J Immunol*, 2006. **177**(9): p. 6192-8.
147. Horton, N.C. and P.A. Mathew, *NKp44 and Natural Cytotoxicity Receptors as Damage-Associated Molecular Pattern Recognition Receptors*. *Front Immunol*, 2015. **6**: p. 31.
148. Ferlazzo, G., et al., *Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells*. *J Exp Med*, 2002. **195**(3): p. 343-51.
149. Arnon, T.I., et al., *Recognition of viral hemagglutinins by NKp44 but not by NKp30*. *Eur J Immunol*, 2001. **31**(9): p. 2680-9.
150. Mandelboim, O., et al., *Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells*. *Nature*, 2001. **409**(6823): p. 1055-60.
151. George, T.C., et al., *Tolerance and alloreactivity of the Ly49D subset of murine NK cells*. *J Immunol*, 1999. **163**(4): p. 1859-67.
152. George, T.C., et al., *Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells*. *J Immunol*, 1999. **162**(4): p. 2035-43.
153. Nakamura, M.C., et al., *Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity*. *J Exp Med*, 1999. **189**(3): p. 493-500.

154. Ortaldo, J.R., et al., *Activating Ly-49 NK receptors: central role in cytokine and chemokine production*. J Immunol, 2001. **166**(8): p. 4994-9.
155. Hanke, T., et al., *Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors*. Immunity, 1999. **11**(1): p. 67-77.
156. Furukawa, H., et al., *A ligand for the murine NK activation receptor Ly-49D: activation of tolerized NK cells from beta 2-microglobulin-deficient mice*. J Immunol, 2002. **169**(1): p. 126-36.
157. Brodin, P., et al., *Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets*. J Immunol, 2012. **188**(5): p. 2218-26.
158. Ortaldo, J.R. and H.A. Young, *Expression of IFN-gamma upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors*. J Immunol, 2003. **170**(4): p. 1763-9.
159. Xiong, S., et al., *Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation*. J Clin Invest, 2013. **123**(10): p. 4264-72.
160. Arase, H., et al., *Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors*. Science, 2002. **296**(5571): p. 1323-6.
161. Davis, A.H., et al., *Characterization of murine cytomegalovirus m157 from infected cells and identification of critical residues mediating recognition by the NK cell receptor Ly49H*. J Immunol, 2008. **181**(1): p. 265-75.
162. Smith, H.R., et al., *Recognition of a virus-encoded ligand by a natural killer cell activation receptor*. Proc Natl Acad Sci U S A, 2002. **99**(13): p. 8826-31.
163. Tripathy, S.K., et al., *Expression of m157, a murine cytomegalovirus-encoded putative major histocompatibility class I (MHC-I)-like protein, is independent of viral regulation of host MHC-I*. J Virol, 2006. **80**(1): p. 545-50.
164. Lee, S.H., et al., *Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily*. Nat Genet, 2001. **28**(1): p. 42-5.
165. Brown, M.G., et al., *Vital involvement of a natural killer cell activation receptor in resistance to viral infection*. Science, 2001. **292**(5518): p. 934-7.
166. Sjolín, H., et al., *Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection*. J Exp Med, 2002. **195**(7): p. 825-34.
167. Gosselin, P., et al., *Induction of DAP12 phosphorylation, calcium mobilization, and cytokine secretion by Ly49H*. J Leukoc Biol, 1999. **66**(1): p. 165-71.
168. Gilfillan, S., et al., *NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation*. Nat Immunol, 2002. **3**(12): p. 1150-5.
169. Diefenbach, A., et al., *Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D*. Nat Immunol, 2002. **3**(12): p. 1142-9.
170. Gasser, S., et al., *The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor*. Nature, 2005. **436**(7054): p. 1186-90.
171. Diefenbach, A., et al., *Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity*. Nature, 2001. **413**(6852): p. 165-71.
172. Cerwenka, A., et al., *Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice*. Immunity, 2000. **12**(6): p. 721-7.
173. Lanier, L.L., *NKG2D Receptor and Its Ligands in Host Defense*. Cancer Immunol Res, 2015. **3**(6): p. 575-82.
174. Wiemann, K., et al., *Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo*. J Immunol, 2005. **175**(2): p. 720-9.
175. Coudert, J.D., et al., *Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells*. Blood, 2005. **106**(5): p. 1711-7.

176. Oppenheim, D.E., et al., *Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance*. *Nat Immunol*, 2005. **6**(9): p. 928-37.
177. Raullet, D.H., et al., *Regulation of ligands for the NKG2D activating receptor*. *Annu Rev Immunol*, 2013. **31**: p. 413-41.
178. Deng, W., et al., *Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection*. *Science*, 2015. **348**(6230): p. 136-9.
179. de Andrade, L.F., M.J. Smyth, and L. Martinet, *DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins*. *Immunol Cell Biol*, 2013.
180. Tahara-Hanaoka, S., et al., *Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands*. *Biochem Biophys Res Commun*, 2005. **329**(3): p. 996-1000.
181. Shibuya, A., et al., *DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes*. *Immunity*, 1996. **4**(6): p. 573-81.
182. Chan, C.J., M.J. Smyth, and L. Martinet, *Molecular mechanisms of natural killer cell activation in response to cellular stress*. *Cell Death Differ*, 2013.
183. Ardolino, M., et al., *DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction*. *Blood*, 2011. **117**(18): p. 4778-86.
184. Shibuya, A., L.L. Lanier, and J.H. Phillips, *Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAM-1 receptor*. *J Immunol*, 1998. **161**(4): p. 1671-6.
185. Shibuya, K., et al., *Physical and functional association of LFA-1 with DNAM-1 adhesion molecule*. *Immunity*, 1999. **11**(5): p. 615-23.
186. Shirakawa, J., K. Shibuya, and A. Shibuya, *Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226)*. *Int Immunol*, 2005. **17**(3): p. 217-23.
187. Shirakawa, J., et al., *LFA-1-dependent lipid raft recruitment of DNAM-1 (CD226) in CD4+ T cell*. *Int Immunol*, 2006. **18**(6): p. 951-7.
188. Zhang, Z., et al., *DNAM-1 controls NK cell activation via an ITT-like motif*. *J Exp Med*, 2015. **212**(12): p. 2165-82.
189. Bottino, C., et al., *Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule*. *J Exp Med*, 2003. **198**(4): p. 557-67.
190. Tahara-Hanaoka, S., et al., *Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)*. *Int Immunol*, 2004. **16**(4): p. 533-8.
191. Takai, Y., et al., *Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization*. *Cancer Sci*, 2003. **94**(8): p. 655-67.
192. Gilfillan, S., et al., *DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors*. *J Exp Med*, 2008. **205**(13): p. 2965-73.
193. Iguchi-Manaka, A., et al., *Accelerated tumor growth in mice deficient in DNAM-1 receptor*. *J Exp Med*, 2008. **205**(13): p. 2959-64.
194. Lakshmikanth, T., et al., *NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo*. *J Clin Invest*, 2009. **119**(5): p. 1251-63.
195. Pende, D., et al., *PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis*. *Mol Immunol*, 2005. **42**(4): p. 463-9.
196. Fuchs, A. and M. Colonna, *The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance*. *Semin Cancer Biol*, 2006. **16**(5): p. 359-66.

197. Mehta, I.K., et al., *Ly49A allelic variation and MHC class I specificity*. Immunogenetics, 2001. **53**(7): p. 572-83.
198. Parham, P., *The genetic and evolutionary balances in human NK cell receptor diversity*. Semin Immunol, 2008. **20**(6): p. 311-6.
199. Kelley, J., L. Walter, and J. Trowsdale, *Comparative genomics of natural killer cell receptor gene clusters*. PLoS Genet, 2005. **1**(2): p. 129-39.
200. Gumperz, J.E. and P. Parham, *The enigma of the natural killer cell*. Nature, 1995. **378**(6554): p. 245-8.
201. Gumbleton, M. and W.G. Kerr, *Role of inositol phospholipid signaling in natural killer cell biology*. Front Immunol, 2013. **4**: p. 47.
202. Liu, D., M.E. Peterson, and E.O. Long, *The adaptor protein Crk controls activation and inhibition of natural killer cells*. Immunity, 2012. **36**(4): p. 600-11.
203. Peterson, M.E. and E.O. Long, *Inhibitory receptor signaling via tyrosine phosphorylation of the adaptor Crk*. Immunity, 2008. **29**(4): p. 578-88.
204. Orange, J.S., *Formation and function of the lytic NK-cell immunological synapse*. Nat Rev Immunol, 2008. **8**(9): p. 713-25.
205. Vance, R.E., et al., *Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b)*. J Exp Med, 1998. **188**(10): p. 1841-8.
206. Braud, V.M., et al., *HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C*. Nature, 1998. **391**(6669): p. 795-9.
207. Kraft, J.R., et al., *Analysis of Qa-1(b) peptide binding specificity and the capacity of CD94/NKG2A to discriminate between Qa-1-peptide complexes*. J Exp Med, 2000. **192**(5): p. 613-24.
208. Borrego, F., et al., *Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis*. J Exp Med, 1998. **187**(5): p. 813-8.
209. Lee, N., et al., *HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A*. Proc Natl Acad Sci U S A, 1998. **95**(9): p. 5199-204.
210. Aldrich, C.J., et al., *Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen*. Cell, 1994. **79**(4): p. 649-58.
211. Vivier, E. and N. Anfossi, *Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future*. Nat Rev Immunol, 2004. **4**(3): p. 190-8.
212. Uhrberg, M., et al., *The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: clones sharing identical alpha beta TCR rearrangement express highly diverse killer cell Ig-like receptor patterns*. J Immunol, 2001. **166**(6): p. 3923-32.
213. Vance, R.E., et al., *Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation*. Proc Natl Acad Sci U S A, 2002. **99**(2): p. 868-73.
214. Sivakumar, P.V., et al., *Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development*. J Immunol, 1999. **162**(12): p. 6976-80.
215. Moretta, A., et al., *Receptors for HLA class-I molecules in human natural killer cells*. Annu Rev Immunol, 1996. **14**: p. 619-48.
216. Anfossi, N., et al., *Human NK cell education by inhibitory receptors for MHC class I*. Immunity, 2006. **25**(2): p. 331-42.
217. Uhrberg, M., et al., *Human diversity in killer cell inhibitory receptor genes*. Immunity, 1997. **7**(6): p. 753-63.

218. Karlhofer, F.M., R.K. Ribaldo, and W.M. Yokoyama, *MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells*. *Nature*, 1992. **358**(6381): p. 66-70.
219. Makrigiannis, A.P., et al., *A BAC contig map of the Ly49 gene cluster in 129 mice reveals extensive differences in gene content relative to C57BL/6 mice*. *Genomics*, 2002. **79**(3): p. 437-44.
220. McQueen, K.L., et al., *Localization of five new Ly49 genes, including three closely related to Ly49c*. *Immunogenetics*, 1998. **48**(3): p. 174-83.
221. Raulet, D.H., et al., *Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors*. *Immunol Rev*, 1997. **155**: p. 41-52.
222. Takei, F., J. Brennan, and D.L. Mager, *The Ly-49 family: genes, proteins and recognition of class I MHC*. *Immunol Rev*, 1997. **155**: p. 67-77.
223. Kim, S., et al., *Licensing of natural killer cells by host major histocompatibility complex class I molecules*. *Nature*, 2005. **436**(7051): p. 709-13.
224. Fernandez, N.C., et al., *A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules*. *Blood*, 2005. **105**(11): p. 4416-23.
225. Kubota, A., et al., *Diversity of NK cell receptor repertoire in adult and neonatal mice*. *J Immunol*, 1999. **163**(1): p. 212-6.
226. Pascal, V., M.J. Stulberg, and S.K. Anderson, *Regulation of class I major histocompatibility complex receptor expression in natural killer cells: one promoter is not enough!* *Immunol Rev*, 2006. **214**: p. 9-21.
227. Michaelsson, J., et al., *Visualization of inhibitory Ly49 receptor specificity with soluble major histocompatibility complex class I tetramers*. *Eur J Immunol*, 2000. **30**(1): p. 300-7.
228. Yawata, M., et al., *MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response*. *Blood*, 2008. **112**(6): p. 2369-80.
229. Roth, C., et al., *Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC*. *Immunity*, 2000. **13**(1): p. 143-53.
230. Salcedo, M., et al., *Role of Qa-1(b)-binding receptors in the specificity of developing NK cells*. *Eur J Immunol*, 2000. **30**(4): p. 1094-101.
231. Held, W. and D.H. Raulet, *Expression of the Ly49A gene in murine natural killer cell clones is predominantly but not exclusively mono-allelic*. *Eur J Immunol*, 1997. **27**(11): p. 2876-84.
232. Held, W. and B. Kunz, *An allele-specific, stochastic gene expression process controls the expression of multiple Ly49 family genes and generates a diverse, MHC-specific NK cell receptor repertoire*. *Eur J Immunol*, 1998. **28**(8): p. 2407-16.
233. Held, W., J. Roland, and D.H. Raulet, *Allelic exclusion of Ly49-family genes encoding class I MHC-specific receptors on NK cells*. *Nature*, 1995. **376**(6538): p. 355-8.
234. Held, W., et al., *Mono-allelic Ly49 NK cell receptor expression*. *Semin Immunol*, 1999. **11**(5): p. 349-55.
235. Rouhi, A., et al., *Evidence for epigenetic maintenance of Ly49a monoallelic gene expression*. *J Immunol*, 2006. **176**(5): p. 2991-9.
236. Tanamachi, D.M., et al., *Expression of natural killer receptor alleles at different Ly49 loci occurs independently and is regulated by major histocompatibility complex class I molecules*. *J Exp Med*, 2001. **193**(3): p. 307-15.

237. Saleh, A., et al., *Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a eukaryotic mechanism for selective gene activation*. *Immunity*, 2004. **21**(1): p. 55-66.
238. Rouhi, A., et al., *Evidence for high bi-allelic expression of activating Ly49 receptors*. *Nucleic Acids Res*, 2009. **37**(16): p. 5331-42.
239. Seth, S., et al., *Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells*. *J Leukoc Biol*, 2009. **86**(1): p. 91-101.
240. Smith, H.R., et al., *Nonstochastic coexpression of activation receptors on murine natural killer cells*. *J Exp Med*, 2000. **191**(8): p. 1341-54.
241. Held, W., et al., *Major histocompatibility complex class I-dependent skewing of the natural killer cell Ly49 receptor repertoire*. *Eur J Immunol*, 1996. **26**(10): p. 2286-92.
242. Salcedo, M., et al., *Altered expression of Ly49 inhibitory receptors on natural killer cells from MHC class I-deficient mice*. *J Immunol*, 1997. **158**(7): p. 3174-80.
243. Hanke, T., H. Takizawa, and D.H. Raulet, *MHC-dependent shaping of the inhibitory Ly49 receptor repertoire on NK cells: evidence for a regulated sequential model*. *Eur J Immunol*, 2001. **31**(11): p. 3370-9.
244. Olsson, M.Y., K. Kärre, and C.L. Sentman, *Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand*. *Proc Natl Acad Sci U S A*, 1995. **92**(5): p. 1649-53.
245. Karlhofer, F.M., et al., *Host MHC class I molecules modulate in vivo expression of a NK cell receptor*. *J Immunol*, 1994. **153**(6): p. 2407-16.
246. Bessoles, S., et al., *Education of murine NK cells requires both cis and trans recognition of MHC class I molecules*. *J Immunol*, 2013. **191**(10): p. 5044-51.
247. Johansson, S., et al., *Probing natural killer cell education by Ly49 receptor expression analysis and computational modelling in single MHC class I mice*. *PLoS One*, 2009. **4**(6): p. e6046.
248. Schonberg, K., et al., *Neonatal NK-cell repertoires are functionally, but not structurally, biased toward recognition of self HLA class I*. *Blood*, 2011. **117**(19): p. 5152-6.
249. Jonsson, A.H., et al., *Effects of MHC class I alleles on licensing of Ly49A+ NK cells*. *J Immunol*, 2010. **184**(7): p. 3424-32.
250. Chen, Y., et al., *Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands*. *IUBMB Life*, 2009. **61**(6): p. 579-90.
251. Orihuela, M., D.H. Margulies, and W.M. Yokoyama, *The natural killer cell receptor Ly-49A recognizes a peptide-induced conformational determinant on its major histocompatibility complex class I ligand*. *Proc Natl Acad Sci U S A*, 1996. **93**(21): p. 11792-7.
252. Correa, I. and D.H. Raulet, *Binding of diverse peptides to MHC class I molecules inhibits target cell lysis by activated natural killer cells*. *Immunity*, 1995. **2**(1): p. 61-71.
253. Deng, L. and R.A. Mariuzza, *Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors*. *Semin Immunol*, 2006. **18**(3): p. 159-66.
254. Dam, J., et al., *Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b)*. *Nat Immunol*, 2003. **4**(12): p. 1213-22.
255. Rajagopalan, S. and E.O. Long, *The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity*. *J Exp Med*, 1997. **185**(8): p. 1523-8.
256. Doucey, M.A., et al., *Cis association of Ly49A with MHC class I restricts natural killer cell inhibition*. *Nat Immunol*, 2004. **5**(3): p. 328-36.

257. Back, J., et al., *Stable masking by H-2Dd cis ligand limits Ly49A relocation to the site of NK cell/target cell contact*. Proc Natl Acad Sci U S A, 2007. **104**(10): p. 3978-83.
258. Held, W. and R.A. Mariuzza, *Cis interactions of immunoreceptors with MHC and non-MHC ligands*. Nat Rev Immunol, 2008. **8**(4): p. 269-78.
259. Plougastel, B.F. and W.M. Yokoyama, *Extending missing-self? Functional interactions between lectin-like NKrp1 receptors on NK cells with lectin-like ligands*. Curr Top Microbiol Immunol, 2006. **298**: p. 77-89.
260. Latchman, Y., P.F. McKay, and H. Reiser, *Identification of the 2B4 molecule as a counter-receptor for CD48*. J Immunol, 1998. **161**(11): p. 5809-12.
261. Watzl, C. and M. Claus, *WhatSAP - 2B4 sends mixed messages in the absence of SAP*. Eur J Immunol, 2014. **44**(5): p. 1281-4.
262. Dong, Z., et al., *The Adaptor SAP Controls NK Cell Activation by Regulating the Enzymes Vav-1 and SHIP-1 and by Enhancing Conjugates with Target Cells*. Immunity, 2012.
263. Eissmann, P., et al., *Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244)*. Blood, 2005. **105**(12): p. 4722-9.
264. Parolini, S., et al., *X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells*. J Exp Med, 2000. **192**(3): p. 337-46.
265. Tangye, S.G., et al., *Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome*. J Immunol, 2000. **165**(6): p. 2932-6.
266. Lee, K.M., et al., *2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells*. J Exp Med, 2004. **199**(9): p. 1245-54.
267. Alari-Pahissa, E., et al., *Activation by SLAM Family Receptors Contributes to NK Cell Mediated "Missing-Self" Recognition*. PLoS One, 2016. **11**(4): p. e0153236.
268. Hanke, T., et al., *2F1 antigen, the mouse homolog of the rat "mast cell function-associated antigen", is a lectin-like type II transmembrane receptor expressed by natural killer cells*. Eur J Immunol, 1998. **28**(12): p. 4409-17.
269. Blaser, C., M. Kaufmann, and H. Pircher, *Virus-activated CD8 T cells and lymphokine-activated NK cells express the mast cell function-associated antigen, an inhibitory C-type lectin*. J Immunol, 1998. **161**(12): p. 6451-4.
270. Robbins, S.H., et al., *Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection*. J Immunol, 2004. **173**(1): p. 259-66.
271. Robbins, S.H., et al., *Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells*. J Immunol, 2002. **168**(6): p. 2585-9.
272. Grundemann, C., et al., *Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1*. J Immunol, 2006. **176**(3): p. 1311-5.
273. Schwartzkopff, S., et al., *Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans*. J Immunol, 2007. **179**(2): p. 1022-9.
274. Banh, C., C. Fugere, and L. Brossay, *Immunoregulatory functions of KLRG1 cadherin interactions are dependent on forward and reverse signaling*. Blood, 2009. **114**(26): p. 5299-306.
275. Ito, M., et al., *Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity*. J Exp Med, 2006. **203**(2): p. 289-95.
276. Tessmer, M.S., et al., *KLRG1 binds cadherins and preferentially associates with SHIP-1*. Int Immunol, 2007. **19**(4): p. 391-400.

277. Hofmann, M., O. Schweier, and H. Pircher, *Different inhibitory capacities of human and mouse KLRG1 are linked to distinct disulfide-mediated oligomerizations*. Eur J Immunol, 2012. **42**(9): p. 2484-90.
278. Corral, L., et al., *NK cell expression of the killer cell lectin-like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules*. Eur J Immunol, 2000. **30**(3): p. 920-30.
279. Trowsdale, J., *Genetic and functional relationships between MHC and NK receptor genes*. Immunity, 2001. **15**(3): p. 363-74.
280. Liao, N.S., et al., *MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity*. Science, 1991. **253**(5016): p. 199-202.
281. Höglund, P., et al., *Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice*. Proc Natl Acad Sci U S A, 1991. **88**(22): p. 10332-6.
282. Johansson, M.H., et al., *Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene*. J Exp Med, 1997. **186**(3): p. 353-64.
283. Brodin, P., K. Kärre, and P. Höglund, *NK cell education: not an on-off switch but a tunable rheostat*. Trends Immunol, 2009. **30**(4): p. 143-9.
284. Brodin, P., et al., *The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells*. Blood, 2009. **113**(11): p. 2434-41.
285. Lowin-Kropf, B., et al., *Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1*. J Immunol, 2000. **165**(3): p. 1314-21.
286. Viant, C., et al., *SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells*. Nat Commun, 2014. **5**: p. 5108.
287. Wu, M.F. and D.H. Raulet, *Class I-deficient hemopoietic cells and nonhemopoietic cells dominantly induce unresponsiveness of natural killer cells to class I-deficient bone marrow cell grafts*. J Immunol, 1997. **158**(4): p. 1628-33.
288. Ioannidis, V., et al., *Cre recombinase-mediated inactivation of H-2Dd transgene expression: evidence for partial missing self-recognition by Ly49A NK cells*. J Immunol, 2001. **167**(11): p. 6256-62.
289. Wagner, A.K., et al., *Retuning of Mouse NK Cells after Interference with MHC Class I Sensing Adjusts Self-Tolerance but Preserves Anticancer Response*. Cancer Immunol Res, 2016. **4**(2): p. 113-23.
290. Brodin, P., et al., *Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice*. PLoS One, 2010. **5**(10).
291. Pittari, G., et al., *NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand*. J Immunol, 2013. **190**(9): p. 4650-60.
292. Kim, S., et al., *HLA alleles determine differences in human natural killer cell responsiveness and potency*. Proc Natl Acad Sci U S A, 2008. **105**(8): p. 3053-8.
293. Raulet, D.H., R.E. Vance, and C.W. McMahon, *Regulation of the natural killer cell receptor repertoire*. Annu Rev Immunol, 2001. **19**: p. 291-330.
294. Yu, J., et al., *Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands*. J Immunol, 2007. **179**(9): p. 5977-89.
295. Joncker, N.T. and D.H. Raulet, *Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells*. Immunol Rev, 2008. **224**: p. 85-97.
296. Fauriat, C., et al., *Education of human natural killer cells by activating killer cell immunoglobulin-like receptors*. Blood, 2010. **115**(6): p. 1166-74.

297. Kadri, N., et al., *Dynamic Regulation of NK Cell Responsiveness*. *Curr Top Microbiol Immunol*, 2016. **395**: p. 95-114.
298. Tripathy, S.K., et al., *Continuous engagement of a self-specific activation receptor induces NK cell tolerance*. *J Exp Med*, 2008. **205**(8): p. 1829-41.
299. Narni-Mancinelli, E., et al., *Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses*. *Science*, 2012. **335**(6066): p. 344-8.
300. Sun, J.C. and L.L. Lanier, *Tolerance of NK cells encountering their viral ligand during development*. *J Exp Med*, 2008. **205**(8): p. 1819-28.
301. Coudert, J.D., et al., *Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways*. *Blood*, 2008. **111**(7): p. 3571-8.
302. Bolanos, F.D. and S.K. Tripathy, *Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversible*. *J Immunol*, 2011. **186**(5): p. 2765-71.
303. Sun, J.C. and L.L. Lanier, *Cutting edge: viral infection breaks NK cell tolerance to "missing self"*. *J Immunol*, 2008. **181**(11): p. 7453-7.
304. Li, Y., et al., *Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition*. *Immunity*, 2009. **31**(1): p. 35-46.
305. Orr, M.T., W.J. Murphy, and L.L. Lanier, *'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection*. *Nat Immunol*, 2010. **11**(4): p. 321-7.
306. Mahmoud, A.B., et al., *Influenza Virus Targets Class I MHC-Educated NK Cells for Immuno-evasion*. *PLoS Pathog*, 2016. **12**(2): p. e1005446.
307. Krebs, P., et al., *NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses*. *Blood*, 2009. **113**(26): p. 6593-602.
308. Kalinski, P., et al., *Helper role of NK cells during the induction of anticancer responses by dendritic cells*. *Mol Immunol*, 2005. **42**(4): p. 535-9.
309. Balsamo, M., et al., *Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30*. *Exp Hematol*, 2009. **37**(10): p. 1167-75.
310. Soderquest, K., et al., *Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses*. *J Immunol*, 2011. **186**(6): p. 3304-8.
311. Chambers, B.J. and H.G. Ljunggren, *NK cells*. In *Dendritic cells*. Academic Press (M. T. Lotze, A. W. Thomson, eds.), 1999: p. 257-268.
312. Persson, C.M., et al., *Critical role of Qa1b in the protection of mature dendritic cells from NK cell-mediated killing*. *Scand J Immunol*, 2008. **67**(1): p. 30-6.
313. Persson, C.M. and B.J. Chambers, *Plasmacytoid dendritic cell-induced migration and activation of NK cells in vivo*. *Eur J Immunol*, 2010. **40**(8): p. 2155-64.
314. Della Chiesa, M., et al., *Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses*. *Blood*, 2006. **108**(12): p. 3851-8.
315. Ferlazzo, G., *Natural killer and dendritic cell liaison: recent insights and open questions*. *Immunol Lett*, 2005. **101**(1): p. 12-7.
316. Ferlazzo, G. and C. Munz, *Dendritic cell interactions with NK cells from different tissues*. *J Clin Immunol*, 2009. **29**(3): p. 265-73.
317. Semino, C., et al., *NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1*. *Blood*, 2005. **106**(2): p. 609-16.
318. O'Leary, J.G., et al., *T cell- and B cell-independent adaptive immunity mediated by natural killer cells*. *Nat Immunol*, 2006. **7**(5): p. 507-16.
319. Paust, S., et al., *Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses*. *Nat Immunol*, 2010. **11**(12): p. 1127-35.

320. Cooper, M.A., et al., *Cytokine-induced memory-like natural killer cells*. Proc Natl Acad Sci U S A, 2009. **106**(6): p. 1915-9.
321. Sun, J.C., J.N. Beilke, and L.L. Lanier, *Adaptive immune features of natural killer cells*. Nature, 2009. **457**(7229): p. 557-61.
322. Guma, M., et al., *Imprint of human cytomegalovirus infection on the NK cell receptor repertoire*. Blood, 2004. **104**(12): p. 3664-71.
323. Beziat, V., et al., *CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients*. Eur J Immunol, 2012. **42**(2): p. 447-57.
324. Foley, B., et al., *Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen*. J Immunol, 2012. **189**(10): p. 5082-8.
325. Romee, R., et al., *Cytokine activation induces human memory-like NK cells*. Blood, 2012. **120**(24): p. 4751-60.
326. Beziat, V., et al., *NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs*. Blood, 2013. **121**(14): p. 2678-88.
327. Foley, B., et al., *Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function*. Blood, 2012. **119**(11): p. 2665-74.
328. Sun, J.C., et al., *Proinflammatory cytokine signaling required for the generation of natural killer cell memory*. J Exp Med, 2012. **209**(5): p. 947-54.
329. Nabekura, T., et al., *Costimulatory Molecule DNAM-1 Is Essential for Optimal Differentiation of Memory Natural Killer Cells during Mouse Cytomegalovirus Infection*. Immunity, 2014.
330. Sun, J.C., J.N. Beilke, and L.L. Lanier, *Immune memory redefined: characterizing the longevity of natural killer cells*. Immunol Rev, 2010. **236**: p. 83-94.
331. Kamimura, Y. and L.L. Lanier, *Homeostatic control of memory cell progenitors in the natural killer cell lineage*. Cell Rep, 2015. **10**(2): p. 280-91.
332. Leong, J.W., et al., *Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells*. Biol Blood Marrow Transplant, 2014. **20**(4): p. 463-73.
333. Ruggeri, L., et al., *Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants*. Science, 2002. **295**(5562): p. 2097-100.
334. Leung, W., et al., *Determinants of antileukemia effects of allogeneic NK cells*. J Immunol, 2004. **172**(1): p. 644-50.
335. Schaffer, M., et al., *Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation*. Transplantation, 2004. **78**(7): p. 1081-5.
336. Malmberg, K.J., et al., *KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation*. Mol Immunol, 2005. **42**(4): p. 531-4.
337. Hsu, K.C., et al., *KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy*. Biol Blood Marrow Transplant, 2006. **12**(8): p. 828-36.
338. Bjorklund, A.T., et al., *NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation*. Blood, 2010. **115**(13): p. 2686-94.
339. Giebel, S., et al., *Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing*. Bone Marrow Transplant, 2003. **31**(11): p. 987-93.
340. Giebel, S., et al., *Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors*. Blood, 2003. **102**(3): p. 814-9.

341. Beelen, D.W., et al., *Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias*. *Blood*, 2005. **105**(6): p. 2594-600.
342. Miller, J.S., et al., *Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT*. *Blood*, 2007. **109**(11): p. 5058-61.
343. Hsu, K.C., et al., *Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes*. *Blood*, 2005. **105**(12): p. 4878-84.
344. Ruggeri, L., et al., *Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation*. *Blood*, 1999. **94**(1): p. 333-9.
345. Pende, D., et al., *Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity*. *Blood*, 2009. **113**(13): p. 3119-29.
346. Cooley, S., et al., *Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia*. *Blood*, 2010. **116**(14): p. 2411-9.
347. Cooley, S., et al., *Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia*. *Blood*, 2009. **113**(3): p. 726-32.
348. Cooley, S., et al., *Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia*. *J Immunol*, 2014. **192**(10): p. 4592-600.
349. Venstrom, J.M., et al., *HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1*. *N Engl J Med*, 2012. **367**(9): p. 805-16.
350. Miller, J.S., et al., *Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer*. *Blood*, 2005. **105**(8): p. 3051-7.
351. Bachanova, V., et al., *Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein*. *Blood*, 2014. **123**(25): p. 3855-63.
352. Dahlberg, C.I., et al., *Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity*. *Front Immunol*, 2015. **6**: p. 605.
353. Alici, E., *IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers*. *Curr Opin Mol Ther*, 2010. **12**(6): p. 724-33.
354. Romagne, F., et al., *Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells*. *Blood*, 2009. **114**(13): p. 2667-77.
355. Vey, N., et al., *A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission*. *Blood*, 2012. **120**(22): p. 4317-23.
356. Vahlne, G., et al., *In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2*. *Eur J Immunol*, 2010. **40**(3): p. 813-23.
357. Kohrt, H.E., et al., *Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies*. *Blood*, 2014. **123**(5): p. 678-86.
358. Koh, C.Y., et al., *Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo*. *Blood*, 2001. **97**(10): p. 3132-7.

359. Benson, D.M., Jr., et al., *IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect*. *Blood*, 2011. **118**(24): p. 6387-91.
360. Kiessling, R., et al., *Non-T-cell resistance against a mouse Moloney lymphoma*. *Int J Cancer*, 1976. **17**(2): p. 275-81.
361. Schmohl, J.U., et al., *Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells*. *Target Oncol*, 2015.
362. Vallera, D.A., et al., *IL-15 Trispecific Killer Engagers (TriKEs) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing In Vivo Expansion, and Enhanced Function*. *Clin Cancer Res*, 2016.
363. Elliott, J.M., J.A. Wahle, and W.M. Yokoyama, *MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment*. *J Exp Med*, 2010. **207**(10): p. 2073-9.
364. Joncker, N.T., et al., *Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment*. *J Exp Med*, 2010. **207**(10): p. 2065-72.
365. Venstrom, J.M., et al., *KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma*. *Clin Cancer Res*, 2009. **15**(23): p. 7330-4.
366. Sola, C., et al., *Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo*. *Proc Natl Acad Sci U S A*, 2009. **106**(31): p. 12879-84.
367. van Hall, T., et al., *Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin*. *J Immunol*, 2000. **165**(2): p. 869-77.
368. Gays, F., et al., *The mouse tumor cell lines EL4 and RMA display mosaic expression of NK-related and certain other surface molecules and appear to have a common origin*. *J Immunol*, 2000. **164**(10): p. 5094-102.
369. Goldman, J.P., et al., *Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain*. *Br J Haematol*, 1998. **103**(2): p. 335-42.
370. Scarpellino, L., et al., *Interactions of Ly49 family receptors with MHC class I ligands in trans and cis*. *J Immunol*, 2007. **178**(3): p. 1277-84.
371. Belanger, S., et al., *Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice*. *Blood*, 2012. **120**(3): p. 592-602.
372. Ardolino, M., et al., *Cytokine therapy reverses NK cell anergy in MHC-deficient tumors*. *J Clin Invest*, 2014. **124**(11): p. 4781-94.
373. Scquizzato, E., et al., *KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation*. *Pediatr Transplant*, 2011. **15**(2): p. 198-204.
374. Ebihara, T., A.H. Jonsson, and W.M. Yokoyama, *Natural killer cell licensing in mice with inducible expression of MHC class I*. *Proc Natl Acad Sci U S A*, 2013. **110**(45): p. E4232-7.
375. Chalifour, A., et al., *A Role for cis Interaction between the Inhibitory Ly49A receptor and MHC class I for natural killer cell education*. *Immunity*, 2009. **30**(3): p. 337-47.
376. Sjöstrom, A., et al., *Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors*. *J Exp Med*, 2001. **194**(10): p. 1519-30.
377. Bornhauser, M., et al., *Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors*. *Blood*, 2004. **103**(7): p. 2860-1; author reply 2862.

378. Davies, S.M., et al., *Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.* Blood, 2002. **100**(10): p. 3825-7.
379. Bishara, A., et al., *The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.* Tissue Antigens, 2004. **63**(3): p. 204-11.
380. Carlsten, M., et al., *DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.* Cancer Res, 2007. **67**(3): p. 1317-25.
381. Carlsten, M., et al., *Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.* J Immunol, 2009. **183**(8): p. 4921-30.
382. Magri, G., et al., *NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.* Blood, 2011. **117**(3): p. 848-56.
383. Castriconi, R., et al., *Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.* Cancer Res, 2004. **64**(24): p. 9180-4.
384. Dardalhon, V., et al., *CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions.* J Immunol, 2005. **175**(3): p. 1558-65.
385. Shibuya, K., et al., *CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation.* J Exp Med, 2003. **198**(12): p. 1829-39.
386. Enqvist, M., et al., *Coordinated expression of DNAM-1 and LFA-1 in educated NK cells.* J Immunol, 2015. **194**(9): p. 4518-27.
387. Martinet, L., et al., *DNAM-1 expression marks an alternative program of NK cell maturation.* Cell Rep, 2015. **11**(1): p. 85-97.
388. Beura, L.K., et al., *Normalizing the environment recapitulates adult human immune traits in laboratory mice.* Nature, 2016. **532**(7600): p. 512-6.
389. Campos, C., et al., *Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.* Biogerontology, 2015. **16**(5): p. 671-83.
390. Mamessier, E., et al., *Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.* Cancer Res, 2011. **71**(21): p. 6621-32.
391. Mamessier, E., et al., *Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.* J Clin Invest, 2011. **121**(9): p. 3609-22.
392. Reymond, N., et al., *DNAM-1 and PVR regulate monocyte migration through endothelial junctions.* J Exp Med, 2004. **199**(10): p. 1331-41.
393. Lopez, M., et al., *The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule.* Blood, 1998. **92**(12): p. 4602-11.
394. Tahara-Hanaoka, S., et al., *Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.* Blood, 2006. **107**(4): p. 1491-6.
395. El-Sherbiny, Y.M., et al., *The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.* Cancer Res, 2007. **67**(18): p. 8444-9.
396. Sanchez-Correa, B., et al., *Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.* Immunol Cell Biol, 2012. **90**(1): p. 109-15.

397. Soriani, A., et al., *ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype*. *Blood*, 2009. **113**(15): p. 3503-11.
398. Thomas, L.M., M.E. Peterson, and E.O. Long, *Cutting edge: NK cell licensing modulates adhesion to target cells*. *J Immunol*, 2013. **191**(8): p. 3981-5.
399. Fauriat, C., et al., *Regulation of human NK-cell cytokine and chemokine production by target cell recognition*. *Blood*, 2010. **115**(11): p. 2167-76.
400. Jia, S.H., et al., *Comparative ability of Qdm/Qa-1b, kb, and Db to protect class IIow cells from NK-mediated lysis in vivo*. *J Immunol*, 2000. **165**(11): p. 6142-7.
401. Seth, S., et al., *Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells*. *J Biol Chem*, 2011. **286**(45): p. 39153-63.
402. Mason, L.H., et al., *Receptor glycosylation regulates Ly-49 binding to MHC class I*. *J Immunol*, 2003. **171**(8): p. 4235-42.
403. Sheppard, S., et al., *Characterization of a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK cell repertoire*. *Blood*, 2013. **121**(25): p. 5025-33.
404. Yu, X., et al., *The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells*. *Nat Immunol*, 2009. **10**(1): p. 48-57.
405. Stanietsky, N., et al., *The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity*. *Proc Natl Acad Sci U S A*, 2009. **106**(42): p. 17858-63.
406. Joller, N., et al., *Cutting edge: TIGIT has T cell-intrinsic inhibitory functions*. *J Immunol*, 2011. **186**(3): p. 1338-42.
407. Levin, S.D., et al., *Vstm3 is a member of the CD28 family and an important modulator of T-cell function*. *Eur J Immunol*, 2011. **41**(4): p. 902-15.
408. Abbas, A.K., et al., *T cell tolerance and autoimmunity*. *Autoimmun Rev*, 2004. **3**(7-8): p. 471-5.
409. Liu, S., et al., *Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells*. *Cell Death Differ*, 2013. **20**(3): p. 456-64.
410. Stanietsky, N., et al., *Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR*. *Eur J Immunol*, 2013.
411. Fuchs, A., et al., *Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)*. *J Immunol*, 2004. **172**(7): p. 3994-8.
412. Chan, C.J., et al., *The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions*. *Nat Immunol*, 2014. **15**(5): p. 431-8.
413. Blake, S.J., et al., *Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy*. *Cancer Discov*, 2016.
414. Guia, S., et al., *Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance*. *Sci Signal*, 2011. **4**(167): p. ra21.
415. Höglund, P. and P. Brodin, *Current perspectives of natural killer cell education by MHC class I molecules*. *Nat Rev Immunol*, 2010. **10**(10): p. 724-34.
416. Chambers, B.J., M. Salcedo, and H.G. Ljunggren, *Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1)*. *Immunity*, 1996. **5**(4): p. 311-7.
417. Ferlazzo, G., et al., *Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs*. *Proc Natl Acad Sci U S A*, 2004. **101**(47): p. 16606-11.
418. Moretta, A., et al., *Early liaisons between cells of the innate immune system in inflamed peripheral tissues*. *Trends Immunol*, 2005. **26**(12): p. 668-75.

419. Vitale, M., et al., *NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor*. *Blood*, 2005. **106**(2): p. 566-71.
420. Pende, D., et al., *Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction*. *Blood*, 2006. **107**(5): p. 2030-6.
421. Morandi, B., et al., *Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response*. *PLoS One*, 2012. **7**(6): p. e39170.
422. Mocikat, R., et al., *Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses*. *Immunity*, 2003. **19**(4): p. 561-9.
423. Della Chiesa, M., et al., *The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors*. *Eur J Immunol*, 2003. **33**(6): p. 1657-66.
424. Wang, R., et al., *Natural killer cell-produced IFN-gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1*. *J Leukoc Biol*, 2012. **91**(2): p. 299-309.
425. Kushner, B.H., K. Kramer, and N.K. Cheung, *Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma*. *J Clin Oncol*, 2001. **19**(22): p. 4189-94.
426. Croce, M., et al., *New immunotherapeutic strategies for the treatment of neuroblastoma*. *Immunotherapy*, 2015. **7**(3): p. 285-300.
427. Stanietsky, N. and O. Mandelboim, *Paired NK cell receptors controlling NK cytotoxicity*. *FEBS Lett*, 2010. **584**(24): p. 4895-900.
428. Masson, D., et al., *Overexpression of the CD155 gene in human colorectal carcinoma*. *Gut*, 2001. **49**(2): p. 236-40.
429. Bryceson, Y.T., et al., *Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells*. *J Exp Med*, 2005. **202**(7): p. 1001-12.
430. Byrne, P., et al., *Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells*. *Eur J Immunol*, 2004. **34**(9): p. 2579-88.
431. Coudert, J.D., C. Coureau, and J.C. Guery, *Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T cell priming and promotes Th type 2 responses to transplantation antigens*. *J Immunol*, 2002. **169**(6): p. 2979-87.
432. Gehrman, U., et al., *Synergistic induction of adaptive antitumor immunity by codelivery of antigen with alpha-galactosylceramide on exosomes*. *Cancer Res*, 2013. **73**(13): p. 3865-76.
433. Li, X.B., et al., *Role of exosomes in immune regulation*. *J Cell Mol Med*, 2006. **10**(2): p. 364-75.
434. Valenti, R., et al., *Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes*. *Cancer Res*, 2006. **66**(18): p. 9290-8.
435. Zitvogel, L., et al., *Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes*. *Nat Med*, 1998. **4**(5): p. 594-600.
436. Escudier, B., et al., *Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial*. *J Transl Med*, 2005. **3**(1): p. 10.
437. Morse, M.A., et al., *A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer*. *J Transl Med*, 2005. **3**(1): p. 9.
438. Viaud, S., et al., *Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha*. *PLoS One*, 2009. **4**(3): p. e4942.

439. Taniguchi, K., et al., *Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens*. Proc Natl Acad Sci U S A, 1987. **84**(10): p. 3405-9.
440. Schweier, O., M. Hofmann, and H. Pircher, *KLRG1 activity is regulated by association with the transferrin receptor*. Eur J Immunol, 2014. **44**(6): p. 1851-6.